<?xml version="1.0" encoding="UTF-8"?><xml><records><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Hadi, Naila Irum</author><author>Jamal, Lamar</author></authors></contributors><titles><title>“OMIC” tumor markers for breast cancer: A review</title><secondary-title>Pak J Med Sci</secondary-title></titles><periodical><full-title>Pak J Med Sci</full-title></periodical><pages>1256-1262</pages><volume>31</volume><issue>5</issue><keywords/><dates><year>2015</year></dates><electronic-resource-num>10.12669/pjms.315.7627</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Hadi, Jamal - 1256 - “OMIC” tumor markers for breast cancer A review.pdf</url></pdf-urls><web-urls><url>www.pjms.com.pk</url></web-urls></urls><label>Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Paik, Soonmyung</author><author>Shak, Steven</author><author>Tang, Gong</author><author>Kim, Chungyeul</author><author>Baker, Joffre</author><author>Cronin, Maureen</author><author>Baehner, Frederick L</author><author>Walker, Michael G</author><author>Watson, Drew</author><author>Park, Taesung</author><author>Hiller, William</author><author>Fisher, Edwin R</author><author>Wickerham, D Lawrence</author><author>Bryant, John</author><author>Wolmark, Norman</author></authors></contributors><titles><title>A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.</title><secondary-title>The New England journal of medicine</secondary-title></titles><periodical><full-title>The New England journal of medicine</full-title></periodical><pages>2817-26</pages><volume>351</volume><issue>27</issue><keywords><keyword>Algorithms</keyword><keyword>Antineoplastic Agents</keyword><keyword>Biological</keyword><keyword>Biological: analysis</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: drug therapy</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Breast Neoplasms: pathology</keyword><keyword>DNA</keyword><keyword>Estrogen</keyword><keyword>Estrogen Antagonists</keyword><keyword>Estrogen Antagonists: therapeutic use</keyword><keyword>Female</keyword><keyword>Follow-Up Studies</keyword><keyword>Gene Expression</keyword><keyword>Genes</keyword><keyword>Hormonal</keyword><keyword>Hormonal: therapeutic use</keyword><keyword>Humans</keyword><keyword>Lymphatic Metastasis</keyword><keyword>Middle Aged</keyword><keyword>Multivariate Analysis</keyword><keyword>Neoplasm</keyword><keyword>Neoplasm Metastasis</keyword><keyword>Neoplasm: analysis</keyword><keyword>Neoplasm: metabolism</keyword><keyword>Progesterone</keyword><keyword>Prognosis</keyword><keyword>Proportional Hazards Models</keyword><keyword>Receptors</keyword><keyword>Recurrence</keyword><keyword>Reverse Transcriptase Polymerase Chain Reaction</keyword><keyword>Risk</keyword><keyword>Survival Analysis</keyword><keyword>Tamoxifen</keyword><keyword>Tamoxifen: therapeutic use</keyword><keyword>Tumor Markers</keyword><keyword>erbB-2</keyword></keywords><dates><year>2004</year></dates><accession-num>15591335</accession-num><electronic-resource-num>10.1056/NEJMoa041588</electronic-resource-num><urls><pdf-urls><url>internal-pdf://</url><url>internal-pdf://Paik et al. - 2004 - A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer(3).pdf</url><url>internal-pdf://Paik et al. - 2004 - A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/15591335</url></web-urls></urls><label>NNT paper;OncoType DX;Oncotype DX</label><abstract>BACKGROUND: The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures. METHODS: We tested whether the results of a reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of 21 prospectively selected genes in paraffin-embedded tumor tissue would correlate with the likelihood of distant recurrence in patients with node-negative, tamoxifen-treated breast cancer who were enrolled in the National Surgical Adjuvant Breast and Bowel Project clinical trial B-14. The levels of expression of 16 cancer-related genes and 5 reference genes were used in a prospectively defined algorithm to calculate a recurrence score and to determine a risk group (low, intermediate, or high) for each patient. RESULTS: Adequate RT-PCR profiles were obtained in 668 of 675 tumor blocks. The proportions of patients categorized as having a low, intermediate, or high risk by the RT-PCR assay were 51, 22, and 27 percent, respectively. The Kaplan-Meier estimates of the rates of distant recurrence at 10 years in the low-risk, intermediate-risk, and high-risk groups were 6.8 percent (95 percent confidence interval, 4.0 to 9.6), 14.3 percent (95 percent confidence interval, 8.3 to 20.3), and 30.5 percent (95 percent confidence interval, 23.6 to 37.4). The rate in the low-risk group was significantly lower than that in the high-risk group (P&lt;0.001). In a multivariate Cox model, the recurrence score provided significant predictive power that was independent of age and tumor size (P&lt;0.001). The recurrence score was also predictive of overall survival (P&lt;0.001) and could be used as a continuous function to predict distant recurrence in individual patients. CONCLUSIONS: The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Rakovitch, Eileen</author><author>Nofech-Mozes, Sharon</author><author>Hanna, Wedad</author><author>Baehner, Frederick L.</author><author>Saskin, Refik</author><author>Butler, Steven M.</author><author>Tuck, Alan</author><author>Sengupta, Sandip</author><author>Elavathil, Leela</author><author>Jani, Prashant a.</author><author>Bonin, Michel</author><author>Chang, Martin C.</author><author>Robertson, Susan J.</author><author>Slodkowska, Elzbieta</author><author>Fong, Cindy</author><author>Anderson, Joseph M.</author><author>Jamshidian, Farid</author><author>Miller, Dave P.</author><author>Cherbavaz, Diana B.</author><author>Shak, Steven</author><author>Paszat, Lawrence</author></authors></contributors><titles><title>A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone</title><secondary-title>Breast Cancer Research and Treatment</secondary-title></titles><periodical><full-title>Breast Cancer Research and Treatment</full-title></periodical><pages>389-398</pages><volume>152</volume><issue>2</issue><keywords><keyword>12-Gene assay</keyword><keyword>DCIS Score</keyword><keyword>DCIS treatment</keyword><keyword>Ductal carcinoma in situ</keyword><keyword>Gene expression profiling</keyword><keyword>Local recurrence</keyword></keywords><dates><year>2015</year></dates><publisher>Springer US</publisher><electronic-resource-num>10.1007/s10549-015-3464-6</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Rakovitch et al. - 2015 - A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by (3).pdf</url></pdf-urls><web-urls><url>http://link.springer.com/10.1007/s10549-015-3464-6</url></web-urls></urls><label>Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Lee, Unjin</author><author>Frankenberger, Casey</author><author>Yun, Jieun</author><author>Bevilacqua, Elena</author><author>Caldas, Carlos</author><author>Chin, Suet-Feung</author><author>Rueda, Oscar M</author><author>Reinitz, John</author><author>Rosner, Marsha Rich</author></authors></contributors><titles><title>A prognostic gene signature for metastasis-free survival of triple negative breast cancer patients.</title><secondary-title>PloS one</secondary-title></titles><periodical><full-title>PloS one</full-title></periodical><pages>e82125</pages><volume>8</volume><issue>12</issue><keywords/><dates><year>2013</year></dates><accession-num>24349199</accession-num><electronic-resource-num>10.1371/journal.pone.0082125</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Lee et al. - 2013 - A prognostic gene signature for metastasis-free survival of triple negative breast cancer patients(2).pdf</url><url>internal-pdf://fetchObject.pdf</url><url>internal-pdf://Lee et al. - 2013 - A prognostic gene signature for metastasis-free survival of triple negative breast cancer patients.pdf</url></pdf-urls><web-urls><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3859562&amp;tool=pmcentrez&amp;rendertype=abstract</url></web-urls></urls><label>Oncotype DX</label><abstract>Although triple negative breast cancers (TNBC) are the most aggressive subtype of breast cancer, they currently lack targeted therapies. Because this classification still includes a heterogeneous collection of tumors, new tools to classify TNBCs are urgently required in order to improve our prognostic capability for high risk patients and predict response to therapy. We previously defined a gene expression signature, RKIP Pathway Metastasis Signature (RPMS), based upon a metastasis-suppressive signaling pathway initiated by Raf Kinase Inhibitory Protein (RKIP). We have now generated a new BACH1 Pathway Metastasis gene signature (BPMS) that utilizes targets of the metastasis regulator BACH1. Specifically, we substituted experimentally validated target genes to generate a new BACH1 metagene, developed an approach to optimize patient tumor stratification, and reduced the number of signature genes to 30. The BPMS significantly and selectively stratified metastasis-free survival in basal-like and, in particular, TNBC patients. In addition, the BPMS further stratified patients identified as having a good or poor prognosis by other signatures including the Mammaprint® and Oncotype® clinical tests. The BPMS is thus complementary to existing signatures and is a prognostic tool for high risk ER-HER2- patients. We also demonstrate the potential clinical applicability of the BPMS as a single sample predictor. Together, these results reveal the potential of this pathway-based BPMS gene signature to identify high risk TNBC patients that can respond effectively to targeted therapy, and highlight BPMS genes as novel drug targets for therapeutic development.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Gage, Michele M</author><author>Rosman, Martin</author><author>Mylander, W Charles</author><author>Giblin, Erica</author><author>Kim, Hyun-Seok</author><author>Cope, Leslie</author><author>Umbricht, Christopher</author><author>Wolff, Antonio C</author><author>Tafra, Lorraine</author></authors></contributors><titles><title>A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay.</title><secondary-title>Clinical breast cancer</secondary-title></titles><periodical><full-title>Clinical breast cancer</full-title></periodical><keywords/><dates><year>2015</year></dates><accession-num>26072275</accession-num><electronic-resource-num>10.1016/j.clbc.2015.04.006</electronic-resource-num><urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/26072275</url></web-urls></urls><label>Oncotype DX</label><abstract>BACKGROUND: Predicting recurrence risk and chemotherapy benefit in early-stage breast cancer can be challenging, and Oncotype DX (ODX) is often used to gain insight. However, it is still unclear whether ODX can benefit in all cases. To clarify ODX's usefulness we sought to develop a model using readily available pathologic markers to help clinicians make that determination.

PATIENTS AND METHODS: Clinical pathologic data from 221 hormone receptor-positive, HER2-negative invasive breast cancer patients was used to create a model. The model was then validated on a second institution's set of 319 patients.

RESULTS: The model has 2 simple rules: low grade and positive progesterone receptor tumors (LG+PR) are low risk, and high grade or low estrogen receptor (ER) (ER &lt; 20%) tumors (HG/LER) are high risk. The TAILORx (Trial Assigning Individualized Options for Treatment (Rx)) trial thresholds of Recurrence Score (RS) ≤ 10, when chemotherapy is of little benefit, and RS ≥ 26 when chemotherapy might be beneficial were used to judge model performance. Impressively, the misclassifications of an HG/LER patient who has an RS ≤ 10 were 0% and 2%, and for LG+PR patients who had an RS ≥ 26 were 0% and 2.6%. In the validation set, 28% (66 of 232) of the indeterminate group (neither in the HG/LER nor the LG+PR groups) had an RS ≤ 10 or an RS ≥ 26; this group might clinically benefit from ODX.

CONCLUSION: A simple 2-rule model based on readily available pathologic data was developed and validated, which categorized patients into high and low risk for recurrence. Identification of patients who are unlikely to benefit from ODX testing could result in significant cost avoidance.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Harris, Lyndsay</author><author>Fritsche, Herbert</author><author>Mennel, Robert</author><author>Norton, Larry</author><author>Ravdin, Peter</author><author>Taube, Sheila</author><author>Somerfield, Mark R</author><author>Hayes, Daniel F</author><author>Bast, Robert C</author></authors></contributors><titles><title>American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.</title><secondary-title>Journal of clinical oncology</secondary-title></titles><periodical><full-title>Journal of clinical oncology</full-title></periodical><pages>5287-312</pages><volume>25</volume><issue>33</issue><keywords><keyword>Antigens</keyword><keyword>Biological</keyword><keyword>Biological: analysis</keyword><keyword>Bone Marrow</keyword><keyword>Bone Marrow: pathology</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: diagnosis</keyword><keyword>Breast Neoplasms: drug therapy</keyword><keyword>Carbohydrate</keyword><keyword>Carbohydrate: blood</keyword><keyword>Carcinoembryonic Antigen</keyword><keyword>Carcinoembryonic Antigen: analysis</keyword><keyword>Cathepsin D</keyword><keyword>Cathepsin D: analysis</keyword><keyword>Cell Proliferation</keyword><keyword>Circulating</keyword><keyword>Cyclin E</keyword><keyword>Cyclin E: analysis</keyword><keyword>Drug Resistance</keyword><keyword>Estrogen</keyword><keyword>Estrogen: analysis</keyword><keyword>Female</keyword><keyword>Gene Expression Profiling</keyword><keyword>Humans</keyword><keyword>Mucin-1</keyword><keyword>Mucin-1: blood</keyword><keyword>Neoplasm</keyword><keyword>Neoplastic Cells</keyword><keyword>Plasminogen Activator Inhibitor 1</keyword><keyword>Plasminogen Activator Inhibitor 1: analysis</keyword><keyword>Practice Guidelines as Topic</keyword><keyword>Progesterone</keyword><keyword>Progesterone: analysis</keyword><keyword>Proteomics</keyword><keyword>Receptor</keyword><keyword>Receptors</keyword><keyword>Tumor Markers</keyword><keyword>Tumor Suppressor Protein p53</keyword><keyword>Tumor Suppressor Protein p53: analysis</keyword><keyword>Tumor-Associated</keyword><keyword>Urokinase-Type Plasminogen Activator</keyword><keyword>Urokinase-Type Plasminogen Activator: analysis</keyword><keyword>erbB-2</keyword><keyword>erbB-2: analysis</keyword></keywords><dates><year>2007</year></dates><accession-num>17954709</accession-num><electronic-resource-num>10.1200/JCO.2007.14.2364</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Harris et al. - 2007 - American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast ca(5).pdf</url><url>internal-pdf://Harris et al. - 2007 - American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast ca(6).pdf</url><url>internal-pdf://Harris et al. - 2007 - American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast ca(7).pdf</url><url>internal-pdf://Harris et al. - 2007 - American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast ca(3).pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/17954709</url><url>http://jco.ascopubs.org.pitt.idm.oclc.org/content/25/33/5287.full</url></web-urls></urls><label>NNT paper;Oncotype DX</label><abstract>To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Paik, Soonmyung</author><author>Tang, Gong</author><author>Fumagalli, Debora</author></authors></contributors><titles><title>An ideal prognostic test for estrogen receptor-positive breast cancer?</title><secondary-title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</secondary-title></titles><periodical><full-title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</full-title></periodical><pages>4058-9</pages><volume>26</volume><issue>25</issue><keywords><keyword>Algorithms</keyword><keyword>Biological</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: diagnosis</keyword><keyword>Breast Neoplasms: metabolism</keyword><keyword>Breast Neoplasms: therapy</keyword><keyword>Computer-Assisted</keyword><keyword>Estrogen</keyword><keyword>Estrogen: biosynthesis</keyword><keyword>Gene Expression Regulation</keyword><keyword>Humans</keyword><keyword>Medical Oncology</keyword><keyword>Medical Oncology: methods</keyword><keyword>Models</keyword><keyword>Neoplastic</keyword><keyword>Prognosis</keyword><keyword>Receptors</keyword><keyword>Risk</keyword><keyword>Statistical</keyword><keyword>Therapy</keyword></keywords><dates><year>2008</year></dates><accession-num>18678837</accession-num><electronic-resource-num>10.1200/JCO.2008.16.7528</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Paik, Tang, Fumagalli - 2008 - An ideal prognostic test for estrogen receptor-positive breast cancer.pdf</url><url>internal-pdf://Paik, Tang, Fumagalli - 2008 - An ideal prognostic test for estrogen receptor-positive breast cancer(2).pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/18678837</url></web-urls></urls><label>NNT paper;OncoType DX;Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Cronin, Maureen</author><author>Sangli, Chithra</author><author>Liu, Mei-Lan</author><author>Pho, Mylan</author><author>Dutta, Debjani</author><author>Nguyen, Anhthu</author><author>Jeong, Jennie</author><author>Wu, Jenny</author><author>Langone, Kim Clark</author><author>Watson, Drew</author></authors></contributors><titles><title>Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer.</title><secondary-title>Clinical chemistry</secondary-title></titles><periodical><full-title>Clinical chemistry</full-title></periodical><pages>1084-91</pages><volume>53</volume><issue>6</issue><keywords><keyword>Biological</keyword><keyword>Biological: analysis</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: diagnosis</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Breast Neoplasms: metabolism</keyword><keyword>Estrogen</keyword><keyword>Estrogen: metabolism</keyword><keyword>Female</keyword><keyword>Gene Expression Profiling</keyword><keyword>Gene Expression Profiling: standards</keyword><keyword>Genome</keyword><keyword>Hormone-Dependent</keyword><keyword>Hormone-Dependent: diagnosis</keyword><keyword>Hormone-Dependent: genetics</keyword><keyword>Hormone-Dependent: metabolism</keyword><keyword>Human</keyword><keyword>Humans</keyword><keyword>Likelihood Functions</keyword><keyword>Local</keyword><keyword>Local: diagnosis</keyword><keyword>Molecular Diagnostic Techniques</keyword><keyword>Molecular Diagnostic Techniques: standards</keyword><keyword>Neoplasm Recurrence</keyword><keyword>Neoplasms</keyword><keyword>Prognosis</keyword><keyword>Receptors</keyword><keyword>Reference Standards</keyword><keyword>Reproducibility of Results</keyword><keyword>Reverse Transcriptase Polymerase Chain Reaction</keyword><keyword>Tumor Markers</keyword></keywords><dates><year>2007</year></dates><accession-num>17463177</accession-num><electronic-resource-num>10.1373/clinchem.2006.076497</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Cronin et al. - 2007 - Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic resp(3).pdf</url></pdf-urls><web-urls><url>http://www.clinchem.org/content/53/6/1084.long</url></web-urls></urls><label>Oncotype DX;labratory outcome</label><abstract>Oncotype DX is a clinically validated, high-complexity, multianalyte reverse transcription-PCR genomic test that predicts the likelihood of breast cancer recurrence in early-stage, node-negative, estrogen receptor-positive breast cancer. The Recurrence Score (RS) provides a more accurate, reproducible measure of breast cancer aggressiveness and therapeutic responsiveness than standard measures. Individualized patient management requires strict performance criteria for clinical laboratory tests. We therefore investigated the analytical performance of the assay.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Mamounas, Eleftherios P.</author><author>Tang, Gong</author><author>Fisher, Bernard</author><author>Paik, Soonmyung</author><author>Shak, Steven</author><author>Costantino, Joseph P.</author><author>Watson, Drew</author><author>Geyer, Charles E.</author><author>Wickerham, D. Lawrence</author><author>Wolmark, Norman</author></authors></contributors><titles><title>Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.</title><secondary-title>Journal of Clinical Oncology</secondary-title></titles><periodical><full-title>Journal of Clinical Oncology</full-title></periodical><pages>1677-83</pages><volume>28</volume><issue>10</issue><keywords><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: drug therapy</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Breast Neoplasms: pathology</keyword><keyword>Clinical Trials as Topic</keyword><keyword>Estrogen</keyword><keyword>Estrogen: metabolism</keyword><keyword>Gene Expression Profiling</keyword><keyword>Hormone-Dependent</keyword><keyword>Hormone-Dependent: drug therapy</keyword><keyword>Hormone-Dependent: genetics</keyword><keyword>Hormone-Dependent: pathology</keyword><keyword>Humans</keyword><keyword>Local</keyword><keyword>Local: genetics</keyword><keyword>Lymphatic Metastasis</keyword><keyword>Middle Aged</keyword><keyword>Neoplasm Metastasis</keyword><keyword>Neoplasm Metastasis: genetics</keyword><keyword>Neoplasm Recurrence</keyword><keyword>Neoplasms</keyword><keyword>Receptors</keyword><keyword>Risk Assessment</keyword><keyword>Tamoxifen</keyword><keyword>Tamoxifen: therapeutic use</keyword></keywords><dates><year>2010</year></dates><isbn>0732-183X</isbn><accession-num>20065188</accession-num><electronic-resource-num>10.1200/JCO.2009.23.7610</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Mamounas et al. - 2010 - Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative,(4).pdf</url><url>internal-pdf://Mamounas et al. - 2010 - Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative,(3).pdf</url><url>internal-pdf://Mamounas et al. - 2010 - Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative,(2).pdf</url><url>internal-pdf://JCO-2010-Mamounas-1677-83.pdf</url></pdf-urls><web-urls><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2849763&amp;tool=pmcentrez&amp;rendertype=abstract</url></web-urls></urls><label>NNT paper;OncoType DX;Oncotype DX</label><abstract>The 21-gene OncotypeDX recurrence score (RS) assay quantifies the risk of distant recurrence in tamoxifen-treated patients with node-negative, estrogen receptor (ER)-positive breast cancer. We investigated the association between RS and risk for locoregional recurrence (LRR) in patients with node-negative, ER-positive breast cancer from two National Surgical Adjuvant Breast and Bowel Project (NSABP) trials (NSABP B-14 and B-20).</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Chae, Eun Young</author><author>Moon, Woo Kyung</author><author>Kim, Hak Hee</author><author>Kim, Won Hwa</author><author>Cha, Joo Hee</author><author>Shin, Hee Jung</author><author>Choi, Woo Jung</author><author>Han, Wonshik</author><author>Noh, Dong-Young</author><author>Lee, Sae Byul</author><author>Ahn, Sei Hyun</author></authors></contributors><titles><title>Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer</title><secondary-title>Plos One</secondary-title></titles><periodical><full-title>Plos One</full-title></periodical><pages>e0158461</pages><volume>11</volume><issue>6</issue><keywords/><dates><year>2016</year></dates><electronic-resource-num>10.1371/journal.pone.0158461</electronic-resource-num><urls><pdf-urls><url>internal-pdf://journal.pone.0158461.PDF</url></pdf-urls><web-urls><url>http://dx.plos.org/10.1371/journal.pone.0158461</url></web-urls></urls><label>Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Muniz, Jeanette</author><author>Kidwell, Kelley M.</author><author>Henry, N. Lynn</author></authors></contributors><titles><title>Associations between metabolic syndrome, breast cancer recurrence, and the 21-gene recurrence score assay</title><secondary-title>Breast Cancer Research and Treatment</secondary-title></titles><periodical><full-title>Breast Cancer Research and Treatment</full-title></periodical><pages>597-603</pages><volume>157</volume><issue>3</issue><keywords><keyword>Breast cancer</keyword><keyword>Metabolic syndrome</keyword><keyword>Obesity</keyword><keyword>Recurrence score</keyword><keyword>obesity á breast cancer</keyword><keyword>recurrence score á metabolic</keyword><keyword>syndrome á</keyword></keywords><dates><year>2016</year></dates><publisher>Springer US</publisher><electronic-resource-num>10.1007/s10549-016-3846-4</electronic-resource-num><urls><pdf-urls><url>internal-pdf://art%3A10.1007%2Fs10549-016-3846-4.pdf</url></pdf-urls><web-urls><url>http://link.springer.com/10.1007/s10549-016-3846-4</url></web-urls></urls><label>Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Parisi, Fabio</author><author>González, Ana M</author><author>Nadler, Yasmine</author><author>Camp, Robert L</author><author>Rimm, David L</author><author>Kluger, Harriet M</author><author>Kluger, Yuval</author></authors></contributors><titles><title>Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models</title></titles><periodical/><pages>R66</pages><volume>12</volume><issue>5</issue><keywords/><dates><year>2010</year></dates><isbn>1465-5411</isbn><accession-num>20809974</accession-num><electronic-resource-num>10.1186/bcr2633</electronic-resource-num><urls><pdf-urls><url>internal-pdf://bcr2633.pdf</url><url>internal-pdf://Parisi et al. - 2010 - Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models.pdf</url></pdf-urls></urls><label>Oncotype DX</label><abstract>Introduction: Multi-marker molecular assays have impacted management of early stage breast cancer, facilitating adjuvant chemotherapy decisions. We generated prognostic models that incorporate protein-based molecular markers and clinico-pathological variables to improve survival prediction. Methods: We used a quantitative immunofluorescence method to study protein expression of 14 markers included in the Oncotype DX™ assay on a 638 breast cancer patient cohort with 15-year follow-up. We performed cross-validation analyses to assess performance of multivariate Cox models consisting of these markers and standard clinico-pathological covariates, using an average time-dependent Area Under the Receiver Operating Characteristic curves and compared it to nested Cox models obtained by robust backward selection procedures. Results: A prognostic index derived from of a multivariate Cox regression model incorporating molecular and clinico-pathological covariates (nodal status, tumor size, nuclear grade, and age) is superior to models based on molecular studies alone or clinico-pathological covariates alone. Performance of this composite model can be further improved using feature selection techniques to prune variables. When stratifying patients by Nottingham Prognostic Index (NPI), the most prognostic markers in high and low NPI groups differed. Similarly, for the node-negative, hormone receptor-positive sub-population, we derived a compact model with three clinico-pathological variables and two protein markers that was superior to the full model. Conclusions: Prognostic models that include both molecular and clinico-pathological covariates can be more accurate than models based on either set of features alone. Furthermore, feature selection can decrease the number of molecular variables needed to predict outcome, potentially resulting in less expensive assays.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Kittaneh, Muaiad</author><author>Montero, Alberto J</author></authors></contributors><titles><title>Biomarkers in Cancer Molecular Profiling for Breast Cancer : A Comprehensive Review</title><secondary-title>Biomarkers in Cancer</secondary-title></titles><periodical><full-title>Biomarkers in Cancer</full-title></periodical><pages>61-70</pages><volume>5</volume><keywords><keyword>10</keyword><keyword>4137</keyword><keyword>5 61</keyword><keyword>70 doi</keyword><keyword>a comprehensive review</keyword><keyword>bic</keyword><keyword>biomarkers in cancer 2013</keyword><keyword>cancer</keyword><keyword>citation</keyword><keyword>early breast cancer</keyword><keyword>kittaneh et al</keyword><keyword>mammaprint</keyword><keyword>molecular profiling</keyword><keyword>molecular profiling for breast</keyword><keyword>oncotype dx</keyword><keyword>pam50</keyword><keyword>prognostic and predictive tests</keyword><keyword>s9455</keyword></keywords><dates><year>2013</year></dates><isbn>1179-299X (Print) 1179-299X (Linking)</isbn><accession-num>24250234</accession-num><electronic-resource-num>10.4137/BIC.S9455.TYPE</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Kittaneh, Montero - 2013 - Biomarkers in Cancer Molecular Profiling for Breast Cancer A Comprehensive Review.pdf</url><url>internal-pdf://bic-5-2013-061.pdf</url></pdf-urls></urls><label>Oncotype DX</label><abstract>ABSTRACT: In recent years advances in molecular biology have launched disruptive innovations in breast cancer diagnostics and thera- peutics. The advent of genomics has revolutionized our understanding of breast cancer as several different biologically and molecularly distinct diseases. This research has led to commercially available polymerase chain reaction (PCR) and microarray tests that have begun to fundamentally change the way medical oncologists quantify recurrence risk in early stage breast cancer patients. The Genomics era has altered the clinicopathologic paradigm of selecting patients for adjuvant cytotoxic chemotherapy. Sufficiently powered prospective studies are underway that may establish these molecular assays as elements of standard clinical practice in breast cancer treatment. In this article, we review the strengths and limitations of currently available breast cancer-specific molecular tests.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Puhalla, Shannon L.</author><author>Davidson, Nancy E.</author></authors></contributors><titles><title>Breast cancer: The 21-gene recurrence score — biology remains at the forefront</title><secondary-title>Nature Reviews Clinical Oncology</secondary-title></titles><periodical><full-title>Nature Reviews Clinical Oncology</full-title></periodical><keywords/><dates><year>2016</year></dates><publisher>Nature Publishing Group</publisher><electronic-resource-num>10.1038/nrclinonc.2016.98</electronic-resource-num><urls><pdf-urls><url>internal-pdf://nrclinonc.2016.98.pdf</url></pdf-urls><web-urls><url>http://www.nature.com/doifinder/10.1038/nrclinonc.2016.98</url></web-urls></urls><label>Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Puhalla, Shannon L.</author><author>Davidson, Nancy E.</author></authors></contributors><titles><title>Breast cancer: The 21-gene recurrence score — biology remains at the forefront</title><secondary-title>Nature Reviews Clinical Oncology</secondary-title></titles><periodical><full-title>Nature Reviews Clinical Oncology</full-title></periodical><keywords/><dates><year>2016</year></dates><publisher>Nature Publishing Group</publisher><electronic-resource-num>10.1038/nrclinonc.2016.98</electronic-resource-num><urls><pdf-urls><url>internal-pdf://nrclinonc.2016.98.pdf</url></pdf-urls><web-urls><url>http://www.nature.com/doifinder/10.1038/nrclinonc.2016.98</url></web-urls></urls><label>Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Madden, Stephen F</author><author>Clarke, Colin</author><author>Gaule, Patricia</author><author>Aherne, Sinead T</author><author>O'Donovan, Norma</author><author>Clynes, Martin</author><author>Crown, John</author><author>Gallagher, William M</author></authors></contributors><titles><title>BreastMark : An Integrated Approach to Mining Publicly Available Transcriptomic Datasets Relating to Breast Cancer Outcome</title><secondary-title>Breast Cancer Research</secondary-title></titles><periodical><full-title>Breast Cancer Research</full-title></periodical><pages>R52</pages><volume>15</volume><issue>4</issue><keywords/><dates><year>2013</year></dates><publisher>BioMed Central Ltd</publisher><accession-num>23820017</accession-num><electronic-resource-num>10.1186/bcr3444</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Madden et al. - 2013 - BreastMark an integrated approach to mining publicly available transcriptomic datasets relating to breast canc(2).pdf</url><url>internal-pdf://Madden et al. - 2013 - BreastMark An Integrated Approach to Mining Publicly Available Transcriptomic Datasets Relating to Breast Canc(3).pdf</url><url>internal-pdf://bcr3444.pdf</url><url>internal-pdf://bcr3444-annotated.pdf</url><url>internal-pdf://Madden et al. - 2013 - BreastMark An Integrated Approach to Mining Publicly Available Transcriptomic Datasets Relating to Breast Cancer.pdf</url></pdf-urls><web-urls><url>http://breast-cancer-research.com/content/15/4/R52</url><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3978487&amp;tool=pmcentrez&amp;rendertype=abstract</url></web-urls></urls><label>Oncotype DX</label><abstract>INTRODUCTION: Breast cancer is a complex heterogeneous disease for which a substantial resource of transcriptomic data is available. Gene expression data have facilitated the division of breast cancer into, at least, five molecular subtypes, namely luminal A, luminal B, HER2, normal-like and basal. Once identified, breast cancer subtypes can inform clinical decisions surrounding patient treatment and prognosis. Indeed, it is important to identify patients at risk of developing aggressive disease so as to tailor the level of clinical intervention. METHODS: We have developed a user-friendly, web-based system to allow the evaluation of genes/microRNAs (miRNAs) that are significantly associated with survival in breast cancer and its molecular subtypes. The algorithm combines gene expression data from multiple microarray experiments which frequently also contain miRNA expression information, and detailed clinical data to correlate outcome with gene/miRNA expression levels. This algorithm integrates gene expression and survival data from 26 datasets on 12 different microarray platforms corresponding to approximately 17,000 genes in up to 4,738 samples. In addition, the prognostic potential of 341 miRNAs can be analysed. RESULTS: We demonstrated the robustness of our approach in comparison to two commercially available prognostic tests, oncotype DX and MammaPrint. Our algorithm complements these prognostic tests and is consistent with their findings. In addition, BreastMark can act as a powerful reductionist approach to these more complex gene signatures, eliminating superfluous genes, potentially reducing the cost and complexity of these multi-index assays. Known miRNA prognostic markers, mir-205 and mir-93, were used to confirm the prognostic value of this tool in a miRNA setting. We also applied the algorithm to examine expression of 58 receptor tyrosine kinases in the basal-like subtype, identifying six receptor tyrosine kinases associated with poor disease-free survival and/or overall survival (EPHA5, FGFR1, FGFR3, VEGFR1, PDGFRβ, and TIE1). A web application for using this algorithm is currently available. CONCLUSIONS: BreastMark is a powerful tool for examining putative gene/miRNA prognostic markers in breast cancer. The value of this tool will be in the preliminary assessment of putative biomarkers in breast cancer. It will be of particular use to research groups with limited bioinformatics facilities.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Sun, Z.</author><author>Prat, a.</author><author>Cheang, M. C. U.</author><author>Gelber, R. D.</author><author>Perou, C. M.</author></authors></contributors><titles><title>Chemotherapy benefit for 'ER-positive' breast cancer and contamination of Nonluminal subtypes--waiting for TAILORx and RxPONDER</title><secondary-title>Annals of Oncology</secondary-title></titles><periodical><full-title>Annals of Oncology</full-title></periodical><pages>70-74</pages><volume>26</volume><issue>1</issue><keywords><keyword>basal-like</keyword><keyword>er-positive</keyword><keyword>her2-enriched</keyword><keyword>luminal a</keyword><keyword>luminal b</keyword><keyword>oncotypedx recurrence score</keyword><keyword>pam50</keyword></keywords><dates><year>2014</year></dates><isbn>1617632244</isbn><electronic-resource-num>10.1093/annonc/mdu493</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Sun et al. - 2014 - Chemotherapy benefit for 'ER-positive' breast cancer and contamination of Nonluminal subtypes--waiting for TAILOR(2).pdf</url><url>internal-pdf://Ann Oncol-2015-Sun-70-4.pdf</url><url>internal-pdf://Sun et al. - 2014 - Chemotherapy benefit for 'ER-positive' breast cancer and contamination of Nonluminal subtypes--waiting for TAILORx a.pdf</url></pdf-urls><web-urls><url>http://annonc.oxfordjournals.org/cgi/doi/10.1093/annonc/mdu493</url></web-urls></urls><label>Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Cardoso, Fatima</author><author>Van’t Veer, Laura</author><author>Rutgers, Emiel</author><author>Loi, Sherene</author><author>Mook, Stella</author><author>Piccart-Gebhart, Martine</author></authors></contributors><titles><title>Clinical Application of the 70-Gene Profile : The MINDACT Trial</title><secondary-title>J Clin Oncol</secondary-title></titles><periodical><full-title>J Clin Oncol</full-title></periodical><pages>729-735</pages><volume>26</volume><issue>5</issue><keywords/><dates><year>2014</year></dates><electronic-resource-num>10.1200/JCO.2007.14.3222</electronic-resource-num><urls><pdf-urls><url>internal-pdf://729.full.pdf</url><url>internal-pdf://Cardoso et al. - 2014 - Clinical Application of the 70-Gene Profile The MINDACT Trial.pdf</url></pdf-urls></urls><label>Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Simon, Richard</author></authors></contributors><titles><title>Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology</title><secondary-title>Personalized Med</secondary-title></titles><periodical><full-title>Personalized Med</full-title></periodical><pages>33-47</pages><volume>7</volume><issue>1</issue><keywords><keyword>adaptive design</keyword><keyword>biomarker</keyword><keyword>clinical trial design</keyword><keyword>of a common primary</keyword><keyword>oncology therapeutics today are</keyword><keyword>predictive</keyword><keyword>prognostic</keyword><keyword>site</keyword><keyword>that are molecularly targeted</keyword><keyword>the development of drugs</keyword><keyword>the dominant themes in</keyword><keyword>the molecular heterogeneity of</keyword><keyword>to</keyword><keyword>tumors</keyword><keyword>validation</keyword></keywords><dates><year>2010</year></dates><electronic-resource-num>10.2217/pme.09.49.Clinical</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Simon - 2010 - Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology.pdf</url></pdf-urls></urls><label>NNT paper;Oncotype DX;biomarker;ctde</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Genomic Health, Inc.</author></authors></contributors><titles><title>Clinical Utility, OncoType DX</title><secondary-title>Oncotype DX® Node+ Breast Cancer Clinical Compendium</secondary-title></titles><periodical><full-title>Oncotype DX® Node+ Breast Cancer Clinical Compendium</full-title></periodical><pages>1-28</pages><issue>1</issue><keywords/><dates><year>2012</year></dates><urls><pdf-urls><url>internal-pdf://Genomic Health - 2012 - Clinical Utility, OncoType DX(2).pdf</url></pdf-urls></urls><label>NNT paper;Oncotype DX;oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Burke, Wylie</author><author>Korngiebel, Diane M.</author></authors></contributors><titles><title>Closing the Gap between Knowledge and Clinical Application: Challenges for Genomic Translation</title><secondary-title>PLOS Genetics</secondary-title></titles><periodical><full-title>PLOS Genetics</full-title></periodical><pages>e1004978</pages><volume>11</volume><issue>2</issue><keywords/><dates><year>2015</year></dates><electronic-resource-num>10.1371/journal.pgen.1004978</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Burke, Korngiebel - 2015 - Closing the Gap between Knowledge and Clinical Application Challenges for Genomic Translation(2).pdf</url></pdf-urls><web-urls><url>http://dx.plos.org/10.1371/journal.pgen.1004978</url></web-urls></urls><label>Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Iglehart, J Dirk</author><author>Valero, Monica G</author></authors></contributors><titles><title>Commentary on &quot;The role of the breast cancer surgeon in personalized cancer care: clinical utility of the 21-gene assay&quot;.</title><secondary-title>American journal of surgery</secondary-title></titles><periodical><full-title>American journal of surgery</full-title></periodical><pages>759-60</pages><volume>203</volume><issue>6</issue><keywords><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: surgery</keyword><keyword>Female</keyword><keyword>Genetic Testing</keyword><keyword>Humans</keyword><keyword>Individualized Medicine</keyword><keyword>Medical Oncology</keyword><keyword>Physician's Role</keyword><keyword>Specialties</keyword><keyword>Surgical</keyword></keywords><dates><year>2012</year></dates><publisher>Elsevier Inc.</publisher><accession-num>22494880</accession-num><electronic-resource-num>10.1016/j.amjsurg.2011.09.030</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Iglehart, Valero - 2012 - Commentary on The role of the breast cancer surgeon in personalized cancer care clinical utility of the 21-(3).pdf</url><url>internal-pdf://Iglehart, Valero - 2012 - Commentary on The role of the breast cancer surgeon in personalized cancer care clinical utility of the 21-(2).pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/22494880</url></web-urls></urls><label>NNT paper;OncoType DX;Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Ross, Jeffrey S Js</author><author>Hatzis, Christos</author><author>Symmans, Wf Fraser</author><author>Pusztai, Lajos</author><author>Hortobágyi, Gabriel N</author><author>Hortobagyi, Gabriel N</author></authors></contributors><titles><title>Commercialized multigene predictors of clinical outcome for breast cancer.</title><secondary-title>The Oncologist</secondary-title></titles><periodical><full-title>The Oncologist</full-title></periodical><pages>477-93</pages><volume>13</volume><issue>5</issue><keywords><keyword>Biological</keyword><keyword>Biological: analysis</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: classification</keyword><keyword>Breast Neoplasms: diagnosis</keyword><keyword>Breast Neoplasms: economics</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Cost-Benefit Analysis</keyword><keyword>Device Approval</keyword><keyword>Estrogen</keyword><keyword>Estrogen: analysis</keyword><keyword>Estrogen: genetics</keyword><keyword>Female</keyword><keyword>Gene Expression Profiling</keyword><keyword>Gene Expression Profiling: methods</keyword><keyword>Humans</keyword><keyword>Molecular Diagnostic Techniques</keyword><keyword>Molecular Diagnostic Techniques: standards</keyword><keyword>Paraffin Embedding</keyword><keyword>Predictive Value of Tests</keyword><keyword>Prognosis</keyword><keyword>Receptors</keyword><keyword>Reverse Transcriptase Polymerase Chain Reaction</keyword><keyword>Tumor Markers</keyword><keyword>United States</keyword><keyword>United States Food and Drug Administration</keyword><keyword>all predictors described in</keyword><keyword>and discloses receipt of</keyword><keyword>and mammaprint</keyword><keyword>biosciences</keyword><keyword>breast cancer</keyword><keyword>c</keyword><keyword>discloses that except for</keyword><keyword>disclosure</keyword><keyword>g</keyword><keyword>h</keyword><keyword>intellectual property rights</keyword><keyword>invasiveness signature</keyword><keyword>is employed by</keyword><keyword>mammaprint</keyword><keyword>n</keyword><keyword>nuvoselect</keyword><keyword>oncotype dx</keyword><keyword>owns stock in</keyword><keyword>patent holder in nuvera</keyword><keyword>rotterdam signature</keyword><keyword>the article</keyword><keyword>two-gene expression ratio</keyword></keywords><dates><year>2008</year></dates><accession-num>18515733</accession-num><electronic-resource-num>10.1634/theoncologist.2007-0248</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Ross et al. - 2008 - Commercialized multigene predictors of clinical outcome for breast cancer.pdf</url><url>internal-pdf://The Oncologist-2008-Ross-477-93.pdf</url></pdf-urls><web-urls><url>http://theoncologist.alphamedpress.org/content/13/5/477.short</url><url>http://www.ncbi.nlm.nih.gov/pubmed/18515733</url></web-urls></urls><label>NNT paper;Oncotype DX;biomarker</label><abstract>In the past 5 years, a number of commercialized multigene prognostic and predictive tests have entered the complex and expanding landscape of breast cancer companion diagnostics. These tests have used a variety of formats ranging from the familiar slide-based assays of immunohistochemistry and fluorescence in situ hybridization to the nonmorphology-driven molecular platforms of quantitative multiplex real-time polymerase chain reaction and genomic microarray profiling. In this review, 14 multigene assays are evaluated as to their scientific validation, current clinical utility, regulatory approval status, and estimated cost-benefit ratio. Emphasis is placed on two tests: oncotype DX and MammaPrint. Current evidence indicates that the oncotype DX test has the advantages of earlier commercial launch, wide acceptance for payment by third-party payors in the U.S., ease of use of formalin-fixed paraffin-embedded tissues, recent listing by the American Society of Clinical Oncology Breast Cancer Tumor Markers Update Committee as recommended for use, continuous scoring system algorithm, ability to serve as both a prognostic test and predictive test for certain hormonal and chemotherapeutic agents, demonstrated cost-effectiveness in one published study, and a high accrual rate for the prospective validation clinical trial (Trial Assigning Individualized Options for Treatment). The MammaPrint assay has the advantages of a 510(k) clearance by the U.S. Food and Drug Administration, a larger gene number, which may enhance further utility, and a potentially wider patient eligibility, including lymph node-positive, estrogen receptor (ER)-negative, and younger patients being accrued into the prospective trial (Microarray in Node-Negative Disease May Avoid Chemotherapy). A number of other assays have specific predictive goals that are most often focused on the efficacy of tamoxifen in ER-positive patients, such as the two-gene ratio test and the cytochrome P450 CYP2D6 genotyping assay.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Nguyen, Bichlien</author><author>Cusumano, Pino G</author><author>Deck, Kenneth</author><author>Kerlin, Deborah</author><author>Garcia, Agustin A</author><author>Barone, Julie L</author><author>Rivera, Edgardo</author><author>Yao, Katharine</author><author>de Snoo, Femke a</author><author>van den Akker, Jeroen</author><author>Stork-Sloots, Lisette</author><author>Generali, Daniele</author><author>Snoo, Femke A De</author><author>de Snoo, Femke a</author><author>van den Akker, Jeroen</author><author>Stork-Sloots, Lisette</author><author>Generali, Daniele</author><author>Snoo, Femke A De</author></authors></contributors><titles><title>Comparison of Molecular Subtyping with BluePrint , MammaPrint , and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients</title><secondary-title>Annals of surgical oncology</secondary-title></titles><periodical><full-title>Annals of surgical oncology</full-title></periodical><pages>3257-63</pages><volume>19</volume><issue>10</issue><keywords><keyword>80 and over</keyword><keyword>Adult</keyword><keyword>Aged</keyword><keyword>Biological</keyword><keyword>Biological: genetics</keyword><keyword>Biological: metabolism</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: classification</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Breast Neoplasms: metabolism</keyword><keyword>Breast Neoplasms: pathology</keyword><keyword>Estrogen</keyword><keyword>Estrogen: metabolism</keyword><keyword>Female</keyword><keyword>Fluorescence</keyword><keyword>Gene Expression Profiling</keyword><keyword>Humans</keyword><keyword>Immunoenzyme Techniques</keyword><keyword>In Situ Hybridization</keyword><keyword>Ki-67 Antigen</keyword><keyword>Ki-67 Antigen: metabolism</keyword><keyword>Messenger</keyword><keyword>Messenger: genetics</keyword><keyword>Microarray Analysis</keyword><keyword>Middle Aged</keyword><keyword>Neoplasm Grading</keyword><keyword>Progesterone</keyword><keyword>Progesterone: metabolism</keyword><keyword>Prognosis</keyword><keyword>RNA</keyword><keyword>Receptor</keyword><keyword>Receptors</keyword><keyword>Survival Rate</keyword><keyword>Tumor Markers</keyword><keyword>erbB-2</keyword><keyword>erbB-2: metabolism</keyword></keywords><dates><year>2012</year></dates><accession-num>22965266</accession-num><electronic-resource-num>10.1245/s10434-012-2561-6</electronic-resource-num><urls><pdf-urls><url>internal-pdf://art%3A10.1245%2Fs10434-012-2561-6.pdf</url><url>internal-pdf://artpdfA10.1245annotatedFs10434-012-2561-6-pdf.%4.pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/22965266</url></web-urls></urls><label>Oncotype DX</label><abstract>PURPOSE: To compare breast cancer subtyping with the three centrally assessed microarray-based assays BluePrint, MammaPrint, and TargetPrint with locally assessed clinical subtyping using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).

METHODS: BluePrint, MammaPrint, and TargetPrint were all performed on fresh tumor samples. Microarray analysis was performed at Agendia Laboratories, blinded for clinical and pathological data. IHC/FISH assessments were performed according to local practice at each institution; estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) assessments were performed on 132 samples, and Ki-67 on 79 samples.

RESULTS: The concordance between BluePrint and IHC/FISH subtyping was 94 % for the Luminal-type, 95 % for the HER2-type, and 94 % for the Basal-type subgroups. The concordance of BluePrint with subtyping using mRNA single gene readout (TargetPrint) was 96 % for the Luminal-type, 97 % for the HER2-type, and 98 % for the Basal-type subgroups. The concordance for substratification into Luminal A and B using MammaPrint and Ki-67 was 68 %. The concordance between TargetPrint and IHC/FISH was 97 % for ER, 80 % for PR, and 95 % for HER2.

CONCLUSIONS: The implementation of multigene assays such as TargetPrint, BluePrint, and MammaPrint may improve the clinical management of breast cancer patients. High discordance between Luminal A and B substratification based on MammaPrint versus locally assessed Ki-67 or grade indicates that chemotherapy decisions should not be based on the basis of Ki-67 readout or tumor grade alone. TargetPrint serves as a second opinion for those local pathology settings where high-quality standardization is harder to maintain.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Tsoi, Daphne T</author><author>Inoue, Miho</author><author>Kelly, Catherine M</author><author>Verma, Sunil</author><author>Pritchard, Kathleen I</author></authors></contributors><titles><title>Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer.</title><secondary-title>The oncologist</secondary-title></titles><periodical><full-title>The oncologist</full-title></periodical><pages>457-465</pages><volume>15</volume><issue>5</issue><keywords><keyword>21-gene assay</keyword><keyword>advisory role</keyword><keyword>and free from</keyword><keyword>article has been reviewed</keyword><keyword>astrazeneca</keyword><keyword>by independent peer reviewers</keyword><keyword>catherine m</keyword><keyword>consultant</keyword><keyword>cost-effectiveness analysis</keyword><keyword>daphne t</keyword><keyword>disclosures</keyword><keyword>early breast cancer</keyword><keyword>is balanced</keyword><keyword>kathleen i</keyword><keyword>kelly</keyword><keyword>miho inoue</keyword><keyword>none</keyword><keyword>objective</keyword><keyword>oncotype dx</keyword><keyword>pfizer</keyword><keyword>pritchard</keyword><keyword>roche</keyword><keyword>sunil verma</keyword><keyword>the content of this</keyword><keyword>to ensure that it</keyword><keyword>tsoi</keyword></keywords><dates><year>2010</year></dates><isbn>1549-490X (Electronic)\n1083-7159 (Linking)</isbn><accession-num>20421264</accession-num><electronic-resource-num>10.1634/theoncologist.2009-0275</electronic-resource-num><urls><pdf-urls><url>internal-pdf://onc457.pdf</url></pdf-urls></urls><label>Oncotype DX</label><abstract>PURPOSE: Most guidelines for hormone receptor (HR)-positive early breast cancer recommend addition of adjuvant chemotherapy for most women, leading to overtreatment, which causes considerable morbidity and cost. There has been recent incorporation of gene expression analysis in aiding decision making. We evaluated the cost-effectiveness of recurrence score (RS)-guided treatment using 21-gene assay as compared with treatment guided by the Adjuvant! Online program (AOL). PATIENTS AND METHODS: A Markov model was developed to compare the cost-effectiveness of treatment guided either by 21-gene assay or by AOL in a 50-year-old woman with lymph node-negative HR-positive breast cancer over a lifetime horizon. We assumed that women classified to be at high risk all received chemotherapy followed by tamoxifen and those classified to be at low risk received tamoxifen only. The model took a health care payer's perspective with results reported in 2008 Canadian dollars ($). Event rates, costs, and utilities were derived from the literature. Both costs and benefits were discounted at 5%. Outcome measures were life years gained, quality-adjusted life years (QALYs), lifetime costs, and incremental cost-effectiveness ratios (ICERs). RESULTS: For a 50-year-old woman, RS-guided treatment was associated with an incremental lifetime cost of $4,102 and a gain in 0.065 QALY, with an ICER of $63,064 per QALY compared with AOL-guided treatment. ICER increased with increasing cost of 21-gene assay and increasing age of patients. Results were most sensitive to probabilities relating to risk categorization and recurrence rate. CONCLUSIONS: The 21-gene assay appears cost-effective from a Canadian health care perspective.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Hannouf, Malek B</author><author>Xie, Bin</author><author>Brackstone, Muriel</author><author>Zaric, Gregory S</author></authors></contributors><titles><title>Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.</title><secondary-title>BMC Cancer</secondary-title></titles><periodical><full-title>BMC Cancer</full-title></periodical><pages>447</pages><volume>12</volume><keywords/><dates><year>2012</year></dates><accession-num>23031196</accession-num><electronic-resource-num>10.1186/1471-2407-12-447</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Hannouf et al. - 2012 - Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-(2).pdf</url><url>internal-pdf://Hannouf et al. - 2012 - Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-sta.pdf</url></pdf-urls><web-urls><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3488327&amp;tool=pmcentrez&amp;rendertype=abstract</url></web-urls></urls><label>NNT paper;Oncotype DX</label><abstract>ABSTRACT:</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Retèl, Valesca P</author><author>Joore, Manuela a</author><author>Knauer, Michael</author><author>Linn, Sabine C</author><author>Hauptmann, Michael</author><author>Harten, Wim H Van</author></authors></contributors><titles><title>Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer.</title><secondary-title>European journal of cancer (Oxford, England : 1990)</secondary-title></titles><periodical><full-title>European journal of cancer (Oxford, England : 1990)</full-title></periodical><pages>1382-91</pages><volume>46</volume><issue>8</issue><keywords><keyword>Adjuvant</keyword><keyword>Adjuvant: economics</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: drug therapy</keyword><keyword>Breast Neoplasms: economics</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Breast Neoplasms: mortality</keyword><keyword>Chemotherapy</keyword><keyword>Cost-Benefit Analysis</keyword><keyword>Disease Progression</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Markov Chains</keyword><keyword>Neoplasm Staging</keyword><keyword>Neoplasm Staging: economics</keyword><keyword>Neoplasm Staging: methods</keyword><keyword>Practice Guidelines as Topic</keyword><keyword>Prognosis</keyword><keyword>Sensitivity and Specificity</keyword></keywords><dates><year>2010</year></dates><accession-num>20359886</accession-num><electronic-resource-num>10.1016/j.ejca.2010.02.035</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Retèl et al. - 2010 - Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast (2).pdf</url><url>internal-pdf://1-s2.0-S0959804910001620-main-annotated.pdf</url><url>internal-pdf://Retèl et al. - 2010 - Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast can.pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/20359886</url></web-urls></urls><label>Oncotype DX</label><abstract>BACKGROUND: The 70-gene signature (MammaPrint) is a prognostic test used to guide adjuvant treatment decisions in patients with node-negative breast cancer. In order to decide upon its use, a systematic comparative analysis of the effects of the 70-gene signature, the Sankt Gallen guidelines and the Adjuvant Online Software for these patients on survival, quality of life and costs is warranted.

METHODS: A Markov decision model was used to simulate the 20-year costs and outcomes (survival and quality-of-life adjusted survival (QALYs)) in a hypothetical cohort of node-negative, estrogen receptor positive breast cancer patients. Sensitivity and specificity of the three prognostic tools were based on 5 and 10 years breast cancer specific survival and distant metastasis as first event, derived from a pooled analysis consisting of 305 tumour samples from 3 previously reported validation studies concerning the 70-gene signature.

RESULTS: Small differences in survival, but substantial differences in quality-adjusted survival between the prognostic tools were observed. Quality-adjusted survival was highest when using the 70-gene signature. Based on costs per QALY, the 70-gene has the highest probability of being cost-effective for a willingness to pay for a QALY higher than euro12.000. Sankt Gallen showed the highest survival rates compared to the 70-gene signature, but leads to a substantial larger amount of adjuvant chemotherapy and lower cost-effectiveness, thus demanding a high willingness to pay to save a life year.

CONCLUSIONS: When deciding upon the cost-effectiveness of the prognostic tests, the 70-gene signature improves quality-adjusted survival and has the highest probability of being cost-effective.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Simon, Richard</author></authors></contributors><titles><title>Development and Validation of Biomarker Classifiers for Treatment Selection</title><secondary-title>J Stat Plan Inference</secondary-title></titles><periodical><full-title>J Stat Plan Inference</full-title></periodical><pages>308-320</pages><volume>138</volume><issue>2</issue><keywords><keyword>biomarker</keyword><keyword>clinical trial design</keyword><keyword>dna microarray</keyword><keyword>genomics</keyword><keyword>pharmacogenomics</keyword><keyword>validation</keyword></keywords><dates><year>2008</year></dates><accession-num>19190712</accession-num><electronic-resource-num>10.1016/j.jspi.2007.06.010</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Simon - 2008 - Development and Validation of Biomarker Classifiers for Treatment Selection(2).pdf</url><url>internal-pdf://Simon - 2008 - Development and Validation of Biomarker Classifiers for Treatment Selection(3).pdf</url><url>internal-pdf://Simon - 2008 - Development and Validation of Biomarker Classifiers for Treatment Selection(4).pdf</url></pdf-urls><web-urls><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2344143&amp;tool=pmcentrez&amp;rendertype=abstract</url></web-urls></urls><label>Oncotype DX</label><abstract>Many syndromes traditionally viewed as individual diseases are heterogeneous in molecular pathogenesis and treatment responsiveness. This often leads to the conduct of large clinical trials to identify small average treatment benefits for heterogeneous groups of patients. Drugs that demonstrate effectiveness in such trials may subsequently be used broadly, resulting in ineffective treatment of many patients. New genomic and proteomic technologies provide powerful tools for the selection of patients likely to benefit from a therapeutic without unacceptable adverse events. In spite of the large literature on developing predictive biomarkers, there is considerable confusion about the development and validation of biomarker based diagnostic classifiers for treatment selection. In this paper we attempt to clarify some of these issues and to provide guidance on the design of clinical trials for evaluating the clinical utility and robustness of pharmacogenomic classifiers.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Simon, Richard</author></authors></contributors><titles><title>Development and Validation of Biomarker Classifiers for Treatment Selection</title><secondary-title>J Stat Plan Inference</secondary-title></titles><periodical><full-title>J Stat Plan Inference</full-title></periodical><pages>308-320</pages><volume>138</volume><issue>2</issue><keywords><keyword>biomarker</keyword><keyword>clinical trial design</keyword><keyword>dna microarray</keyword><keyword>genomics</keyword><keyword>pharmacogenomics</keyword><keyword>validation</keyword></keywords><dates><year>2008</year></dates><accession-num>19190712</accession-num><electronic-resource-num>10.1016/j.jspi.2007.06.010</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Simon - 2008 - Development and Validation of Biomarker Classifiers for Treatment Selection(4).pdf</url></pdf-urls><web-urls><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2344143&amp;tool=pmcentrez&amp;rendertype=abstract</url></web-urls></urls><label>Oncotype DX</label><abstract>Many syndromes traditionally viewed as individual diseases are heterogeneous in molecular pathogenesis and treatment responsiveness. This often leads to the conduct of large clinical trials to identify small average treatment benefits for heterogeneous groups of patients. Drugs that demonstrate effectiveness in such trials may subsequently be used broadly, resulting in ineffective treatment of many patients. New genomic and proteomic technologies provide powerful tools for the selection of patients likely to benefit from a therapeutic without unacceptable adverse events. In spite of the large literature on developing predictive biomarkers, there is considerable confusion about the development and validation of biomarker based diagnostic classifiers for treatment selection. In this paper we attempt to clarify some of these issues and to provide guidance on the design of clinical trials for evaluating the clinical utility and robustness of pharmacogenomic classifiers.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Sparano, Joseph a</author><author>Paik, Soonmyung</author></authors></contributors><titles><title>Development of the 21-gene assay and its application in clinical practice and clinical trials</title><secondary-title>Journal of Clinical Oncology</secondary-title></titles><periodical><full-title>Journal of Clinical Oncology</full-title></periodical><pages>721-728</pages><volume>26</volume><issue>5</issue><keywords><keyword>Antineoplastic Agents</keyword><keyword>Antineoplastic Agents: therapeutic use</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: drug therapy</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Clinical Trials as Topic</keyword><keyword>Decision Making</keyword><keyword>Epidemiologic Research Design</keyword><keyword>Estrogen</keyword><keyword>Female</keyword><keyword>Gene Expression Profiling</keyword><keyword>Gene Expression Profiling: methods</keyword><keyword>Hormonal</keyword><keyword>Hormonal: therapeutic use</keyword><keyword>Humans</keyword><keyword>Postmarketing</keyword><keyword>Predictive Value of Tests</keyword><keyword>Product Surveillance</keyword><keyword>Prognosis</keyword><keyword>Receptors</keyword><keyword>Validation Studies as Topic</keyword></keywords><dates><year>2008</year></dates><accession-num>18258979</accession-num><electronic-resource-num>10.1200/JCO.2007.15.1068</electronic-resource-num><urls><pdf-urls><url>internal-pdf://721.full.pdf</url><url>internal-pdf://Sparano, Paik - 2008 - Development of the 21-gene assay and its application in clinical practice and clinical trials(2).pdf</url><url>internal-pdf://Sparano, Paik - 2008 - Development of the 21-gene assay and its application in clinical practice and clinical trials.pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/18258979</url></web-urls></urls><label>Oncotype DX</label><abstract>Several multigene markers that predict relapse more accurately than classical clinicopathologic features have been developed. The 21-gene assay was developed specifically for patients with estrogen receptor (ER)-positive breast cancer, and has been shown to predict distant recurrence more accurately that classical clinicopathologic features in patients with ER-positive breast cancer and negative axillary nodes treated with adjuvant tamoxifen; validation studies in this population led to its approval as a diagnostic test. In a similar population, it also may be used to assess the benefit of adding chemotherapy to hormonal therapy. Other validation studies indicate that it also predicts the risk of distant and local recurrence in other populations with ER-positive disease, including node-negative patients receiving no adjuvant therapy and patients with positive axillary nodes treated with doxorubicin-containing chemotherapy. The Trial Assigning Individualized Options for Treatment (TAILORx) is multicenter trial that integrates the 21-gene assay into the clinical decision-making process and is designed to refine the utility of the assay in clinical practice and to provide a resource for evaluating additional molecular markers as they are developed in the future.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Report">10</ref-type><contributors><authors><author>NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE)</author></authors></contributors><titles><title>Diagnostics consultation document Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management : Provisional recommendations C</title></titles><periodical/><pages>1-43</pages><issue>January</issue><keywords/><dates><year>2012</year></dates><urls><pdf-urls><url>internal-pdf://Dx - 2012 - NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Diagnostics consultation document Gene expression profiling and exp(3).pdf</url><url>internal-pdf://Dx - 2012 - NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Diagnostics consultation document Gene expression profiling and expand.pdf</url><url>internal-pdf://Dx - 2012 - NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Diagnostics consultation document Gene expression profiling and exp(2).pdf</url></pdf-urls></urls><label>Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Asad, Juhi</author><author>Jacobson, Allyson F</author><author>Estabrook, Alison</author><author>Smith, Sharon Rosenbaum</author><author>Boolbol, Susan K</author><author>Feldman, Sheldon M</author><author>Osborne, Michael P</author><author>Boachie-Adjei, Kwadwo</author><author>Twardzik, Wendy</author><author>Tartter, Paul I</author></authors></contributors><titles><title>Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?</title><secondary-title>American journal of surgery</secondary-title></titles><periodical><full-title>American journal of surgery</full-title></periodical><pages>527-9</pages><volume>196</volume><issue>4</issue><keywords><keyword>Adjuvant</keyword><keyword>Adult</keyword><keyword>Aged</keyword><keyword>Biological</keyword><keyword>Biological: analysis</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: diagnosis</keyword><keyword>Breast Neoplasms: drug therapy</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Breast Neoplasms: metabolism</keyword><keyword>Chemotherapy</keyword><keyword>Decision Making</keyword><keyword>Estrogen</keyword><keyword>Estrogen: metabolism</keyword><keyword>Female</keyword><keyword>Gene Expression Profiling</keyword><keyword>Gene Expression Profiling: methods</keyword><keyword>Hormone-Dependent</keyword><keyword>Hormone-Dependent: diagnosis</keyword><keyword>Hormone-Dependent: drug therapy</keyword><keyword>Hormone-Dependent: genetics</keyword><keyword>Hormone-Dependent: metabolism</keyword><keyword>Humans</keyword><keyword>Local</keyword><keyword>Local: diagnosis</keyword><keyword>Local: drug therapy</keyword><keyword>Middle Aged</keyword><keyword>Molecular Diagnostic Techniques</keyword><keyword>Molecular Diagnostic Techniques: methods</keyword><keyword>Neoplasm Recurrence</keyword><keyword>Neoplasm Staging</keyword><keyword>Neoplasms</keyword><keyword>Prognosis</keyword><keyword>Receptors</keyword><keyword>Reproducibility of Results</keyword><keyword>Retrospective Studies</keyword><keyword>Risk Assessment</keyword><keyword>Tumor Markers</keyword></keywords><dates><year>2008</year></dates><accession-num>18809056</accession-num><electronic-resource-num>10.1016/j.amjsurg.2008.06.021</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Asad et al. - 2008 - Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer(2).pdf</url><url>internal-pdf://Asad et al. - 2008 - Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer(3).pdf</url><url>internal-pdf://Asad et al. - 2008 - Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer.pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/18809056</url></web-urls></urls><label>Oncotype DX</label><abstract>Oncotype DX is a 21-gene assay that calculates a risk of distant recurrence in women with estrogen-receptor-positive, lymph node-negative breast cancer. The purpose of this study was to determine whether the results of Oncotype DX influence the decision to administer chemotherapy.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Kondo, Masahide</author><author>Hoshi, Shu-Ling</author><author>Ishiguro, Hiroshi</author><author>Toi, Masakazu</author></authors></contributors><titles><title>Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan.</title><secondary-title>Breast cancer research and treatment</secondary-title></titles><periodical><full-title>Breast cancer research and treatment</full-title></periodical><pages>759-68</pages><volume>133</volume><issue>2</issue><keywords><keyword>70-gene prognosis-signature</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: diagnosis</keyword><keyword>Breast Neoplasms: economics</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Cost-Benefit Analysis</keyword><keyword>Decision Trees</keyword><keyword>Female</keyword><keyword>Gene Expression Profiling</keyword><keyword>Gene Expression Profiling: economics</keyword><keyword>Humans</keyword><keyword>Japan</keyword><keyword>Lymph Nodes</keyword><keyword>Lymph Nodes: pathology</keyword><keyword>Neoplasm Staging</keyword><keyword>Prognosis</keyword><keyword>Receptor</keyword><keyword>Receptors</keyword><keyword>Recurrence</keyword><keyword>Steroid</keyword><keyword>Steroid: analysis</keyword><keyword>adjuvant therapy á breast</keyword><keyword>cancer á</keyword><keyword>cost-effectiveness á gene diagnosis</keyword><keyword>erbB-2</keyword><keyword>erbB-2: analysis</keyword><keyword>á</keyword></keywords><dates><year>2012</year></dates><accession-num>22315134</accession-num><electronic-resource-num>10.1007/s10549-012-1979-7</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Hoshi, Á - 2012 - Economic evaluation of the 70-gene prognosis-signature ( MammaPrint Ò ) in hormone receptor-positive , lymph node-ne.pdf</url><url>internal-pdf://Kondo et al. - 2012 - Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-neg.pdf</url><url>internal-pdf://Hoshi, Á - 2012 - Economic evaluation of the 70-gene prognosis-signature ( MammaPrint Ò ) in hormone receptor-positive , lymph node(2).pdf</url><url>internal-pdf://art%3A10.1007%2Fs10549-012-1979-7.pdf</url><url>internal-pdf://artpdfA10.1007annotatedFs10549-012-1979-7-pdf.%4.pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/22315134</url></web-urls></urls><label>Oncotype DX</label><abstract>The 70-gene prognosis-signature is validated as a good predictor of recurrence for hormone receptor-positive (ER+), lymph node-negative (LN-), human epidermal growth factor receptor type 2-negative (HER2-) early stage breast cancer (ESBC) in Japanese patient population. Its high cost and potential in avoiding unnecessary adjuvant chemotherapy arouse interest in its economic impact. This study evaluates the cost-effectiveness of including the assay into Japan's social health insurance benefit package. An economic decision tree and Markov model under Japan's health system from the societal perspective is constructed with clinical evidence from the pool analysis of validation studies. One-way sensitivity analyses are also performed. Incremental cost-effectiveness ratio is estimated as ¥3,873,922/quality adjusted life year (QALY) (US$43,044/QALY), which is not more than the suggested social willingness-to-pay for one QALY gain from an innovative medical intervention in Japan, ¥5,000,000/QALY (US$55,556/QALY). However, sensitivity analyses show the instability of this estimation. The introduction of the assay into Japanese practice of ER+, LN-, HER2- ESBC treatment by including it to Japan's social health insurance benefit package has a reasonable chance to be judged as cost-effective and may be justified as an efficient deployment of finite health care resources.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Book">1</ref-type><contributors><authors><author>Micheel, Christine M</author><author>Nass, Sharly J</author><author>Omenn, Gilbert S</author><author>Policy, Health Sciences</author></authors></contributors><titles><title>Evolution of Translational Omics Lessons Learned and the Path Forward</title></titles><periodical/><keywords/><dates><year>2012</year></dates><isbn>9780309224185</isbn><urls><pdf-urls><url>internal-pdf://Micheel et al. - 2012 - Evolution of Translational Omics Lessons Learned and the Path Forward(3).pdf</url><url>internal-pdf://Micheel et al. - 2012 - Evolution of Translational Omics Lessons Learned and the Path Forward(2).pdf</url><url>internal-pdf://Micheel et al. - 2012 - Evolution of Translational Omics Lessons Learned and the Path Forward.pdf</url></pdf-urls></urls><label>Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Paik, Soonmyung</author><author>Tang, Gong</author><author>Shak, Steven</author><author>Kim, Chungyeul</author><author>Baker, Joffre</author><author>Kim, Wanseop</author><author>Cronin, Maureen</author><author>Baehner, Frederick L</author><author>Watson, Drew</author><author>Bryant, John</author><author>Costantino, Joseph P</author><author>Geyer, Charles E</author><author>Wickerham, D Lawrence</author><author>Wolmark, Norman</author></authors></contributors><titles><title>Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.</title><secondary-title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</secondary-title></titles><periodical><full-title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</full-title></periodical><pages>3726-34</pages><volume>24</volume><issue>23</issue><keywords><keyword>Adult</keyword><keyword>Aged</keyword><keyword>Antineoplastic Combined Chemotherapy Protocols</keyword><keyword>Antineoplastic Combined Chemotherapy Protocols: ad</keyword><keyword>Antineoplastic Combined Chemotherapy Protocols: th</keyword><keyword>Biological</keyword><keyword>Biological: metabolism</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: drug therapy</keyword><keyword>Breast Neoplasms: metabolism</keyword><keyword>Breast Neoplasms: pathology</keyword><keyword>Breast Neoplasms: prevention &amp; control</keyword><keyword>Cisplatin</keyword><keyword>Cisplatin: administration &amp; dosage</keyword><keyword>Estrogen</keyword><keyword>Estrogen: metabolism</keyword><keyword>Female</keyword><keyword>Fluorouracil</keyword><keyword>Fluorouracil: administration &amp; dosage</keyword><keyword>Gene Expression Regulation</keyword><keyword>Humans</keyword><keyword>Linear Models</keyword><keyword>Local</keyword><keyword>Local: metabolism</keyword><keyword>Local: prevention &amp; control</keyword><keyword>Lymphatic Metastasis</keyword><keyword>Methotrexate</keyword><keyword>Methotrexate: administration &amp; dosage</keyword><keyword>Middle Aged</keyword><keyword>Mitomycins</keyword><keyword>Mitomycins: administration &amp; dosage</keyword><keyword>Neoplasm Proteins</keyword><keyword>Neoplasm Proteins: metabolism</keyword><keyword>Neoplasm Recurrence</keyword><keyword>Neoplastic</keyword><keyword>Odds Ratio</keyword><keyword>Predictive Value of Tests</keyword><keyword>Prognosis</keyword><keyword>Proportional Hazards Models</keyword><keyword>Randomized Controlled Trials as Topic</keyword><keyword>Receptors</keyword><keyword>Recurrence</keyword><keyword>Recurrence: prevention &amp; control</keyword><keyword>Reverse Transcriptase Polymerase Chain Reaction</keyword><keyword>Risk Assessment</keyword><keyword>Risk Factors</keyword><keyword>Tamoxifen</keyword><keyword>Tamoxifen: administration &amp; dosage</keyword><keyword>Tumor Markers</keyword></keywords><dates><year>2006</year></dates><accession-num>16720680</accession-num><electronic-resource-num>10.1200/JCO.2005.04.7985</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Paik et al. - 2006 - Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.pdf</url><url>internal-pdf://Paik et al. - 2006 - Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cance(2).pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/16720680</url></web-urls></urls><label>NNT paper;OncoType DX;Oncotype DX</label><abstract>The 21-gene recurrence score (RS) assay quantifies the likelihood of distant recurrence in women with estrogen receptor-positive, lymph node-negative breast cancer treated with adjuvant tamoxifen. The relationship between the RS and chemotherapy benefit is not known.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Gianni, Luca</author><author>Zambetti, Milvia</author><author>Clark, Kim</author><author>Baker, Joffre</author><author>Cronin, Maureen</author><author>Wu, Jenny</author><author>Mariani, Gabriella</author><author>Rodriguez, Jaime</author><author>Carcangiu, Marialuisa</author><author>Watson, Drew</author><author>Valagussa, Pinuccia</author><author>Rouzier, Roman</author><author>Symmans, W. Fraser</author><author>Ross, Jeffrey S.</author><author>Hortobagyi, Gabriel N.</author><author>Pusztai, Lajos</author><author>Shak, Steven</author></authors></contributors><titles><title>Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer</title><secondary-title>Journal of Clinical Oncology</secondary-title></titles><periodical><full-title>Journal of Clinical Oncology</full-title></periodical><pages>7265-7277</pages><volume>23</volume><issue>29</issue><keywords/><dates><year>2005</year></dates><isbn>0732-183X</isbn><accession-num>16145055</accession-num><electronic-resource-num>10.1200/JCO.2005.02.0818</electronic-resource-num><urls><pdf-urls><url>internal-pdf://JCO-2005-Gianni-7265-77.pdf</url></pdf-urls></urls><label>Oncotype DX</label><abstract>PURPOSE: We sought to identify gene expression markers that predict the likelihood of chemotherapy response. We also tested whether chemotherapy response is correlated with the 21-gene Recurrence Score assay that quantifies recurrence risk. METHODS: Patients with locally advanced breast cancer received neoadjuvant paclitaxel and doxorubicin. RNA was extracted from the pretreatment formalin-fixed paraffin-embedded core biopsies. The expression of 384 genes was quantified using reverse transcriptase polymerase chain reaction and correlated with pathologic complete response (pCR). The performance of genes predicting for pCR was tested in patients from an independent neoadjuvant study where gene expression was obtained using DNA microarrays. RESULTS:Of 89 assessable patients (mean age, 49.9 years; mean tumor size, 6.4 cm), 11 (12%) had a pCR. Eighty-six genes correlated with pCR (unadjusted P &lt; .05); pCR was more likely with higher expression of proliferation-related genes and immune-related genes, and with lower expression of estrogen receptor (ER) -related genes. In 82 independent patients treated with neoadjuvant paclitaxel and doxorubicin, DNA microarray data were available for 79 of the 86 genes. In univariate analysis, 24 genes correlated with pCR with P &lt; .05 (false discovery, four genes) and 32 genes showed correlation with P &lt; .1 (false discovery, eight genes). The Recurrence Score was positively associated with the likelihood of pCR (P = .005), suggesting that the patients who are at greatest recurrence risk are more likely to have chemotherapy benefit. CONCLUSION: Quantitative expression of ER-related genes, proliferation genes, and immune-related genes are strong predictors of pCR in women with locally advanced breast cancer receiving neoadjuvant anthracyclines and paclitaxel.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Subramanian, Jyothi</author><author>Simon, Richard</author></authors></contributors><titles><title>Gene expression-based prognostic signatures in lung cancer: ready for clinical use?</title><secondary-title>Journal of the National Cancer Institute</secondary-title></titles><periodical><full-title>Journal of the National Cancer Institute</full-title></periodical><pages>464-74</pages><volume>102</volume><issue>7</issue><keywords><keyword>Adjuvant</keyword><keyword>Animals</keyword><keyword>Biological</keyword><keyword>Biological: metabolism</keyword><keyword>Carcinoma</keyword><keyword>Chemotherapy</keyword><keyword>Clinical Trials as Topic</keyword><keyword>Gene Expression Profiling</keyword><keyword>Gene Expression Regulation</keyword><keyword>Humans</keyword><keyword>Kaplan-Meier Estimate</keyword><keyword>Lung Neoplasms</keyword><keyword>Lung Neoplasms: drug therapy</keyword><keyword>Lung Neoplasms: metabolism</keyword><keyword>Lung Neoplasms: pathology</keyword><keyword>Lung Neoplasms: surgery</keyword><keyword>Lung Neoplasms: therapy</keyword><keyword>Neoplasm Staging</keyword><keyword>Neoplastic</keyword><keyword>Non-Small-Cell Lung</keyword><keyword>Non-Small-Cell Lung: metabolism</keyword><keyword>Non-Small-Cell Lung: therapy</keyword><keyword>Predictive Value of Tests</keyword><keyword>Prognosis</keyword><keyword>Proportional Hazards Models</keyword><keyword>Reproducibility of Results</keyword><keyword>Research Design</keyword><keyword>Risk Factors</keyword><keyword>Tumor Markers</keyword></keywords><dates><year>2010</year></dates><accession-num>20233996</accession-num><electronic-resource-num>10.1093/jnci/djq025</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Subramanian, Simon - 2010 - Gene expression-based prognostic signatures in lung cancer ready for clinical use(3).bin</url><url>internal-pdf://Subramanian, Simon - 2010 - Gene expression-based prognostic signatures in lung cancer ready for clinical use.bin</url><url>internal-pdf://Subramanian, Simon - 2010 - Gene expression-based prognostic signatures in lung cancer ready for clinical use(2).bin</url></pdf-urls><web-urls><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2902824&amp;tool=pmcentrez&amp;rendertype=abstract</url></web-urls></urls><label>NNT paper;Oncotype DX;biomarker</label><abstract>A substantial number of studies have reported the development of gene expression-based prognostic signatures for lung cancer. The ultimate aim of such studies should be the development of well-validated clinically useful prognostic signatures that improve therapeutic decision making beyond current practice standards. We critically reviewed published studies reporting the development of gene expression-based prognostic signatures for non-small cell lung cancer to assess the progress made toward this objective. Studies published between January 1, 2002, and February 28, 2009, were identified through a PubMed search. Following hand-screening of abstracts of the identified articles, 16 were selected as relevant. Those publications were evaluated in detail for appropriateness of the study design, statistical validation of the prognostic signature on independent datasets, presentation of results in an unbiased manner, and demonstration of medical utility for the new signature beyond that obtained using existing treatment guidelines. Based on this review, we found little evidence that any of the reported gene expression signatures are ready for clinical application. We also found serious problems in the design and analysis of many of the studies. We suggest a set of guidelines to aid the design, analysis, and evaluation of prognostic signature studies. These guidelines emphasize the importance of focused study planning to address specific medically important questions and the use of unbiased analysis methods to evaluate whether the resulting signatures provide evidence of medical utility beyond standard of care-based prognostic factors.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Rodenhiser, David I</author><author>Andrews, Joseph D</author><author>Vandenberg, Theodore A</author><author>Chambers, Ann F</author></authors></contributors><titles><title>Gene signatures of breast cancer progression and metastasis.</title><secondary-title>Breast cancer research : BCR</secondary-title></titles><periodical><full-title>Breast cancer research : BCR</full-title></periodical><pages>201</pages><volume>13</volume><issue>1</issue><keywords/><dates><year>2011</year></dates><accession-num>21345283</accession-num><electronic-resource-num>10.1186/bcr2791</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Rodenhiser et al. - 2011 - Gene signatures of breast cancer progression and metastasis(3).pdf</url><url>internal-pdf://Rodenhiser et al. - 2011 - Gene signatures of breast cancer progression and metastasis.pdf</url><url>internal-pdf://Rodenhiser et al. - 2011 - Gene signatures of breast cancer progression and metastasis(2).pdf</url></pdf-urls><web-urls><url>http://breast-cancer-research.com/content/13/1/201</url></web-urls></urls><label>NNT paper;Oncotype DX;biomarker</label><abstract>Breast cancer is a heterogeneous disease. Patient outcome varies significantly, depending on prognostic features of patients and their tumors, including patient age, menopausal status, tumor size and histology, nodal status, and so on. Response to treatment also depends on a series of predictive factors, such as hormone receptor and HER2 status. Current treatment guidelines use these features to determine treatment. However, these guidelines are imperfect, and do not always predict response to treatment or survival. Evolving technologies are permitting increasingly large amounts of molecular data to be obtained from tumors, which may enable more personalized treatment decisions to be made. The challenge is to learn what information leads to improved prognostic accuracy and treatment outcome for individual patients.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Kim, Chungyeul</author><author>Paik, Soonmyung</author></authors></contributors><titles><title>Gene-expression-based prognostic assays for breast cancer.</title><secondary-title>Nature reviews. Clinical oncology</secondary-title></titles><periodical><full-title>Nature reviews. Clinical oncology</full-title></periodical><pages>340-7</pages><volume>7</volume><issue>6</issue><keywords><keyword>Biological Assay</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: diagnosis</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Female</keyword><keyword>Gene Expression</keyword><keyword>Gene Expression Profiling</keyword><keyword>Gene Expression Profiling: methods</keyword><keyword>Humans</keyword><keyword>Microarray Analysis</keyword><keyword>Prognosis</keyword></keywords><dates><year>2010</year></dates><publisher>Nature Publishing Group</publisher><accession-num>20440284</accession-num><electronic-resource-num>10.1038/nrclinonc.2010.61</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Kim, Paik - 2010 - Gene-expression-based prognostic assays for breast cancer.pdf</url><url>internal-pdf://Kim, Paik - 2010 - Gene-expression-based prognostic assays for breast cancer(2).pdf</url><url>internal-pdf://Kim, Paik - 2010 - Gene-expression-based prognostic assays for breast cancer(3).pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/20440284</url></web-urls></urls><label>GI SPORE;NNT paper;OncoType DX;Oncotype DX</label><abstract>Several gene-expression-based reference laboratory tests are now available for prognostication of patients diagnosed with breast cancer. For clinical oncologists, it is important to understand the clinical contexts for which these assays were developed in order to use them properly. This Review is aimed at providing a conceptual and technical overview of the steps involved in the development of gene-expression profiling-based prognostic assays. MammaPrint and Oncotype DX, two widely utilized assays, are compared with respect to differences in the clinical contexts for their development, technologies used, and clinical utilities with the aim of providing a guide to clinical oncologists for utilization of these assays.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Web Page">16</ref-type><contributors><authors><author>Cigna</author></authors></contributors><titles><title>Genetic Expression Assays for Breast Cancer Prognosis</title></titles><periodical/><keywords/><dates><year>2012</year></dates><notes>From Duplicate 1 (Genetic Expression Assays for Breast Cancer Prognosis - Cigna)

From Duplicate 2 (Genetic Expression Assays for Breast Cancer Prognosis - Cigna)

Cigna Medical Coverage Policy

From Duplicate 2 (Genetic Expression Assays for Breast Cancer Prognosis - Cigna)

Cigna Medical Coverage Policy</notes><research-notes>From Duplicate 1 (Genetic Expression Assays for Breast Cancer Prognosis - Cigna)

From Duplicate 2 (Genetic Expression Assays for Breast Cancer Prognosis - Cigna)

Cigna Medical Coverage Policy

From Duplicate 2 (Genetic Expression Assays for Breast Cancer Prognosis - Cigna)

Cigna Medical Coverage Policy</research-notes><urls><pdf-urls><url>internal-pdf://Cigna - Unknown - Genetic Expression Assays for Breast Cancer Prognosis.html</url><url>internal-pdf://Prognosis - 2013 - Cigna Medical Coverage Policy.pdf</url><url>internal-pdf://Cigna Medical Coverage Policy - 2012 - Genetic Expression Assays for Breast Cancer Prognosis.pdf</url></pdf-urls><web-urls><url>http://www.cigna.com/assets/docs/health-care-professionals/coverage_positions/mm_0298_coveragepositioncriteria_assay_genetic_expr_breast_cancer_patients.pdf</url></web-urls></urls><label>NNT paper;Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Report">10</ref-type><contributors><authors><author>Cigna Medical Coverage Policy</author></authors></contributors><titles><title>Genetic Expression Assays for Breast Cancer Prognosis</title></titles><periodical/><keywords/><dates><year>2012</year></dates><urls><pdf-urls><url>internal-pdf://Prognosis - 2013 - Cigna Medical Coverage Policy.pdf</url></pdf-urls></urls><label>NNT paper;Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Unpublished Work">37</ref-type><contributors><authors><author>Day, Roger S.</author></authors></contributors><titles><title>Grant application</title></titles><periodical/><keywords/><urls><pdf-urls><url>internal-pdf://The et al. - Unknown - fit t s m(2).pdf</url><url>internal-pdf://The et al. - Unknown - fit t s m(3).pdf</url><url>internal-pdf://Day - Unknown - Grant application.pdf</url></pdf-urls></urls><label>Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Unpublished Work">37</ref-type><contributors><authors><author>Day, Roger</author></authors></contributors><titles><title>grant proposal oncotcap in breast cancer</title></titles><periodical/><keywords/><urls><pdf-urls><url>internal-pdf://The et al. - Unknown - fit t s m(3).pdf</url></pdf-urls></urls><label>Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Retèl, Valesca P</author><author>Joore, Manuela a</author><author>van Harten, Wim H</author></authors></contributors><titles><title>Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance.</title><secondary-title>Breast cancer research and treatment</secondary-title></titles><periodical><full-title>Breast cancer research and treatment</full-title></periodical><pages>627-36</pages><volume>131</volume><issue>2</issue><keywords><keyword>Adjuvant</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: diagnosis</keyword><keyword>Breast Neoplasms: drug therapy</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Chemotherapy</keyword><keyword>Cost-Benefit Analysis</keyword><keyword>Decision Support Techniques</keyword><keyword>Female</keyword><keyword>Gene Expression Profiling</keyword><keyword>Gene Expression Profiling: economics</keyword><keyword>Gene Expression Profiling: methods</keyword><keyword>Guideline Adherence</keyword><keyword>Humans</keyword><keyword>Prognosis</keyword><keyword>Sensitivity and Specificity</keyword></keywords><dates><year>2012</year></dates><accession-num>21947677</accession-num><electronic-resource-num>10.1007/s10549-011-1769-7</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Retèl, Joore, van Harten - 2012 - Head-to-head comparison of the 70-gene signature versus the 21-gene assay cost-effectiveness and t(3).pdf</url><url>internal-pdf://artpdfA10.1007annotatedFs10549-011-1769-7-pdf.%4.pdf</url><url>internal-pdf://Retèl, Joore, van Harten - 2012 - Head-to-head comparison of the 70-gene signature versus the 21-gene assay cost-effectiveness and the.pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/21947677</url></web-urls></urls><label>Oncotype DX</label><abstract>Both the 70-gene signature and the 21-gene assay are novel prognostic tests used to guide adjuvant chemotherapy decisions in patients with early breast cancer. Although the results of ongoing prospective trials will only become available in some years, the tests have already been included in clinical guidelines such as St. Gallen's. In literature, the cost-effectiveness (CE) of both tests as compared to conventional prognostic tests has been described. We report on a direct comparison of CE; as different compliance rates were reported, we also taken these into account. A Markov decision model with a time horizon of 20 years was developed to assess the effects, costs and CE of three alternatives; 21-gene, 70-gene, and St. Gallen (SG) or Adjuvant Online (AO), dependent on the dataset used in patients with early, node-negative, breast cancer. Sensitivity and specificity were based on two datasets, incorporating compliances rates based on literature. For both datasets, whereas the 70-gene signature yielded more quality adjusted life years (QALYs) and was less costly; the 21-gene amounted more life years (LYs) but was more costly. The decision uncertainty surrounding the probability of CE of the Thomassen-series amounted 55% for both cost/LY and cost/QALY, for the Fan-series 80% for LY and 65% for QALYs. Taking reported compliance with discordant test results into account, in general, the effect of all strategies decreased, while the costs increased, without relatively influencing the CEA performance. This comparison indicates that the performances of the 70-gene and the 21-gene based on reported studies are close. The 21-gene has the highest probability of being cost-effective when focusing on cost/LY, while focusing on cost/QALY, the 70-gene signature was most cost-effective. The level of compliance can have serious impact on the CE. With additional data, preferably from head-to-head outcome studies and especially on compliance concerning discordant test results, calculations can be made with higher degrees of certainty.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Flanagan, Melina B</author><author>Dabbs, David J</author><author>Brufsky, Adam M</author><author>Beriwal, Sushil</author><author>Bhargava, Rohit</author></authors></contributors><titles><title>Histopathologic variables predict Oncotype DX recurrence score.</title><secondary-title>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</secondary-title></titles><periodical><full-title>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</full-title></periodical><pages>1255-1261</pages><volume>21</volume><issue>10</issue><keywords><keyword>40</keyword><keyword>460</keyword><keyword>480 new cases and</keyword><keyword>breast cancer</keyword><keyword>breast cancer is the</keyword><keyword>cancer death among women</keyword><keyword>most frequent cancer and</keyword><keyword>most frequent cause of</keyword><keyword>onco type dx t</keyword><keyword>recurrence score</keyword><keyword>second</keyword><keyword>with an estimated 178</keyword></keywords><dates><year>2008</year></dates><isbn>1530-0285 (Electronic)</isbn><accession-num>18360352</accession-num><electronic-resource-num>10.1038/modpathol.2008.54</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Flanagan et al. - 2008 - Histopathologic variables predict Oncotype DX recurrence score.pdf</url></pdf-urls></urls><label>Oncotype DX</label><abstract>Oncotype DX is a commercially available reverse transcriptase-polymerase chain reaction based assay that provides a Recurrence Score (RS) and has been shown to provide prognostic and predictive information in estrogen receptor-positive lymph node-negative breast cancers. Independent studies of its utility in routine practice are lacking. Slides and surgical pathology reports from 42 cases of breast carcinomas evaluated by Oncotype DX were retrospectively reviewed to determine patient age, tumor size, histologic grade, estrogen and progesterone receptor (ER and PR) and ERBB2 (HER-2/neu) data, with ER and PR reported as a semi-quantitative score reflecting both intensity of staining and proportion of positive cells. We show here that Recurrence Score is significantly correlated with tubule formation, nuclear grade, mitotic count, ER immunohistochemical score, PR immunohistochemical score, and HER-2/neu status, and that the equation RS=13.424+5.420 (nuclear grade) +5.538 (mitotic count) -0.045 (ER immunohistochemical score) -0.030 (PR immunohistochemical score) +9.486 (HER-2/neu) predicts the Recurrence Score with an R2 of 0.66, indicating that the full model accounts for 66% of the data variability. Although the Oncotype DX Recurrence Score holds potential, further validation of its independent value beyond that of histopathologic analysis is necessary before it can be implemented in clinical decision making.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Knauer, M</author><author>Cardoso, F</author><author>Wesseling, J</author><author>Bedard, P L</author><author>Linn, S C</author><author>Rutgers, E J T</author><author>van 't Veer, L J</author></authors></contributors><titles><title>Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.</title><secondary-title>British journal of cancer</secondary-title></titles><periodical><full-title>British journal of cancer</full-title></periodical><pages>1788-93</pages><volume>103</volume><issue>12</issue><keywords><keyword>Adult</keyword><keyword>Aged</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: drug therapy</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Breast Neoplasms: mortality</keyword><keyword>Female</keyword><keyword>Gene Expression Profiling</keyword><keyword>Humans</keyword><keyword>Middle Aged</keyword><keyword>Prognosis</keyword><keyword>Proportional Hazards Models</keyword><keyword>Receptor</keyword><keyword>erbB-2</keyword><keyword>erbB-2: analysis</keyword></keywords><dates><year>2010</year></dates><accession-num>21081926</accession-num><electronic-resource-num>10.1038/sj.bjc.6605916</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Knauer et al. - 2010 - Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.pdf</url><url>internal-pdf://Knauer et al. - 2010 - Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature(2).pdf</url><url>internal-pdf://Knauer et al. - 2010 - Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature-annotated.pdf</url></pdf-urls><web-urls><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3008599&amp;tool=pmcentrez&amp;rendertype=abstract</url></web-urls></urls><label>Oncotype DX</label><abstract>BACKGROUND: overexpression of HER-2 is observed in 15-25% of breast cancers, and is associated with increased risk of recurrence. Current guidelines recommend trastuzumab and chemotherapy for most HER-2-positive patients. However, the majority of patients does not recur and might thus be overtreated with adjuvant systemic therapy. We investigated whether the 70-gene MammaPrint signature identifies HER-2-positive patients with favourable outcome.

METHODS: in all, 168 T1-3, N0-1, HER-2-positive patients were identified from a pooled database, classified by the 70-gene signature as good or poor prognosis, and correlated with long-term outcome. A total of 89 of these patients did not receive adjuvant chemotherapy.

RESULTS: in the group of 89 chemotherapy-naive patients, after a median follow-up of 7.4 years, 35 (39%) distant recurrences and 29 (33%) breast cancer-specific deaths occurred. The 70-gene signature classified 20 (22%) patients as good prognosis, with 10-year distant disease-free survival (DDFS) of 84%, compared with 69 (78%) poor prognosis patients with 10-year DDFS of 55%. The estimated hazard ratios (HRs) were 4.5 (95% confidence interval (CI) 1.1-18.7, P=0.04) and 3.8 (95% CI 0.9-15.8, P=0.07) for DDFS and breast cancer-specific survival (BCSS), respectively. In multivariate analysis adjusted for known prognostic factors and hormonal therapy, HRs were 5.8 (95% CI 1.3-26.7, P=0.03) and 4.7 (95% CI 1.0-21.7, P=0.05) for DDFS and BCSS, respectively.

INTERPRETATION: the 70-gene prognosis signature is an independent prognostic indicator that identifies a subgroup of HER-2-positive early breast cancer with a favourable long-term outcome.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Lyman, Gary H</author><author>Cosler, Leon E</author><author>Kuderer, Nicole M</author><author>Hornberger, John</author></authors></contributors><titles><title>Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.</title><secondary-title>Cancer</secondary-title></titles><periodical><full-title>Cancer</full-title></periodical><pages>1011-8</pages><volume>109</volume><issue>6</issue><keywords><keyword>Adjuvant</keyword><keyword>Antineoplastic Agents</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: diagnosis</keyword><keyword>Breast Neoplasms: drug therapy</keyword><keyword>Breast Neoplasms: pathology</keyword><keyword>Chemotherapy</keyword><keyword>Cost-Benefit Analysis</keyword><keyword>Disease-Free Survival</keyword><keyword>Female</keyword><keyword>Gene Expression</keyword><keyword>Hormonal</keyword><keyword>Hormonal: therapeutic use</keyword><keyword>Humans</keyword><keyword>Local</keyword><keyword>Local: diagnosis</keyword><keyword>Local: pathology</keyword><keyword>Lymph Nodes</keyword><keyword>Lymph Nodes: pathology</keyword><keyword>Messenger</keyword><keyword>Messenger: analysis</keyword><keyword>Monte Carlo Method</keyword><keyword>Neoplasm Recurrence</keyword><keyword>Prognosis</keyword><keyword>RNA</keyword><keyword>Reverse Transcriptase Polymerase Chain Reaction</keyword><keyword>Reverse Transcriptase Polymerase Chain Reaction: e</keyword><keyword>Reverse Transcriptase Polymerase Chain Reaction: m</keyword><keyword>Tamoxifen</keyword><keyword>Tamoxifen: therapeutic use</keyword><keyword>Treatment Outcome</keyword></keywords><dates><year>2007</year></dates><accession-num>17311307</accession-num><electronic-resource-num>10.1002/cncr.22506</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Lyman et al. - 2007 - Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer an economic analysis based(3).pdf</url><url>internal-pdf://Lyman et al. - 2007 - Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer an economic analysis based on.pdf</url><url>internal-pdf://Lyman et al. - 2007 - Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer an economic analysis based(2).pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/17311307</url></web-urls></urls><label>Oncotype DX;economic focus</label><abstract>The prognostic accuracy for distant recurrence-free survival using a 21-gene reverse-transcriptase polymerase chain reaction (RT-PCR) assay underwent validation in 668 lymph node-negative, estrogen receptor-positive women with early-stage breast cancer receiving tamoxifen on National Surgical Adjuvant Breast Program (NSABP) B-14. The predictive accuracy for treatment efficacy also underwent validation in 651 patients randomized on NSABP B-20 and 645 patients on NSABP B-14.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Lyman, Gary H</author><author>Cosler, Leon E</author><author>Kuderer, Nicole M</author><author>Hornberger, John</author></authors></contributors><titles><title>Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.</title><secondary-title>Cancer</secondary-title></titles><periodical><full-title>Cancer</full-title></periodical><pages>1011-8</pages><volume>109</volume><issue>6</issue><keywords><keyword>Antineoplastic Agents, Hormonal</keyword><keyword>Antineoplastic Agents, Hormonal: therapeutic use</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: diagnosis</keyword><keyword>Breast Neoplasms: drug therapy</keyword><keyword>Breast Neoplasms: pathology</keyword><keyword>Chemotherapy, Adjuvant</keyword><keyword>Cost-Benefit Analysis</keyword><keyword>Disease-Free Survival</keyword><keyword>Female</keyword><keyword>Gene Expression</keyword><keyword>Humans</keyword><keyword>Lymph Nodes</keyword><keyword>Lymph Nodes: pathology</keyword><keyword>Monte Carlo Method</keyword><keyword>Neoplasm Recurrence, Local</keyword><keyword>Neoplasm Recurrence, Local: diagnosis</keyword><keyword>Neoplasm Recurrence, Local: pathology</keyword><keyword>Prognosis</keyword><keyword>RNA, Messenger</keyword><keyword>RNA, Messenger: analysis</keyword><keyword>Reverse Transcriptase Polymerase Chain Reaction</keyword><keyword>Reverse Transcriptase Polymerase Chain Reaction: e</keyword><keyword>Reverse Transcriptase Polymerase Chain Reaction: m</keyword><keyword>Tamoxifen</keyword><keyword>Tamoxifen: therapeutic use</keyword><keyword>Treatment Outcome</keyword></keywords><dates><year>2007</year></dates><accession-num>17311307</accession-num><electronic-resource-num>10.1002/cncr.22506</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Lyman et al. - 2007 - Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer an economic analysis based on.pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/17311307</url></web-urls></urls><label>JULIA;Oncotype DX</label><abstract>The prognostic accuracy for distant recurrence-free survival using a 21-gene reverse-transcriptase polymerase chain reaction (RT-PCR) assay underwent validation in 668 lymph node-negative, estrogen receptor-positive women with early-stage breast cancer receiving tamoxifen on National Surgical Adjuvant Breast Program (NSABP) B-14. The predictive accuracy for treatment efficacy also underwent validation in 651 patients randomized on NSABP B-20 and 645 patients on NSABP B-14.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Marchionni, Luigi</author><author>Wilson, Renee F</author><author>Marinopoulos, Spyridon S</author><author>Wolff, Antonio C</author><author>Parmigiani, Giovanni</author><author>Bass, Eric B</author><author>Goodman, Steven N</author></authors></contributors><titles><title>Impact of gene expression profiling tests on breast cancer outcomes.</title><secondary-title>Evidence report/technology assessment</secondary-title></titles><periodical><full-title>Evidence report/technology assessment</full-title></periodical><pages>1-105</pages><issue>160</issue><keywords><keyword>Adult</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Breast Neoplasms: therapy</keyword><keyword>Female</keyword><keyword>Gene Expression Profiling</keyword><keyword>Humans</keyword><keyword>Microarray Analysis</keyword><keyword>Middle Aged</keyword><keyword>Prognosis</keyword><keyword>Reverse Transcriptase Polymerase Chain Reaction</keyword><keyword>Treatment Outcome</keyword></keywords><dates><year>2007</year></dates><publisher>Agency for Healthcare Research and Quality (US)</publisher><accession-num>18457476</accession-num><urls><web-urls><url>http://www.ncbi.nlm.nih.gov/books/PMH0007356/</url></web-urls></urls><label>JULIA;Oncotype DX</label><abstract>OBJECTIVES: To assess the evidence that three marketed gene expression-based assays improve prognostic accuracy, treatment choice, and health outcomes in women diagnosed with early stage breast cancer.

REVIEW METHODS: We evaluated the evidence for three gene expression assays on the market; Oncotype DX, MammaPrint and the Breast Cancer Profiling (BCP or H/I ratio) test, and for gene expression signatures underlying the assays. We sought evidence on: analytic performance of tests, clinical validity (i.e., prognostic accuracy and discrimination), clinical utility (i.e., prediction of treatment benefit), harms, impact on clinical decision making and health care costs.

RESULTS: Few papers were found on the analytic validity of the Oncotype DX and MammaPrint tests, but these showed reasonable within-laboratory replicability. Pre-analytic issues related to sample storage and preparation may play a larger role than within-laboratory variation. For clinical validity, studies differed according to whether they examined the actual test that is currently being offered to patients or the underlying gene signature. Almost all of the Oncotype DX evidence was for the marketed test, the strongest validation study being from one arm of a randomized controlled trial (NSABP-14) with a clinically homogeneous population. This study showed that the test, added in a clinically meaningful manner to standard prognostic indices. The MammaPrint signature and test itself was examined in studies with clinically heterogeneous populations (e.g., mix of ER positivity and tamoxifen treatment) and showed a clinically relevant separation of patients into risk categories, but it was not clear exactly how many predictions would be shifted across decision thresholds if this were used in combination with traditional indices. The BCP test itself was examined in one study, and the signature was tested in a variety of formulations in several studies. One randomized controlled trial provided high quality retrospective evidence of the clinical utility of Oncotype DX to predict chemotherapy treatment benefit, but evidence for clinical utility was not found for MammaPrint or the H/I ratio. Three decision analyses examined the cost-effectiveness of breast cancer gene expression assays, and overall were inconclusive.

CONCLUSIONS: Oncotype DX is furthest along the validation pathway, with strong retrospective evidence that it predicts distant spread and chemotherapy benefit to a clinically relevant extent over standard predictors, in a well-defined clinical subgroup with clear treatment implications. The evidence for clinical implications of using MammaPrint was not as clear as with Oncotype DX, and the ability to predict chemotherapy benefit does not yet exist. The H/I ratio test requires further validation. For all tests, the relationship of predicted to observed risk in different populations still needs further study, as does their incremental contribution, optimal implementation, and relevance to patients on current therapies.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Partin, Jessica F</author><author>Mamounas, Eleftherios P</author></authors></contributors><titles><title>Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.</title><secondary-title>Annals of surgical oncology</secondary-title></titles><periodical><full-title>Annals of surgical oncology</full-title></periodical><pages>3399-406</pages><volume>18</volume><issue>12</issue><keywords><keyword>Adjuvant</keyword><keyword>Antineoplastic Combined Chemotherapy Protocols</keyword><keyword>Antineoplastic Combined Chemotherapy Protocols: th</keyword><keyword>Biological</keyword><keyword>Biological: genetics</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: drug therapy</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Breast Neoplasms: pathology</keyword><keyword>Chemotherapy</keyword><keyword>Estrogen</keyword><keyword>Estrogen: analysis</keyword><keyword>Female</keyword><keyword>Follow-Up Studies</keyword><keyword>Humans</keyword><keyword>Local</keyword><keyword>Local: drug therapy</keyword><keyword>Local: genetics</keyword><keyword>Local: pathology</keyword><keyword>Lymph Nodes</keyword><keyword>Lymph Nodes: pathology</keyword><keyword>Lymphatic Metastasis</keyword><keyword>Male</keyword><keyword>Middle Aged</keyword><keyword>Neoplasm Invasiveness</keyword><keyword>Neoplasm Recurrence</keyword><keyword>Neoplasm Staging</keyword><keyword>Practice Guidelines as Topic</keyword><keyword>Progesterone</keyword><keyword>Progesterone: analysis</keyword><keyword>Prognosis</keyword><keyword>Receptor</keyword><keyword>Receptors</keyword><keyword>Retrospective Studies</keyword><keyword>Risk Factors</keyword><keyword>Tumor Markers</keyword><keyword>erbB-2</keyword><keyword>erbB-2: analysis</keyword></keywords><dates><year>2011</year></dates><accession-num>21537874</accession-num><electronic-resource-num>10.1245/s10434-011-1698-z</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Partin, Mamounas - 2011 - Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvan(3).pdf</url><url>internal-pdf://Partin, Mamounas - 2011 - Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant t.pdf</url><url>internal-pdf://Partin, Mamounas - 2011 - Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvan(2).pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/21537874</url></web-urls></urls><label>JULIA;Oncotype DX;clinical;oncotype DX</label><abstract>The development of multigene assays has proved useful in the clinical management of early-stage breast cancer. The 21-gene recurrence score (RS) assay has been shown to quantify risk of distant recurrence and predict chemotherapy benefit in node-negative and node-positive, estrogen-receptor (ER)-positive breast cancer patients. Small, single-institution series have shown that, compared with standard clinicopathologic criteria, use of RS significantly affects adjuvant chemotherapy recommendations.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Bast, Robert C</author><author>Hortobagyi, Gabriel N</author></authors></contributors><titles><title>Individualized Care for Patients with Cancer —</title></titles><periodical/><pages>2865-2867</pages><keywords/><dates><year>2004</year></dates><urls><pdf-urls><url>internal-pdf://Bast, Hortobagyi - 2004 - Individualized Care for Patients with Cancer —(2).pdf</url></pdf-urls></urls><label>JULIA;NNT paper;OncoType DX;Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Cheung, P Sy</author><author>Tong, A C</author><author>Leung, R Cy</author><author>Kwan, W H</author><author>Yau, T Cc</author></authors></contributors><titles><title>Initial experience with the Oncotype DX assay in decision-making for adjuvant therapy of early oestrogen receptor-positive breast cancer in Hong Kong.</title><secondary-title>Hong Kong medical journal = Xianggang yi xue za zhi / Hong Kong Academy of Medicine</secondary-title></titles><periodical><full-title>Hong Kong medical journal = Xianggang yi xue za zhi / Hong Kong Academy of Medicine</full-title></periodical><keywords/><dates><year>2014</year></dates><accession-num>24948666</accession-num><electronic-resource-num>10.12809/hkmj134140</electronic-resource-num><urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/24948666</url></web-urls></urls><label>JULIA;Oncotype DX;unsure</label><abstract>OBJECTIVE. To examine the impact of the 21-gene Oncotype DX Breast Cancer Assay on the adjuvant treatment decision-making process for early-stage breast cancer in Hong Kong. DESIGN. Retrospective study. SETTING. Private hospital, Hong Kong. PATIENTS. Study included cases of early-stage breast cancer (T1-2N0-1M0, oestrogen receptor-positive, human epidermal growth factor receptor 2-negative) that were presented at a multidisciplinary breast meeting at a single site. Cases were selected for Oncotype DX testing with the assistance of Adjuvant! Online. The recommendations for adjuvant therapy before and after obtaining the Oncotype DX Recurrence Score results were analysed. RESULTS. A total of 154 cases that met the inclusion criteria were discussed at our multidisciplinary breast meeting. Of these, 64 cases with no clear recommendation by the Meeting Panel were selected for this study and reviewed. The distribution of Recurrence Score results was similar to that reported by others, with a somewhat higher proportion of low Recurrence Scores. Treatment recommendation was changed for 20 (31%) patients after the Oncotype DX result was received. Of the changes in treatment decisions, 16 (80%) were changes to lower-intensity regimens (either equipoise or hormonal therapy). The number of cases receiving an equipoise recommendation decreased by nine (82%), based on the additional information provided by the Oncotype DX test. CONCLUSION. The Oncotype DX Recurrence Score information impacts the decision-making process for adjuvant therapy for early-stage breast cancer in the multidisciplinary care setting in Hong Kong. A larger-scale study is required to gain more experience, evaluate its impact more thoroughly, and assess its cost-effectiveness.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Ramsey, Scott D</author><author>Barlow, William E</author><author>Gonzalez-Angulo, Ana M</author><author>Tunis, Sean</author><author>Baker, Laurence</author><author>Crowley, John</author><author>Deverka, Patricia</author><author>Veenstra, David</author><author>Hortobagyi, Gabriel N</author></authors></contributors><titles><title>Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes.</title><secondary-title>Contemporary clinical trials</secondary-title></titles><periodical><full-title>Contemporary clinical trials</full-title></periodical><pages>1-9</pages><volume>34</volume><issue>1</issue><keywords><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Breast Neoplasms: secondary</keyword><keyword>Breast Neoplasms: therapy</keyword><keyword>Clinical Trials</keyword><keyword>Combined Modality Therapy</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Lymph Nodes</keyword><keyword>Lymph Nodes: pathology</keyword><keyword>Lymphatic Metastasis</keyword><keyword>Phase III as Topic</keyword><keyword>Randomized Controlled Trials as Topic</keyword><keyword>Randomized Controlled Trials as Topic: methods</keyword></keywords><dates><year>2013</year></dates><publisher>Elsevier Inc.</publisher><accession-num>23000081</accession-num><electronic-resource-num>10.1016/j.cct.2012.09.003</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Ramsey et al. - 2013 - Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (.pdf</url></pdf-urls><web-urls><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3525786&amp;tool=pmcentrez&amp;rendertype=abstract</url></web-urls></urls><label>JULIA;Oncotype DX</label><abstract>Women with breast cancer involving the lymph nodes are typically treated with cytotoxic chemotherapy. Retrospective evaluations of prior studies suggest that the 21-gene test (OncotypeDX®), may allow identification of those who can safely avoid chemotherapy. To better understand the performance of the 21-gene test, the RxPONDER (Rx for Positive Node, Endocrine Responsive breast cancer) study was designed, a multicenter Phase III trial randomizing women with hormone receptor-positive and HER2-negative breast cancer involving 1-3 lymph nodes and a 21-gene assay recurrence score (RS) of 25 or less to endocrine therapy alone versus chemotherapy followed by endocrine therapy. As one of the first large-scale comparative-effectiveness studies in oncology, RxPONDER utilized an external stakeholder group to help inform the design of the trial. Stakeholders met with representatives of SWOG over several months through a structured discussion process. The stakeholder engagement process resulted in several changes being made to the trial design. In addition, stakeholder representatives from the health insurance industry provided guidance regarding a mechanism whereby the costs of OncotypeDX® would be paid by the majority of health insurers as part of the trial. The process may serve as a template for future studies evaluating the comparative effectiveness of genomic tests in oncology, particularly those that are conducted within cooperative clinical trials groups.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Paik, Soonmyung</author></authors></contributors><titles><title>Is gene array testing to be considered routine now?</title><secondary-title>Breast (Edinburgh, Scotland)</secondary-title></titles><periodical><full-title>Breast (Edinburgh, Scotland)</full-title></periodical><pages>S87-91</pages><volume>20 Suppl 3</volume><keywords><keyword>Adult</keyword><keyword>Aged</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Breast Neoplasms: pathology</keyword><keyword>Breast Neoplasms: therapy</keyword><keyword>Diagnostic Tests</keyword><keyword>Estrogen</keyword><keyword>Estrogen: genetics</keyword><keyword>Estrogen: metabolism</keyword><keyword>Female</keyword><keyword>Forecasting</keyword><keyword>Gene Expression Profiling</keyword><keyword>Gene Expression Profiling: standards</keyword><keyword>Gene Expression Profiling: trends</keyword><keyword>Gene Expression Regulation</keyword><keyword>Humans</keyword><keyword>Microarray Analysis</keyword><keyword>Microarray Analysis: standards</keyword><keyword>Microarray Analysis: trends</keyword><keyword>Middle Aged</keyword><keyword>Neoplastic</keyword><keyword>Receptor</keyword><keyword>Receptors</keyword><keyword>Reproducibility of Results</keyword><keyword>Routine</keyword><keyword>Routine: trends</keyword><keyword>erbB-2</keyword><keyword>erbB-2: genetics</keyword><keyword>erbB-2: metabolism</keyword></keywords><dates><year>2011</year></dates><accession-num>22015300</accession-num><electronic-resource-num>10.1016/S0960-9776(11)70301-0</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Paik - 2011 - Is gene array testing to be considered routine now(2).pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/22015300</url></web-urls></urls><label>Oncotype DX;review</label><abstract>BACKGROUND: There are five multi-gene expression based prognostic tests for breast cancer offered as reference lab tests - Mammaprint, MapQuant Dx, OncotypeDx, PAM50 Breast Cancer Intrinsic Subtype Classifier, and Theros Breast Cancer Index. Each claims to provide additional prognostic information beyond conventional prognostic markers and to aid in determining who should receive systemic therapy. Evidence for their clinical utility was reviewed to determine whether any of them should be considered as routine clinical test.

METHODS: Peer reviewed publications, meeting abstracts, and information provided by company web sites have been reviewed to compile information regarding their clinical utility according to the following criteria; (1) Analytical validity and regulatory approval of the reference lab test. (2) Level of evidence for clinical utility. (3) Whether published evidences support prognostic and/or predictive claim.

RESULTS: While published evidences for clinical claims for OncotypeDx and Mammaprint used reference lab tests, and the supporting evidences for other tests come from academic assays before being converted to reference lab tests, results from two large randomized clinical trials testing the clinical utility of OncotypeDx and Mammaprint are still several years away and until that time none of the markers would reach level I evidence by Marker Utility Grading System. However Oncotype Dx has reached a level IB evidence according to Simon modification to Marker Utility Grading System. Therefore OncotypeDx may be considered for routine clinical use as an adjunct to clinical and pathological information and has been incorporated into clinical guidelines in USA. While Mammaprint, MapQuantDx, and PAM50 have been repeatedly demonstrated to provide robust prognostic information, evidence for its worth as a predictive marker for chemotherapy benefit is yet to come from randomize clinical trials and therefore its utility is limited to prognostication. Meta-analysis of publicly available microarray based gene expression studies demonstrated that gene expression assays provide similar information and the most important information they provide is the proliferation activity. In untreated population, the prognostic impact of proliferation genes is limited to ER+HER2- subset since HER2+ or ER-HER2- subsets are associated with high proliferation activity. Therefore the clinical utility of these gene expression based tests is mainly for ER+HER2- subset. Since they are usually treated with adjuvant anti-estrogen therapies, for their clinical utility, demonstration of the interaction between the gene expression markers and chemotherapy in anti-estrogen treated cohort in a randomized clinical trial would be required. While OncoytpeDx is the only test supported by studies in a randomized clinical trial for adjuvant chemotherapy, other gene expression based tests are expected to provide similar information. Gene expression profiling assays as more reproducible and precise surrogates for tumor grade (MapQauntDx and Theros Breast Cancer Index) are very promising assays. However, absence of definitive predefined cut-off for defining the subset that benefit from chemotherapy validated in cohorts from randomized trials limit their clinical application.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Milburn, Meghan</author><author>Rosman, Martin</author><author>Mylander, Charles</author><author>Tafra, Lorraine</author></authors></contributors><titles><title>Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. Low-ER expression patients are removed?</title><secondary-title>Breast Journal</secondary-title></titles><periodical><full-title>Breast Journal</full-title></periodical><pages>357-364</pages><volume>19</volume><issue>4</issue><keywords><keyword>breast cancer</keyword><keyword>immunohistochemistry</keyword><keyword>oncotype</keyword></keywords><dates><year>2013</year></dates><accession-num>23701403</accession-num><electronic-resource-num>10.1111/tbj.12126</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Milburn et al. - 2013 - Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. Low-ER expression patients are.pdf</url><url>internal-pdf://tbj12126.pdf</url></pdf-urls></urls><label>Oncotype DX</label><abstract>Oncotype DX has been criticized for not providing significantly more prognostic information than histopathologic analysis. Oncotype DX was validated in cohorts that included poor prognostic factors (HER2-positive, low-estrogen receptor [ER] expression), raising the question: if patients with known high recurrence rates are excluded, is the Recurrence Score (RS) still valid? Our purpose was to determine if RS can be predicted with readily available measures. One hundred and twenty samples from August 2006 to November 2010 that underwent Oncotype DX testing were analyzed. Data included RS, ER, progesterone receptor (PR), HER2, and Ki67 status by immunohistochemistry (IHC). IHC data were used to create two linear regression models to predict RS. SAS's JMP-7 was used for statistical analysis. When comparing Oncotype DX- and IHC-derived ER and PR values, there were 21 discordant samples. The linear regression model PRS-F created with IHC data (ER, PR, HER2, Ki67) from all samples (n = 120) had an adjusted R(2) = 0.60 indicating a good model for predicting RS. The PRS-R model was built without low-ER and HER2-positive samples (n = 110). It had an adjusted R(2) = 0.38 indicating poor prediction of RS. Oncotype DX data showed good concordance with IHC for ER- and PR-expression in this cohort. Low-ER samples had high RS. After removing low-ER and HER2-positives, calculating RS with PRS-R from remaining data showed poor predictive power for RS (adjusted R(2) = 0.38). This result questions whether RS is prognostic in this subgroup (who would most benefit from further clarification of recurrence risk) and independent of pathology, or is simply producing random RS values. Data bases available to Genomic Health can resolve this issue.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Buchanan, James</author><author>Wordsworth, Sarah</author><author>Schuh, Anna</author></authors></contributors><titles><title>Issues surrounding the health economic evaluation of genomic technologies.</title><secondary-title>Pharmacogenomics</secondary-title></titles><periodical><full-title>Pharmacogenomics</full-title></periodical><pages>1833-47</pages><volume>14</volume><issue>15</issue><keywords><keyword>benefit ana</keyword><keyword>cost</keyword><keyword>costs</keyword><keyword>cost–benefit analysis</keyword><keyword>cost–effectiveness analysis</keyword><keyword>economic</keyword><keyword>economic evaluation</keyword><keyword>effectiveness</keyword><keyword>effectiveness ana</keyword><keyword>evaluation n effectiveness n</keyword><keyword>extra-welfarism</keyword><keyword>extra-welfarism n genetics n</keyword><keyword>genetics</keyword><keyword>genomics</keyword><keyword>genomics n outcomes</keyword><keyword>lysis n cost</keyword><keyword>lysis n costs n</keyword><keyword>outcomes</keyword><keyword>review</keyword><keyword>welfarism</keyword></keywords><dates><year>2013</year></dates><isbn>10.2217/pgs.13.183</isbn><accession-num>24236483</accession-num><electronic-resource-num>10.2217/pgs.13.183</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Buchanan, Wordsworth, Schuh - 2013 - Issues surrounding the health economic evaluation of genomic technologies(2).pdf</url></pdf-urls><web-urls><url>http://www.futuremedicine.com/doi/abs/10.2217/pgs.13.183\nhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3909837&amp;tool=pmcentrez&amp;rendertype=abstract</url></web-urls></urls><label>JULIA;Oncotype DX</label><abstract>AIM: Genomic interventions could enable improved disease stratification and individually tailored therapies. However, they have had a limited impact on clinical practice to date due to a lack of evidence, particularly economic evidence. This is partly because health economists are yet to reach consensus on whether existing methods are sufficient to evaluate genomic technologies. As different approaches may produce conflicting adoption decisions, clarification is urgently required. This article summarizes the methodological issues associated with conducting economic evaluations of genomic interventions. MATERIALS &amp; METHODS: A structured literature review was conducted to identify references that considered the methodological challenges faced when conducting economic evaluations of genomic interventions. RESULTS: Methodological challenges related to the analytical approach included the choice of comparator, perspective and timeframe. Challenges in costing centered around the need to collect a broad range of costs, frequently, in a data-limited environment. Measuring outcomes is problematic as standard measures have limited applicability, however, alternative metrics (e.g., personal utility) are underdeveloped and alternative approaches (e.g., cost-benefit analysis) underused. Effectiveness data quality is weak and challenging to incorporate into standard economic analyses, while little is known about patient and clinician behavior in this context. Comprehensive value of information analyses are likely to be helpful. CONCLUSION: Economic evaluations of genomic technologies present a particular challenge for health economists. New methods may be required to resolve these issues, but the evidence to justify alternative approaches is yet to be produced. This should be the focus of future work in this field.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Simon, Richard</author></authors></contributors><titles><title>Lost in translation : Problems and pitfalls in translating laboratory observations to clinical utility</title><secondary-title>European Journal of Cancer</secondary-title></titles><periodical><full-title>European Journal of Cancer</full-title></periodical><pages>1-7</pages><keywords/><dates><year>2008</year></dates><publisher>Elsevier Ltd</publisher><electronic-resource-num>10.1016/j.ejca.2008.09.009</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Simon - 2008 - Lost in translation Problems and pitfalls in translating laboratory observations to clinical utility(2).pdf</url></pdf-urls></urls><label>JULIA;NNT paper;OncoType DX;Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Espinel, C Francisco</author><author>Keating, Shaughn</author><author>Hibshoosh, Hanina</author><author>Taback, Bret</author><author>Joseph, Kathie-Ann</author><author>El-Tamer, Mahmoud</author><author>Feldman, Sheldon</author></authors></contributors><titles><title>MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience.</title><secondary-title>Scientifica</secondary-title></titles><periodical><full-title>Scientifica</full-title></periodical><pages>942507</pages><volume>2012</volume><keywords/><dates><year>2012</year></dates><accession-num>24278759</accession-num><electronic-resource-num>10.6064/2012/942507</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Espinel et al. - 2012 - MammaPrint Feasibility in a Large Tertiary Urban Medical Center An Initial Experience(7).pdf</url><url>internal-pdf://Espinel et al. - 2012 - MammaPrint Feasibility in a Large Tertiary Urban Medical Center An Initial Experience(2).pdf</url></pdf-urls><web-urls><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3820467&amp;tool=pmcentrez&amp;rendertype=abstract</url></web-urls></urls><label>JULIA;Oncotype DX</label><abstract>Background. The MammaPrint (MP) diagnostic assay stratifies breast cancer patients into high- and low-risk groups using mRNA analysis of a 70-gene profile. The assay is validated for assessment of patients with estrogen receptor positive or negative tumors less than 5 cm with 3 or fewer malignant lymph nodes. TargetPrint (TP) is an assay for assessing estrogen, progesterone, and HER2-neu receptor status based on mRNA expression. A potential limitation of these assays is that they require an evaluation of fresh tissue samples. There is limited published experience describing MP or TP implementation. Methods. Over 10 months, 4 breast surgeons obtained samples from 54 patients for MP/TP analysis. The samples were analyzed by Agendia Labs. The tumors were independently evaluated for receptor status using immunohistochemistry (IHC). Retrospectively, we identified patients who were assessed by MP/TP during this period. Patients who underwent OncotypeDx evaluation were also identified. Results. Of the 54 patients receiving MP, 4 were found ineligible for MP risk assessment because &gt;3 lymph nodes were found to be malignant. Out of all eligible patients, 14/50 (28%) had samples whose quantity of tumor was not sufficient for analysis (QNS). Out of eligible patients with tumors &lt;1 cm, 7/8 (88%) had QNS samples. 7/42 with tumors ≥1 cm (17%) had QNS samples. Nine patients had discordant receptor results when evaluated by IHC versus. TP. Of patients who also underwent OncotypeDx testing, 6/14 (43%) had discordant results with MP. Conclusions. This study indicates that using MP/TP assay is feasible in a tertiary care center but there may be utility in limiting MP testing to patients with tumors between 1 and 5 cm due to high likelihood of uninformative results in subcentimeter tumors. Further study is needed to explore the discordance between oncotype and MP results.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Janes, Holly</author><author>Pepe, Margaret S</author><author>Bossuyt, Patrick M</author><author>Barlow, William E</author></authors></contributors><titles><title>Measuring the performance of markers for guiding treatment decisions</title><secondary-title>Annals of Internal Medicine</secondary-title></titles><periodical><full-title>Annals of Internal Medicine</full-title></periodical><pages>253-260</pages><volume>154</volume><issue>4</issue><keywords><keyword>Biological Markers</keyword><keyword>Clinical Protocols</keyword><keyword>Clinical Protocols: standards</keyword><keyword>Decision Making</keyword><keyword>Humans</keyword><keyword>Randomized Controlled Trials as Topic</keyword><keyword>Randomized Controlled Trials as Topic: methods</keyword><keyword>Randomized Controlled Trials as Topic: standards</keyword><keyword>Treatment Outcome</keyword></keywords><dates><year>2011</year></dates><isbn>0110215000006</isbn><accession-num>21320940</accession-num><electronic-resource-num>10.7326/0003-4819-154-4-201102150-00006</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Janes et al. - 2011 - Measuring the performance of markers for guiding treatment decisions.pdf</url><url>internal-pdf://Janes et al. - 2011 - Measuring the performance of markers for guiding treatment decisions.pdf</url></pdf-urls><web-urls><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3085402&amp;tool=pmcentrez&amp;rendertype=abstract</url></web-urls></urls><label>JULIA;NNT paper;Oncotype DX</label><abstract>Treatment selection markers, sometimes called predictive markers, are factors that help clinicians select therapies that maximize good outcomes and minimize adverse outcomes for patients. Existing statistical methods for evaluating a treatment selection marker include assessing its prognostic value, evaluating treatment effects in patients with a restricted range of marker values, and testing for a statistical interaction between marker value and treatment. These methods are inadequate, because they give misleading measures of performance that do not answer key clinical questions about how the marker might help patients choose treatment, how treatment decisions should be made on the basis of a continuous marker measurement, what effect using the marker to select treatment would have on the population, or what proportion of patients would have treatment changes on the basis of marker measurement. Marker-by-treatment predictiveness curves are proposed as a more useful aid to answering these clinically relevant questions, because they illustrate treatment effects as a function of marker value, outcomes when using or not using the marker to select treatment, and the proportion of patients for whom treatment recommendations change after marker measurement. Randomized therapeutic clinical trials, in which entry criteria and treatment regimens are not restricted by the marker, are also proposed as the basis for constructing the curves and evaluating and comparing markers.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Harbeck, Nadia</author><author>Sotlar, Karl</author><author>Wuerstlein, Rachel</author><author>Doisneau-Sixou, Sophie</author></authors></contributors><titles><title>Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow.</title><secondary-title>Cancer treatment reviews</secondary-title></titles><periodical><full-title>Cancer treatment reviews</full-title></periodical><pages>434-44</pages><volume>40</volume><issue>3</issue><keywords><keyword>Biological</keyword><keyword>Biological: blood</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: blood</keyword><keyword>Breast Neoplasms: diagnosis</keyword><keyword>Breast Neoplasms: therapy</keyword><keyword>Combined Modality Therapy</keyword><keyword>Combined Modality Therapy: methods</keyword><keyword>Decision Making</keyword><keyword>Early Diagnosis</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Tumor Markers</keyword></keywords><dates><year>2014</year></dates><publisher>Elsevier Ltd</publisher><accession-num>24138841</accession-num><electronic-resource-num>10.1016/j.ctrv.2013.09.014</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Harbeck et al. - 2014 - Molecular and protein markers for clinical decision making in breast cancer today and tomorrow.pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/24138841</url></web-urls></urls><label>JULIA;Oncotype DX</label><abstract>In early breast cancer (eBC), established clinicopathological factors are not sufficient for clinical decision making particularly regarding adjuvant chemotherapy since substantial over- or undertreatment may occur. Thus, novel protein- and molecular markers have been put forward as decision aids. Since these potential prognosis and/or predictive tests differ substantially regarding their methodology, analytical and clinical validation, this review attempts to summarize the essential facts for clinicians. This review focuses on those markers which are the most advanced so far in their development towards routine clinical application, i.e. two protein markers (i.e. uPA/PAI-1 and IHC4) and six molecular multigene tests (i.e. Mammaprint®, Oncotype DX®, PAM50, Endopredict®, the 97-gene genomic grade, and 76 gene Rotterdam signatures). Next to methodological aspects, we summarized the clinical evidences, in particular the main prospective clinical trials which have already been fully recruited (i.e. MINDACT, TAILORx, WSG PLAN B) or are still ongoing (i.e. RxPONDER/SWOG S1007, WSG-ADAPT). Last but not least, this review points out the key elements for clinicians to select one test among the wide panel of proposed assays, for a specific population of patients in term of level of evidence, analytical and clinical validity as well as cost effectiveness.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Rouzier, Roman</author><author>Pronzato, Paolo</author><author>Chéreau, Elisabeth</author><author>Carlson, Josh</author><author>Hunt, Barnaby</author><author>Valentine, William J</author></authors></contributors><titles><title>Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses.</title><secondary-title>Breast cancer research and treatment</secondary-title></titles><periodical><full-title>Breast cancer research and treatment</full-title></periodical><pages>621-37</pages><volume>139</volume><issue>3</issue><keywords><keyword>Biological Markers</keyword><keyword>Biological Markers: analysis</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: economics</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Breast Neoplasms: metabolism</keyword><keyword>Cost-Benefit Analysis</keyword><keyword>Female</keyword><keyword>Gene Expression Profiling</keyword><keyword>Gene Expression Profiling: economics</keyword><keyword>Humans</keyword></keywords><dates><year>2013</year></dates><isbn>1054901325</isbn><accession-num>23722312</accession-num><electronic-resource-num>10.1007/s10549-013-2559-1</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Rouzier et al. - 2013 - Multigene assays and molecular markers in breast cancer systematic review of health economic analyses.pdf</url><url>internal-pdf://10549_2013_Article_2559.pdf</url></pdf-urls><web-urls><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3695325&amp;tool=pmcentrez&amp;rendertype=abstract</url></web-urls></urls><label>JULIA;Oncotype DX</label><abstract>Breast cancer is the most common female cancer and is associated with a significant clinical and economic burden. Multigene assays and molecular markers represent an opportunity to direct chemotherapy only to patients likely to have significant benefit. This systematic review examines published health economic analyses to assess the support for adjuvant therapy decision making. Literature searches of PubMed, the Cochrane Library, and congress databases were carried out to identify economic evaluations of multigene assays and molecular markers published between 2002 and 2012. After screening and data extraction, study quality was assessed using the Quality of Health Economic Studies instrument. The review identified 29 publications that reported evaluations of two assays: Oncotype DX(®) and MammaPrint. Studies of both tests provided evidence that their routine use was cost saving or cost-effective versus conventional approaches. Benefits were driven by optimal allocation of adjuvant chemotherapy and reduction in chemotherapy utilization. Findings were sensitive to variation in the frequency of chemotherapy prescription, chemotherapy costs, and patients' risk profiles. Evidence suggests that multigene assays are likely cost saving or cost-effective relative to current approaches to adjuvant therapy. They should benefit decision making in early-stage breast cancer in a variety of settings worldwide.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Sinn, P</author><author>Aulmann, S</author><author>Wirtz, R</author><author>Schott, S</author><author>Marmé, F</author><author>Varga, Z</author><author>Lebeau, a</author><author>Kreipe, H</author><author>Schneeweiss, a</author></authors></contributors><titles><title>Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.</title><secondary-title>Geburtshilfe und Frauenheilkunde</secondary-title></titles><periodical><full-title>Geburtshilfe und Frauenheilkunde</full-title></periodical><pages>932-940</pages><volume>73</volume><issue>9</issue><keywords/><dates><year>2013</year></dates><accession-num>24771945</accession-num><electronic-resource-num>10.1055/s-0033-1350831</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Sinn et al. - 2013 - Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer a Critical Review on the Backgro(2).pdf</url><url>internal-pdf://Sinn et al. - 2013 - Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer a Critical Review on the Background.pdf</url><url>internal-pdf://s-0033-1350831.pdf</url></pdf-urls><web-urls><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3859151&amp;tool=pmcentrez&amp;rendertype=abstract</url></web-urls></urls><label>JULIA;Oncotype DX</label><abstract>Gene signatures which are based on multigene profiling assays have been developed for the purpose to better define the prognosis and prediction of therapy results in early-stage breast cancer. These assays were designed to be more specific than conventional clinico-pathologic parameters in the selection of patients for (neo-)adjuvant treatment and in effect help to avoid unnecessary cytotoxic treatment. In this review we describe molecular risk scores, for which tests are commercially available (PAM50®, MammaTyper®, MammaPrint®, Oncotype DX®, Endopredict®, Genomic Grade Index®) and IHC risk scores (Mammostrat® and IHC4), and discuss the current evidence of their clinical use.

Abstract available from the publisher.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Genomic Health</author></authors></contributors><titles><title>Multiple Studies Presented at the American Society of Clinical Oncology Meeting Show Consistent Positive Results for the Oncotype DX ™ Breast Cancer Assay</title></titles><periodical/><issue>December 2004</issue><keywords/><dates><year>2005</year></dates><urls><pdf-urls><url>internal-pdf://Genomic Health et al. - 2005 - Multiple Studies Presented at the American Society of Clinical Oncology Meeting Show Consistent Positiv.pdf</url></pdf-urls></urls><label>JULIA;Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Dx, Oncotype</author></authors></contributors><titles><title>NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Diagnostics consultation document Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management : Provisional recommendations C</title></titles><periodical/><pages>1-43</pages><issue>January</issue><keywords/><dates><year>2012</year></dates><urls><pdf-urls><url>internal-pdf://Dx - 2012 - NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Diagnostics consultation document Gene expression profiling and expand.pdf</url></pdf-urls></urls><label>JULIA;Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Carlson, Robert</author></authors></contributors><titles><title>NCCN Task force report: Adjuvant therapy for breast cancer - Clarification and expansion of NCCN Clinical Practice Guidelines</title><secondary-title>Journal of the National Comprehensive Cancer Network : JNCCN</secondary-title></titles><periodical><full-title>Journal of the National Comprehensive Cancer Network : JNCCN</full-title></periodical><volume>4</volume><keywords/><dates><year>2006</year></dates><urls><pdf-urls><url>internal-pdf://Carlson - 2006 - NCCN Task force report Adjuvant therapy for breast cancer - Clarification and expansion of NCCN Clinical Practice Gu(2).pdf</url></pdf-urls></urls><label>JULIA;Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Web Page">16</ref-type><contributors><authors><author>OncoTypeDx.com</author></authors></contributors><titles><title>OncoType DX Professional Guidelines</title></titles><periodical/><keywords/><urls><web-urls><url>http://breast-cancer.oncotypedx.com/en-US/Professional-Invasive.aspx</url></web-urls></urls><label>JULIA;NNT paper;OncoType DX;Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Web Page">16</ref-type><titles><title>OncoType DX Recurrence Challenge</title></titles><periodical/><keywords/><urls><web-urls><url>http://www.oncotypedx.com/en-US/Breast/HealthcareProfessionalsInvasive/CaseStudies/~/media/6CFE11AB749C4BF7A859C515A42830DB.ashx</url></web-urls></urls><label>JULIA;OncoType DX;Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Web Page">16</ref-type><titles><title>OncoType DX Recurrence Challenge</title></titles><periodical/><keywords/><urls><web-urls><url>http://www.oncotypedx.com/en-US/Breast/HealthcareProfessionalsInvasive/CaseStudies/~/media/6CFE11AB749C4BF7A859C515A42830DB.ashx</url></web-urls></urls><label>JULIA;OncoType DX;Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Shai, A</author><author>Rabkin, A</author><author>Sikorsky, N</author><author>Steiner, M</author></authors></contributors><titles><title>PR Negative Tumors in Prognosis and Results of Oncotype Dx</title><secondary-title>European Journal of Cancer</secondary-title></titles><periodical><full-title>European Journal of Cancer</full-title></periodical><pages>S132-S133</pages><volume>48</volume><issue>March</issue><keywords/><dates><year>2012</year></dates><publisher>Elsevier Ltd</publisher><electronic-resource-num>10.1016/S0959-8049(12)70375-1</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Shai et al. - 2012 - PR Negative Tumors in Prognosis and Results of Oncotype Dx(2).pdf</url><url>internal-pdf://Shai et al. - 2012 - PR Negative Tumors in Prognosis and Results of Oncotype Dx(3).pdf</url><url>internal-pdf://Shai et al. - 2012 - PR Negative Tumors in Prognosis and Results of Oncotype Dx.pdf</url></pdf-urls><web-urls><url>http://dx.doi.org/10.1016/S0959-8049(12)70375-1</url></web-urls></urls><label>JULIA;Oncotype DX</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Shai, A</author><author>Rabkin, A</author><author>Sikorsky, N</author><author>Steiner, M</author></authors></contributors><titles><title>PR Negative Tumors in Prognosis and Results of Oncotype Dx</title><secondary-title>European Journal of Cancer</secondary-title></titles><periodical><full-title>European Journal of Cancer</full-title></periodical><pages>S132-S133</pages><volume>48</volume><issue>March</issue><keywords/><dates><year>2012</year></dates><publisher>Elsevier Ltd</publisher><electronic-resource-num>10.1016/S0959-8049(12)70375-1</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Shai et al. - 2012 - PR Negative Tumors in Prognosis and Results of Oncotype Dx.pdf</url></pdf-urls><web-urls><url>http://dx.doi.org/10.1016/S0959-8049(12)70375-1</url></web-urls></urls><label>JULIA;Oncotype DX;not sure</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Naoi, Yasuto</author><author>Kishi, Kazuki</author><author>Tanei, Tomonori</author><author>Tsunashima, Ryo</author><author>Tominaga, Naoomi</author><author>Baba, Yosuke</author><author>Kim, Seung Jin</author><author>Taguchi, Tetsuya</author><author>Tamaki, Yasuhiro</author><author>Noguchi, Shinzaburo</author></authors></contributors><titles><title>Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.</title><secondary-title>Cancer</secondary-title></titles><periodical><full-title>Cancer</full-title></periodical><pages>3682-90</pages><volume>117</volume><issue>16</issue><keywords><keyword>80 and over</keyword><keyword>Adult</keyword><keyword>Aged</keyword><keyword>Antineoplastic Combined Chemotherapy Protocols</keyword><keyword>Antineoplastic Combined Chemotherapy Protocols: th</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: drug therapy</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Breast Neoplasms: pathology</keyword><keyword>Cyclophosphamide</keyword><keyword>Cyclophosphamide: administration &amp; dosage</keyword><keyword>Epirubicin</keyword><keyword>Epirubicin: administration &amp; dosage</keyword><keyword>Estrogen</keyword><keyword>Estrogen: analysis</keyword><keyword>Female</keyword><keyword>Fluorouracil</keyword><keyword>Fluorouracil: administration &amp; dosage</keyword><keyword>Gene Expression Profiling</keyword><keyword>Humans</keyword><keyword>Middle Aged</keyword><keyword>Neoadjuvant Therapy</keyword><keyword>Paclitaxel</keyword><keyword>Paclitaxel: administration &amp; dosage</keyword><keyword>Predictive Value of Tests</keyword><keyword>Prognosis</keyword><keyword>Receptors</keyword><keyword>Sensitivity and Specificity</keyword></keywords><dates><year>2011</year></dates><accession-num>21305539</accession-num><electronic-resource-num>10.1002/cncr.25953</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Naoi et al. - 2011 - Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracilepirubicincyclophosphamide(2).pdf</url><url>internal-pdf://Naoi et al. - 2011 - Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracilepirubicincyclophosphamide(4).pdf</url><url>internal-pdf://Naoi et al. - 2011 - Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracilepirubicincyclophosphamide(3).pdf</url><url>internal-pdf://Naoi et al. - 2011 - Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracilepirubicincyclophosphamide th.pdf</url><url>internal-pdf://25953_ftp.pdf</url><url>internal-pdf://25953_ftp-annotated.pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/21305539</url></web-urls></urls><label>Oncotype DX</label><abstract>BACKGROUND: Sequential administration of paclitaxel plus combined fluorouracil, epirubicin, and cyclophosphamide (P-FEC) is 1 of the most common neoadjuvant chemotherapies for patients with primary breast cancer and produces pathologic complete response (pCR) rates of 20% to 30%. However, a predictor of pCR to this chemotherapy has yet to be developed. The authors developed such a predictor by using a proprietary DNA microarray for gene expression analysis of breast tumor tissues.

METHODS: Tumor samples were obtained from 84 patients with breast cancer by core-needle biopsy before the patients received P-FEC, and the gene expression profile was analyzed in those samples to construct a classifier for predicting pCR to P-FEC. In addition, the authors analyzed the gene expression profile of tumor tissues that were obtained at surgery from 105 patients with lymph node-negative and estrogen receptor-positive breast cancer who received adjuvant hormone therapy alone to determine the prognostic significance of the classifier.

RESULTS: The 70-gene classifier for predicting pCR to P-FEC was constructed by using the training set (n = 50) and subsequently was validated successfully in the validation set (n = 34), revealing high sensitivity (88%; 95% confidence interval [CI], 47%-100%) and high negative predictive value (93%; 95% CI, 68%-100%). Specificity and positive predictive value were 54% (95% CI, 33%-73%) and 37% (95% CI, 16%-62%), respectively. Among the various parameters (estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 status, etc), the 70-gene classifier had the strongest association with pCR (P = .015). In an additional study, genetically assumed complete responders were associated significantly (P = .047) with a poor prognosis.

CONCLUSIONS: The 70-gene classifier that was constructed for predicting pCR to P-FEC for breast tumors was successful, with high sensitivity and high negative predictive value. The classifier also appeared to be useful for predicting the prognosis of patients with lymph node-negative and estrogen receptor-positive breast cancer who receive adjuvant hormone therapy alone.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Dowsett, Mitch</author><author>Cuzick, Jack</author><author>Wale, Christopher</author><author>Forbes, John</author><author>Mallon, Elizabeth a</author><author>Salter, Janine</author><author>Quinn, Emma</author><author>Dunbier, Anita</author><author>Baum, Michael</author><author>Buzdar, Aman</author><author>Howell, Anthony</author><author>Bugarini, Roberto</author><author>Baehner, Frederick L</author><author>Shak, Steven</author></authors></contributors><titles><title>Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.</title><secondary-title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</secondary-title></titles><periodical><full-title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</full-title></periodical><pages>1829-34</pages><volume>28</volume><issue>11</issue><keywords><keyword>Adjuvant</keyword><keyword>Aged</keyword><keyword>Antineoplastic Combined Chemotherapy Protocols</keyword><keyword>Antineoplastic Combined Chemotherapy Protocols: th</keyword><keyword>Biological</keyword><keyword>Biological: genetics</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: diagnosis</keyword><keyword>Breast Neoplasms: drug therapy</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Chemotherapy</keyword><keyword>Female</keyword><keyword>Genetic Testing</keyword><keyword>Genetic Testing: methods</keyword><keyword>Humans</keyword><keyword>Local</keyword><keyword>Local: diagnosis</keyword><keyword>Local: drug therapy</keyword><keyword>Local: genetics</keyword><keyword>Lymph Nodes</keyword><keyword>Lymph Nodes: pathology</keyword><keyword>Neoplasm Recurrence</keyword><keyword>Nitriles</keyword><keyword>Nitriles: administration &amp; dosage</keyword><keyword>Postmenopause</keyword><keyword>Risk Factors</keyword><keyword>Survival Rate</keyword><keyword>Tamoxifen</keyword><keyword>Tamoxifen: administration &amp; dosage</keyword><keyword>Treatment Outcome</keyword><keyword>Triazoles</keyword><keyword>Triazoles: administration &amp; dosage</keyword><keyword>Tumor Markers</keyword></keywords><dates><year>2010</year></dates><accession-num>20212256</accession-num><electronic-resource-num>10.1200/JCO.2009.24.4798</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Dowsett et al. - 2010 - Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive p.pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/20212256</url></web-urls></urls><label>JULIA;Oncotype DX</label><abstract>PURPOSE To determine whether the Recurrence Score (RS) provided independent information on risk of distant recurrence (DR) in the tamoxifen and anastrozole arms of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trial. PATIENTS AND METHODS RNA was extracted from 1,372 tumor blocks from postmenopausal patients with hormone receptor-positive primary breast cancer in the monotherapy arms of ATAC. Twenty-one genes were assessed by quantitative reverse transcriptase polymerase chain reaction, and the RS was calculated. Cox proportional hazards models assessed the value of adding RS to a model with clinical variables (age, tumor size, grade, and treatment) in node-negative (N0) and node-positive (N+) women. RESULTS Reportable scores were available from 1,231 evaluable patients (N0, n = 872; N+, n = 306; and node status unknown, n = 53); 72, 74, and six DRs occurred in N0, N+, and node status unknown patients, respectively. For both N0 and N+ patients, RS was significantly associated with time to DR in multivariate analyses (P &lt; .001 for N0 and P = .002 for N+). RS also showed significant prognostic value beyond that provided by Adjuvant! Online (P &lt; .001). Nine-year DR rates in low (RS &lt; 18), intermediate (RS = 18 to 30), and high RS (RS &gt; or = 31) groups were 4%, 12%, and 25%, respectively, in N0 patients and 17%, 28%, and 49%, respectively, in N+ patients. The prognostic value of RS was similar in anastrozole- and tamoxifen-treated patients. CONCLUSION This study confirmed the performance of RS in postmenopausal HR+ patients treated with tamoxifen in a large contemporary population and demonstrated that RS is an independent predictor of DR in N0 and N+ hormone receptor-positive patients treated with anastrozole, adding value to estimates with standard clinicopathologic features.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Klein, Molly E</author><author>Dabbs, David J</author><author>Shuai, Yongli</author><author>Brufsky, Adam M</author><author>Jankowitz, Rachel</author><author>Puhalla, Shannon L</author><author>Bhargava, Rohit</author></authors></contributors><titles><title>Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.</title><secondary-title>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</secondary-title></titles><periodical><full-title>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</full-title></periodical><pages>658-64</pages><volume>26</volume><issue>5</issue><keywords><keyword>breast cancer</keyword><keyword>er</keyword><keyword>her2</keyword><keyword>immunohistochemistry</keyword><keyword>ki-67</keyword><keyword>morphology</keyword><keyword>oncotype dx recurrence</keyword><keyword>pr</keyword></keywords><dates><year>2013</year></dates><publisher>Nature Publishing Group</publisher><accession-num>23503643</accession-num><electronic-resource-num>10.1038/modpathol.2013.36</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Klein et al. - 2013 - Prediction of the Oncotype DX recurrence score use of pathology-generated equations derived by linear regression a.pdf</url></pdf-urls><web-urls><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3647116&amp;tool=pmcentrez&amp;rendertype=abstract</url></web-urls></urls><label>Oncotype DX;rogerjob</label><abstract>Oncotype DX is a commercial assay frequently used for making chemotherapy decisions in estrogen receptor (ER)-positive breast cancers. The result is reported as a recurrence score ranging from 0 to 100, divided into low-risk (&lt;18), intermediate-risk (18-30), and high-risk (≥31) categories. Our pilot study showed that recurrence score can be predicted by an equation incorporating standard morphoimmunohistologic variables (referred to as original Magee equation). Using a data set of 817 cases, we formulated three additional equations (referred to as new Magee equations 1, 2, and 3) to predict the recurrence score category for an independent set of 255 cases. The concordance between the risk category of Oncotype DX and our equations was 54.3%, 55.8%, 59.4%, and 54.4% for original Magee equation, new Magee equations 1, 2, and 3, respectively. When the intermediate category was eliminated, the concordance increased to 96.9%, 100%, 98.6%, and 98.7% for original Magee equation, new Magee equations 1, 2, and 3, respectively. Even when the estimated recurrence score fell in the intermediate category with any of the equations, the actual recurrence score was either intermediate or low in more than 80% of the cases. Any of the four equations can be used to estimate the recurrence score depending on available data. If the estimated recurrence score is clearly high or low, the oncologists should not expect a dramatically different result from Oncotype DX, and the Oncotype DX test may not be needed. Conversely, an Oncotype DX result that is dramatically different from what is expected based on standard morphoimmunohistologic variables should be thoroughly investigated.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Albain, Kathy S</author><author>Barlow, William E</author><author>Shak, Steven</author><author>Hortobagyi, Gabriel N</author><author>Livingston, Robert B</author><author>Yeh, I-Tien Tien</author><author>Ravdin, Peter</author><author>Bugarini, Roberto</author><author>Baehner, Frederick L</author><author>Davidson, Nancy E</author><author>Sledge, George W</author><author>Winer, Eric P</author><author>Hudis, Clifford</author><author>Ingle, James N</author><author>Perez, Edith a</author><author>Pritchard, Kathleen I</author><author>Shepherd, Lois</author><author>Gralow, Julie R</author><author>Yoshizawa, Carlo</author><author>Allred, D Craig</author><author>Osborne, C Kent</author><author>Hayes, Daniel F</author></authors></contributors><titles><title>Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial</title><secondary-title>The Lancet Oncology</secondary-title></titles><periodical><full-title>The Lancet Oncology</full-title></periodical><pages>55-65</pages><volume>11</volume><issue>1</issue><keywords><keyword>Adult</keyword><keyword>Aged</keyword><keyword>Antineoplastic Combined Chemotherapy Protocols</keyword><keyword>Antineoplastic Combined Chemotherapy Protocols: th</keyword><keyword>Biological</keyword><keyword>Biological: genetics</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: chemistry</keyword><keyword>Breast Neoplasms: drug therapy</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Breast Neoplasms: mortality</keyword><keyword>Breast Neoplasms: secondary</keyword><keyword>Clinical Trials</keyword><keyword>Cyclophosphamide</keyword><keyword>Cyclophosphamide: therapeutic use</keyword><keyword>Disease-Free Survival</keyword><keyword>Doxorubicin</keyword><keyword>Doxorubicin: therapeutic use</keyword><keyword>Estrogen</keyword><keyword>Estrogen: analysis</keyword><keyword>Female</keyword><keyword>Fluorouracil</keyword><keyword>Fluorouracil: therapeutic use</keyword><keyword>Gene Expression Profiling</keyword><keyword>Gene Expression Regulation</keyword><keyword>Genetic Testing</keyword><keyword>Genetic Testing: methods</keyword><keyword>Humans</keyword><keyword>Kaplan-Meier Estimate</keyword><keyword>Lymphatic Metastasis</keyword><keyword>Middle Aged</keyword><keyword>Neoplastic</keyword><keyword>Patient Selection</keyword><keyword>Phase III as Topic</keyword><keyword>Postmenopause</keyword><keyword>Predictive Value of Tests</keyword><keyword>Proportional Hazards Models</keyword><keyword>Randomized Controlled Trials as Topic</keyword><keyword>Receptors</keyword><keyword>Recurrence</keyword><keyword>Retrospective Studies</keyword><keyword>Reverse Transcriptase Polymerase Chain Reaction</keyword><keyword>Risk Assessment</keyword><keyword>Tamoxifen</keyword><keyword>Tamoxifen: therapeutic use</keyword><keyword>Time Factors</keyword><keyword>Treatment Outcome</keyword><keyword>Tumor Markers</keyword><keyword>United States</keyword><keyword>United States: epidemiology</keyword></keywords><dates><year>2010</year></dates><isbn>1474-5488 (Electronic)\r1470-2045 (Linking)</isbn><accession-num>20005174</accession-num><electronic-resource-num>10.1016/S1470-2045(09)70314-6</electronic-resource-num><urls><pdf-urls><url>internal-pdf://</url><url>internal-pdf://</url><url>internal-pdf://nihms227230.pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058239/</url><url>http://linkinghub.elsevier.com/retrieve/pii/S1470204509703146</url><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3058239&amp;tool=pmcentrez&amp;rendertype=abstract</url></web-urls></urls><label>JULIA;Oncotype DX;rogerjob</label><abstract>BACKGROUND: The 21-gene recurrence score assay is prognostic for women with node-negative, oestrogen-receptor-positive breast cancer treated with tamoxifen. A low recurrence score predicts little benefit of chemotherapy. For node-positive breast cancer, we investigated whether the recurrence score was prognostic in women treated with tamoxifen alone and whether it identified those who might not benefit from anthracycline-based chemotherapy, despite higher risks of recurrence. METHODS: The phase 3 trial SWOG-8814 for postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer showed that chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil (CAF) before tamoxifen (CAF-T) added survival benefit to treatment with tamoxifen alone. Optional tumour banking yielded specimens for determination of recurrence score by RT-PCR. In this retrospective analysis, we assessed the effect of recurrence score on disease-free survival by treatment group (tamoxifen vs CAF-T) using Cox regression, adjusting for number of positive nodes. FINDINGS: There were 367 specimens (40% of the 927 patients in the tamoxifen and CAF-T groups) with sufficient RNA for analysis (tamoxifen, n=148; CAF-T, n=219). The recurrence score was prognostic in the tamoxifen-alone group (p=0.006; hazard ratio [HR] 2.64, 95% CI 1.33-5.27, for a 50-point difference in recurrence score). There was no benefit of CAF in patients with a low recurrence score (score &lt;18; log-rank p=0.97; HR 1.02, 0.54-1.93), but an improvement in disease-free survival for those with a high recurrence score (score &gt; or =31; log-rank p=0.033; HR 0.59, 0.35-1.01), after adjustment for number of positive nodes. The recurrence score by treatment interaction was significant in the first 5 years (p=0.029), with no additional prediction beyond 5 years (p=0.58), although the cumulative benefit remained at 10 years. Results were similar for overall survival and breast-cancer-specific survival. INTERPRETATION: The recurrence score is prognostic for tamoxifen-treated patients with positive nodes and predicts significant benefit of CAF in tumours with a high recurrence score. A low recurrence score identifies women who might not benefit from anthracycline-based chemotherapy, despite positive nodes. FUNDING: National Cancer Institute and Genomic Health.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Volinia, Stefano</author><author>Croce, Carlo M</author></authors></contributors><titles><title>Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer.</title><secondary-title>Proceedings of the National Academy of Sciences of the United States of America</secondary-title></titles><periodical><full-title>Proceedings of the National Academy of Sciences of the United States of America</full-title></periodical><pages>7413-7</pages><volume>110</volume><issue>18</issue><keywords><keyword>Breast</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: classification</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Breast Neoplasms: pathology</keyword><keyword>Breast: genetics</keyword><keyword>Breast: pathology</keyword><keyword>Carcinoma</keyword><keyword>Cohort Studies</keyword><keyword>DNA Methylation</keyword><keyword>DNA Methylation: genetics</keyword><keyword>Ductal</keyword><keyword>Female</keyword><keyword>Gene Expression Profiling</keyword><keyword>Gene Expression Regulation</keyword><keyword>Genes</keyword><keyword>Genome</keyword><keyword>Human</keyword><keyword>Human: genetics</keyword><keyword>Humans</keyword><keyword>Kaplan-Meier Estimate</keyword><keyword>Messenger</keyword><keyword>Messenger: genetics</keyword><keyword>Messenger: metabolism</keyword><keyword>MicroRNAs</keyword><keyword>MicroRNAs: genetics</keyword><keyword>MicroRNAs: metabolism</keyword><keyword>Neoplasm</keyword><keyword>Neoplasm Invasiveness</keyword><keyword>Neoplasm: genetics</keyword><keyword>Neoplastic</keyword><keyword>Prognosis</keyword><keyword>RNA</keyword><keyword>ROC Curve</keyword><keyword>Reproducibility of Results</keyword><keyword>Risk Factors</keyword></keywords><dates><year>2013</year></dates><isbn>1304977110</isbn><accession-num>23589849</accession-num><electronic-resource-num>10.1073/pnas.1304977110</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Volinia, Croce - 2013 - Prognostic microRNAmRNA signature from the integrated analysis of patients with invasive breast cancer.pdf</url><url>internal-pdf://pnas.201304977.pdf</url></pdf-urls><web-urls><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3645522&amp;tool=pmcentrez&amp;rendertype=abstract</url></web-urls></urls><label>JULIA;Oncotype DX;rogerjob</label><abstract>The optimal management of breast cancer (BC) presents challenges due to the heterogeneous molecular classification of the disease. We performed survival analysis on a cohort of 466 patients with primary invasive ductal carcinoma (IDC), the most frequent type of BC, by integrating mRNA, microRNA (miRNA), and DNA methylation next-generation sequencing data from The Cancer Genome Atlas (TCGA). Expression data from eight other BC cohorts were used for validation. The prognostic value of the resulting miRNA/mRNA signature was compared with that of other prognostic BC signatures. Thirty mRNAs and seven miRNAs were associated with overall survival across different clinical and molecular subclasses of a 466-patient IDC cohort from TCGA. The prognostic RNAs included PIK3CA, one of the two most frequently mutated genes in IDC, and miRNAs such as hsa-miR-328, hsa-miR-484, and hsa-miR-874. The area under the curve of the receiver-operator characteristic for the IDC risk predictor in the TCGA cohort was 0.74 at 60 mo of overall survival (P &lt; 0.001). Most relevant for clinical application, the integrated signature had the highest prognostic value in early stage I and II tumors (receiver-operator characteristic area under the curve = 0.77, P value &lt; 0.001). The genes in the RNA risk predictor had an independent prognostic value compared with the clinical covariates, as shown by multivariate analysis. The integrated RNA signature was successfully validated on eight BC cohorts, comprising a total of 2,399 patients, and it had superior performance for risk stratification with respect to other RNA predictors, including the mRNAs used in MammaPrint and Oncotype DX assays.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Goldstein, Lori J</author><author>Gray, Robert</author><author>Badve, Sunil</author><author>Childs, Barrett H</author><author>Yoshizawa, Carl</author><author>Rowley, Steve</author><author>Shak, Steven</author><author>Baehner, Frederick L</author><author>Ravdin, Peter M</author><author>Davidson, Nancy E</author><author>Sledge, George W</author><author>Perez, Edith a</author><author>Shulman, Lawrence N</author><author>Martino, Silvana</author><author>Sparano, Joseph a</author></authors></contributors><titles><title>Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.</title><secondary-title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</secondary-title></titles><periodical><full-title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</full-title></periodical><pages>4063-71</pages><volume>26</volume><issue>25</issue><keywords><keyword>Adult</keyword><keyword>Aged</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: diagnosis</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Breast Neoplasms: surgery</keyword><keyword>Estrogen</keyword><keyword>Estrogen: biosynthesis</keyword><keyword>Female</keyword><keyword>Gene Expression Profiling</keyword><keyword>Gene Expression Profiling: methods</keyword><keyword>Gene Expression Regulation</keyword><keyword>Humans</keyword><keyword>Lymph Nodes</keyword><keyword>Lymph Nodes: pathology</keyword><keyword>Medical Oncology</keyword><keyword>Medical Oncology: methods</keyword><keyword>Middle Aged</keyword><keyword>Neoplastic</keyword><keyword>Prognosis</keyword><keyword>Receptors</keyword><keyword>Recurrence</keyword><keyword>Risk</keyword><keyword>Time Factors</keyword></keywords><dates><year>2008</year></dates><accession-num>18678838</accession-num><electronic-resource-num>10.1200/JCO.2007.14.4501</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Goldstein et al. - 2008 - Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with c(3).pdf</url><url>internal-pdf://Goldstein et al. - 2008 - Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with clas.pdf</url><url>internal-pdf://Goldstein et al. - 2008 - Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with c(2).pdf</url></pdf-urls><web-urls><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2654377&amp;tool=pmcentrez&amp;rendertype=abstract</url></web-urls></urls><label>JULIA;Oncotype DX;rogerjob</label><abstract>Adjuvant! is a standardized validated decision aid that projects outcomes in operable breast cancer based on classical clinicopathologic features and therapy. Genomic classifiers offer the potential to more accurately identify individuals who benefit from chemotherapy than clinicopathologic features.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Jonsdottir, Kristin</author><author>Assmus, Jörg</author><author>Slewa, Aida</author><author>Gudlaugsson, Einar</author><author>Skaland, Ivar</author><author>Baak, Jan P a</author><author>Janssen, Emiel a M</author></authors></contributors><titles><title>Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer.</title><secondary-title>PloS one</secondary-title></titles><periodical><full-title>PloS one</full-title></periodical><pages>e90642</pages><volume>9</volume><issue>3</issue><keywords/><dates><year>2014</year></dates><accession-num>24599057</accession-num><electronic-resource-num>10.1371/journal.pone.0090642</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Jonsdottir et al. - 2014 - Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer(2).pdf</url><url>internal-pdf://Jonsdottir et al. - 2014 - Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer.pdf</url><url>internal-pdf://pone.0090642.pdf</url></pdf-urls><web-urls><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3944091&amp;tool=pmcentrez&amp;rendertype=abstract</url><url>http://www.ncbi.nlm.nih.gov/pubmed/24599057</url><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3944091</url></web-urls></urls><label>JULIA;Oncotype DX;rogerjob</label><abstract>INTRODUCTION: The overall survival rate is good for lymph-node-negative breast cancer patients, but they still suffer from serious over- and some undertreatments. Prognostic and predictive gene signatures for node-negative breast cancer have a high number of genes related to proliferation. The prognostic value of gene sets from commercial gene-expression assays were compared with proliferation markers. METHODS: Illumina WG6 mRNA microarray analysis was used to examine 94 fresh-frozen tumour samples from node-negative breast cancer patients. The patients were divided into low- and high-risk groups for distant metastasis based on the MammaPrint-related genes, and into low-, intermediate- and high-risk groups based on the recurrence score algorithm with genes included in Oncotype DX. These data were then compared to proliferation status, as measured by the mitotic activity index, the expressions of phosphohistone H3 (PPH3), and Ki67. RESULTS: Kaplan-Meier survival analysis for distant-metastasis-free survival revealed that patients with weak and strong PPH3 expressions had 14-year survival rates of 87% (n=45), and 65% (n=49, p=0.014), respectively. Analysis of the MammaPrint classification resulted in 14-year survival rates of 80% (n=45) and 71% (n=49, p=0.287) for patients with low and high risks of recurrence, respectively. The Oncotype DX categorization yielded 14-year survival rates of 83% (n=18), 79% (n=42) and 68% (n=34) for those in the low-, intermediate- and high-risk groups, respectively (p=0.52). Supervised hierarchical cluster analysis for distant-metastasis-free survival in the subgroup of patients with strong PPH3 expression revealed that the genes involved in Notch signalling and cell adhesion were expressed at higher levels in those patients with distant metastasis. CONCLUSION: This pilot study indicates that proliferation has greater prognostic value than the expressions of either MammaPrint- or Oncotype-DX-related genes. Furthermore, in the subgroup of patients with high proliferation, Notch signalling pathway genes appear to be expressed at higher levels in patients who develop distant metastasis.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Gligoriv, Joseph</author><author>Pivot, X.B.</author><author>Jacot, William</author><author>Nama, Herve L.</author><author>Spaieth, D.</author><author>Misset, J-L</author><author>Largillier, Remy</author><author>Sautier, J-L</author><author>de Roquancourt, Anne</author><author>Pomel, C</author><author>Rouaet, P</author><author>Rouzier, R</author></authors></contributors><titles><title>Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer : Results From the SWITCH Study</title><secondary-title>The Oncologist</secondary-title></titles><periodical><full-title>The Oncologist</full-title></periodical><pages>1-7</pages><volume>20</volume><keywords><keyword>adjuvant x chemotherapy x</keyword><keyword>early breast cancer x</keyword><keyword>estrogen receptor-positive</keyword></keywords><dates><year>2015</year></dates><urls><pdf-urls><url>internal-pdf://The Oncologist-2015-Gligorov-theoncologist.2014-0467.pdf</url></pdf-urls></urls><label>JULIA;Oncotype DX;rogerjob</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Sparano, Joseph A.</author><author>Gray, Robert J.</author><author>Makower, Della F.</author><author>Pritchard, Kathleen I.</author><author>Albain, Kathy S.</author><author>Hayes, Daniel F.</author><author>Geyer, Charles E.</author><author>Dees, Elizabeth C.</author><author>Perez, Edith A.</author><author>Olson, John A.</author><author>Zujewski, JoAnne</author><author>Lively, Tracy</author><author>Badve, Sunil S.</author><author>Saphner, Thomas J.</author><author>Wagner, Lynne I.</author><author>Whelan, Timothy J.</author><author>Ellis, Matthew J.</author><author>Paik, Soonmyung</author><author>Wood, William C.</author><author>Ravdin, Peter</author><author>Keane, Maccon M.</author><author>Gomez Moreno, Henry L.</author><author>Reddy, Pavan S.</author><author>Goggins, Timothy F.</author><author>Mayer, Ingrid A.</author><author>Brufsky, Adam M.</author><author>Toppmeyer, Deborah L.</author><author>Kaklamani, Virginia G.</author><author>Atkins, James N.</author><author>Berenberg, Jeffrey L.</author><author>Sledge, George W.</author></authors></contributors><titles><title>Prospective Validation of a 21-Gene Expression Assay in Breast Cancer</title><secondary-title>New England Journal of Medicine</secondary-title></titles><periodical><full-title>New England Journal of Medicine</full-title></periodical><pages>150927220039001</pages><keywords/><dates><year>2015</year></dates><electronic-resource-num>10.1056/NEJMoa1510764</electronic-resource-num><urls><pdf-urls><url>internal-pdf://nejmoa1510764.pdf</url></pdf-urls><web-urls><url>http://www.nejm.org/doi/abs/10.1056/NEJMoa1510764</url></web-urls></urls><label>Oncotype DX;rogerjob</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Creighton, Chad J</author><author>Fu, Xiaoyong</author><author>Hennessy, Bryan T</author><author>Casa, Angelo J</author><author>Zhang, Yiqun</author><author>Gonzalez-Angulo, Ana Maria</author><author>Lluch, Ana</author><author>Gray, Joe W</author><author>Brown, Powell H</author><author>Hilsenbeck, Susan G</author><author>Osborne, C Kent</author><author>Mills, Gordon B</author><author>Lee, Adrian V</author><author>Schiff, Rachel</author></authors></contributors><titles><title>Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.</title><secondary-title>Breast cancer research : BCR</secondary-title></titles><periodical><full-title>Breast cancer research : BCR</full-title></periodical><pages>R40</pages><volume>12</volume><issue>3</issue><keywords><keyword>Biological</keyword><keyword>Biological: genetics</keyword><keyword>Biological: metabolism</keyword><keyword>Blotting</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Breast Neoplasms: metabolism</keyword><keyword>Breast Neoplasms: pathology</keyword><keyword>Cell Proliferation</keyword><keyword>Cultured</keyword><keyword>Estrogen</keyword><keyword>Estrogen: metabolism</keyword><keyword>Female</keyword><keyword>Gene Expression Profiling</keyword><keyword>Gene Expression Regulation</keyword><keyword>Humans</keyword><keyword>Insulin-Like Growth Factor I</keyword><keyword>Insulin-Like Growth Factor I: pharmacology</keyword><keyword>Messenger</keyword><keyword>Messenger: genetics</keyword><keyword>Neoplastic</keyword><keyword>Oligonucleotide Array Sequence Analysis</keyword><keyword>Phosphatidylinositol 3-Kinases</keyword><keyword>Phosphatidylinositol 3-Kinases: metabolism</keyword><keyword>Prognosis</keyword><keyword>Proteome</keyword><keyword>Proteome: analysis</keyword><keyword>Proto-Oncogene Proteins c-akt</keyword><keyword>Proto-Oncogene Proteins c-akt: metabolism</keyword><keyword>RNA</keyword><keyword>Receptors</keyword><keyword>Reverse Transcriptase Polymerase Chain Reaction</keyword><keyword>Signal Transduction</keyword><keyword>Tumor Cells</keyword><keyword>Tumor Markers</keyword><keyword>Western</keyword></keywords><dates><year>2010</year></dates><accession-num>20569503</accession-num><electronic-resource-num>10.1186/bcr2594</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Creighton et al. - 2010 - Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER.pdf</url><url>internal-pdf://Creighton et al. - 2010 - Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (2).pdf</url></pdf-urls><web-urls><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2917035&amp;tool=pmcentrez&amp;rendertype=abstract</url></web-urls></urls><label>JULIA;Oncotype DX;rogerjob</label><abstract>Accumulating evidence suggests that both levels and activity of the estrogen receptor (ER) and the progesterone receptor (PR) are dramatically influenced by growth-factor receptor (GFR) signaling pathways, and that this crosstalk is a major determinant of both breast cancer progression and response to therapy. The phosphatidylinositol 3-kinase (PI3K) pathway, a key mediator of GFR signaling, is one of the most altered pathways in breast cancer. We thus examined whether deregulated PI3K signaling in luminal ER+ breast tumors is associated with ER level and activity and intrinsic molecular subtype.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>McShane, Lisa M</author><author>Hayes, Daniel F</author></authors></contributors><titles><title>Publication of tumor marker research results: the necessity for complete and transparent reporting.</title><secondary-title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</secondary-title></titles><periodical><full-title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</full-title></periodical><pages>4223-32</pages><volume>30</volume><issue>34</issue><keywords/><dates><year>2012</year></dates><accession-num>23071235</accession-num><electronic-resource-num>10.1200/JCO.2012.42.6858</electronic-resource-num><urls><pdf-urls><url>internal-pdf://McShane, Hayes - 2012 - Publication of tumor marker research results the necessity for complete and transparent reporting(2).pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/23071235</url></web-urls></urls><label>JULIA;NNT paper;Oncotype DX;biomarker;economic focus;rogerjob</label><abstract>Clinical management decisions for patients with cancer are increasingly being guided by prognostic and predictive markers. Use of these markers should be based on a sufficiently comprehensive body of unbiased evidence to establish that benefits to patients outweigh harms and to justify expenditure of health care dollars. Careful assessments of the clinical utility of markers by using comparative effectiveness research methods are urgently needed to more rigorously summarize and evaluate the evidence, but multiple factors have made such assessments difficult. The literature on tumor markers is plagued by nonpublication bias, selective reporting, and incomplete reporting. Several measures to address these problems are discussed, including development of a tumor marker study registry, greater attention to assay analytic performance and specimen quality, use of more rigorous study designs and analysis plans to establish clinical utility, and adherence to higher standards for reporting tumor marker studies. More complete and transparent reporting by adhering to criteria such as BRISQ [Biospecimen Reporting for Improved Study Quality] criteria for reporting details about specimens and REMARK [Reporting Recommendations for Tumor Marker Prognostic Studies] criteria for reporting a multitude of aspects relating to study design, analysis, and results, is essential for reliable assessment of study quality, detection of potential biases, and proper interpretation of study findings. Adopting these measures will improve the quality of the body of evidence available for comparative effectiveness research and enhance the ability to establish the clinical utility of prognostic and predictive tumor markers.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Blonder, Josip</author><author>Johann, Donald J</author><author>Veenstra, Timothy D</author><author>Xiao, Zhen</author><author>Michael, R</author><author>Ziegler, Regina G</author><author>Rodriguez-canales, Jaime</author><author>Hanson, Jeffrey A</author><author>Xu, Xia</author><author>Emmert-buck, Michael R</author></authors></contributors><titles><title>Quantitation of Steroid Hormones in Thin Fresh Frozen Tissue Sections Quantitation of Steroid Hormones in Thin Fresh Frozen Tissue Sections</title></titles><periodical/><keywords/><dates><year>2008</year></dates><electronic-resource-num>10.1021/ac801402a</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Blonder et al. - 2008 - Quantitation of Steroid Hormones in Thin Fresh Frozen Tissue Sections Quantitation of Steroid Hormones in Thi(3).pdf</url></pdf-urls></urls><label>JULIA;Oncotype DX;rogerjob</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Conference Proceedings">3</ref-type><contributors><authors><author>Klein, EA</author><author>Falzarano, SM</author><author>Maddala, T</author><author>Millward, C</author><author>Novotny, WF</author><author>Pelham, RJ</author><author>Cherbavaz, D</author><author>Magi-Galuzzi, C</author></authors></contributors><titles><title>Quantitative Gene Expression in Primary and Highest Gleason Pattern Cancers Identifies Genes Associated with Clinical Recurrence After Radical Prostatectomy</title><secondary-title>Cleveland Clinic</secondary-title></titles><periodical><full-title>Cleveland Clinic</full-title></periodical><pages>1</pages><keywords/><urls><pdf-urls><url>internal-pdf://Ea et al. - Unknown - Quantitative Gene Expression in Primary and Highest Gleason Pattern Cancers Identifies Genes Associated with Cl(3).pdf</url><url>internal-pdf://Ea et al. - Unknown - Quantitative Gene Expression in Primary and Highest Gleason Pattern Cancers Identifies Genes Associated with Clini.pdf</url><url>internal-pdf://Ea et al. - Unknown - Quantitative Gene Expression in Primary and Highest Gleason Pattern Cancers Identifies Genes Associated with Cl(2).pdf</url></pdf-urls></urls><label>NNT paper;Oncotype DX;rogerjob</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Conference Proceedings">3</ref-type><contributors><authors><author>Klein, E.A.</author><author>Falzarano, SM</author><author>Maddala, T</author><author>MilwardC</author><author>Novotny, WF</author><author>Pelhan, RJ</author><author>Cherbavez, D</author></authors></contributors><titles><title>Quantitative gene expression in primary and highest gleason pattern cancers identifies genes associated with clinical recurrence after radical prostatectomy</title></titles><periodical/><pages>95</pages><keywords/><urls><pdf-urls><url>internal-pdf://Klein et al. - Unknown - Quantitative gene expression in primary and highest gleason pattern cancers identifies genes associated with cl.pdf</url></pdf-urls></urls><label>NNT paper;Oncotype DX;rogerjob</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Tang, Gong</author><author>Cuzick, Jack</author><author>Costantino, Joseph P</author><author>Dowsett, Mitch</author><author>Forbes, John F</author><author>Crager, Michael</author><author>Mamounas, Eleftherios P</author><author>Shak, Steven</author><author>Wolmark, Norman</author></authors></contributors><titles><title>Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.</title><secondary-title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</secondary-title></titles><periodical><full-title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</full-title></periodical><pages>4365-72</pages><volume>29</volume><issue>33</issue><keywords><keyword>Aged</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: chemistry</keyword><keyword>Breast Neoplasms: drug therapy</keyword><keyword>Breast Neoplasms: pathology</keyword><keyword>Estrogen</keyword><keyword>Estrogen: analysis</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Local</keyword><keyword>Local: etiology</keyword><keyword>Lymphatic Metastasis</keyword><keyword>Middle Aged</keyword><keyword>Neoplasm Recurrence</keyword><keyword>Predictive Value of Tests</keyword><keyword>Proportional Hazards Models</keyword><keyword>Receptors</keyword><keyword>Risk Assessment</keyword></keywords><dates><year>2011</year></dates><accession-num>22010013</accession-num><electronic-resource-num>10.1200/JCO.2011.35.3714</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Tang et al. - 2011 - Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast c(3).pdf</url><url>internal-pdf://Tang et al. - 2011 - Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast c(4).pdf</url><url>internal-pdf://Tang et al. - 2011 - Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast c(2).pdf</url></pdf-urls><web-urls><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3221521&amp;tool=pmcentrez&amp;rendertype=abstract</url></web-urls></urls><label>Oncotype DX;rogerjob</label><abstract>The 21-gene breast cancer assay recurrence score (RS) is widely used for assessing recurrence risk and predicting chemotherapy benefit in patients with estrogen receptor (ER) -positive breast cancer. Pathologic and clinical factors such as tumor size, grade, and patient age also provide independent prognostic utility. We developed a formal integration of these measures and evaluated its prognostic and predictive value.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Retèl, Valesca P</author><author>Joore, Manuela a</author><author>Linn, Sabine C</author><author>Rutgers, Emiel J T</author><author>van Harten, Wim H</author></authors></contributors><titles><title>Scenario drafting to anticipate future developments in technology assessment.</title><secondary-title>BMC research notes</secondary-title></titles><periodical><full-title>BMC research notes</full-title></periodical><pages>442</pages><volume>5</volume><keywords><keyword>Antineoplastic Agents</keyword><keyword>Antineoplastic Agents: therapeutic use</keyword><keyword>Biomedical</keyword><keyword>Biomedical: economics</keyword><keyword>Biomedical: trends</keyword><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: diagnosis</keyword><keyword>Breast Neoplasms: drug therapy</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Computer Simulation</keyword><keyword>Cost-Benefit Analysis</keyword><keyword>Decision Support Techniques</keyword><keyword>Diffusion of Innovation</keyword><keyword>Economic</keyword><keyword>Female</keyword><keyword>Forecasting</keyword><keyword>Gene Expression Profiling</keyword><keyword>Gene Expression Profiling: economics</keyword><keyword>Gene Expression Profiling: trends</keyword><keyword>Genetic Predisposition to Disease</keyword><keyword>Genetic Testing</keyword><keyword>Genetic Testing: economics</keyword><keyword>Genetic Testing: trends</keyword><keyword>Health Care Costs</keyword><keyword>Health Care Costs: trends</keyword><keyword>Humans</keyword><keyword>Markov Chains</keyword><keyword>Middle Aged</keyword><keyword>Models</keyword><keyword>Oligonucleotide Array Sequence Analysis</keyword><keyword>Oligonucleotide Array Sequence Analysis: economics</keyword><keyword>Oligonucleotide Array Sequence Analysis: trends</keyword><keyword>Patient Selection</keyword><keyword>Practice Guidelines as Topic</keyword><keyword>Predictive Value of Tests</keyword><keyword>Quality-Adjusted Life Years</keyword><keyword>Questionnaires</keyword><keyword>Statistical</keyword><keyword>Technology Assessment</keyword><keyword>Time Factors</keyword><keyword>Uncertainty</keyword></keywords><dates><year>2012</year></dates><accession-num>22894140</accession-num><electronic-resource-num>10.1186/1756-0500-5-442</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Retèl et al. - 2012 - Scenario drafting to anticipate future developments in technology assessment(2).pdf</url><url>internal-pdf://1756-0500-5-442.pdf</url><url>internal-pdf://Retèl et al. - 2012 - Scenario drafting to anticipate future developments in technology assessment.pdf</url></pdf-urls><web-urls><url>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3444406&amp;tool=pmcentrez&amp;rendertype=abstract</url></web-urls></urls><label>Oncotype DX;rogerjob</label><abstract>BACKGROUND: Health Technology Assessment (HTA) information, and in particular cost-effectiveness data is needed to guide decisions, preferably already in early stages of technological development. However, at that moment there is usually a high degree of uncertainty, because evidence is limited and different development paths are still possible. We developed a multi-parameter framework to assess dynamic aspects of a technology -still in development-, by means of scenario drafting to determine the effects, costs and cost-effectiveness of possible future diffusion patterns. Secondly, we explored the value of this method on the case of the clinical implementation of the 70-gene signature for breast cancer, a gene expression profile for selecting patients who will benefit most from chemotherapy.

METHODS: To incorporate process-uncertainty, ten possible scenarios regarding the introduction of the 70-gene signature were drafted with European experts. Out of 5 most likely scenarios, 3 drivers of diffusion (non-compliance, technical failure, and uptake) were quantitatively integrated in a decision-analytical model. For these scenarios, the cost-effectiveness of the 70-gene signature expressed in Incremental Cost-Effectiveness Ratios (ICERs) was compared to clinical guidelines, calculated from the past (2005) until the future (2020).

RESULTS: In 2005 the ICER was €1,9 million/quality-adjusted-life-year (QALY), meaning that the 70-gene signature was not yet cost-effective compared to the current clinical guideline. The ICER for the 70-gene signature improved over time with a range of €1,9 million to €26,145 in 2010 and €1,9 million to €11,123/QALY in 2020 depending on the separate scenario used. From 2010, the 70-gene signature should be cost-effective, based on the combined scenario. The uptake-scenario had strongest influence on the cost-effectiveness.

CONCLUSIONS: When optimal diffusion of a technology is sought, incorporating process-uncertainty by means of scenario drafting into a decision model may reveal unanticipated developments and can demonstrate a range of possible cost-effectiveness outcomes. The effect of scenarios give additional information on the speed with cost effectiveness might be reached and thus provide a more realistic picture for policy makers, opinion leaders and manufacturers.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Yamauchi, Hideko</author><author>Nakagawa, Chizuko</author><author>Yamashige, Shinji</author><author>Takei, Hiroyuki</author><author>Yagata, Hiroshi</author><author>Yoshida, Atsushi</author><author>Hayashi, Naoki</author><author>Hornberger, John</author><author>Yu, Tiffany</author><author>Chao, Calvin</author><author>Yoshizawa, Carl</author><author>Nakamura, Seigo</author></authors></contributors><titles><title>Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor – positive , lymph-node – negative early-stage breast cancer in Japan</title></titles><periodical/><pages>1-9</pages><keywords><keyword>breast cancer</keyword><keyword>correspondence</keyword><keyword>cost-benefit</keyword><keyword>cost-effectiveness</keyword><keyword>edu</keyword><keyword>genetic testing</keyword><keyword>molecular diagnostic testing</keyword><keyword>stanford</keyword><keyword>ujch</keyword></keywords><dates><year>2014</year></dates><urls><pdf-urls><url>internal-pdf://Yamauchi et al. - 2014 - Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor – positive , lymph-node –(2).pdf</url><url>internal-pdf://12913_2013_Article_3476.pdf</url><url>internal-pdf://Yamauchi et al. - 2014 - Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor – positive , lymph-node – ne.pdf</url></pdf-urls></urls><label>Oncotype DX;rogerjob</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Biankin, Andrew V</author><author>Hudson, Thomas J</author></authors></contributors><titles><title>Somatic variation and cancer: therapies lost in the mix.</title><secondary-title>Human genetics</secondary-title></titles><periodical><full-title>Human genetics</full-title></periodical><pages>79-91</pages><volume>130</volume><issue>1</issue><keywords><keyword>Biological</keyword><keyword>Biological: analysis</keyword><keyword>DNA Damage</keyword><keyword>Genes</keyword><keyword>Genetic Variation</keyword><keyword>Genotype</keyword><keyword>Humans</keyword><keyword>Molecular Targeted Therapy</keyword><keyword>Mutation</keyword><keyword>Neoplasm</keyword><keyword>Neoplasms</keyword><keyword>Neoplasms: genetics</keyword><keyword>Neoplasms: therapy</keyword><keyword>Randomized Controlled Trials as Topic</keyword><keyword>Randomized Controlled Trials as Topic: methods</keyword><keyword>Tumor Markers</keyword></keywords><dates><year>2011</year></dates><accession-num>21643984</accession-num><electronic-resource-num>10.1007/s00439-011-1010-0</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Biankin, Hudson - 2011 - Somatic variation and cancer therapies lost in the mix.pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/21643984</url></web-urls></urls><label>Oncotype DX;rogerjob</label><abstract>Cancer arises as a consequence of mutations in genomes of cancer cells, which over time allow them to proliferate and spread to distant sites. Large-scale sequencing of cancer genomes is revealing an increasing number of potential driver mutations that may allow specific targeting of cancer genes, proteins, and pathways. Comprehensive views of cancer genomes are also revealing enormous heterogeneity of mutation profiles, even among tumours derived from the same organs and having similar pathological characteristics. There are now many examples where mutation profiles observed in tumours have been shown to correlate with clinical features of disease, drug response, and patient outcomes. When ignored, molecular heterogeneity can lead to failures in drug development, as drugs that may have efficacy in subgroups of patients with specific molecular phenotypes may show marginal response when tested in large groups of unselected patients. This article explores issues relevant to the clinical translation of sequence-based mutation profiles in the clinical development of targeted therapies and in the future management of cancer patients.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Stemmer, Salomon M.</author><author>Klang, Shmuel H.</author><author>Ben-Baruch, Noa</author><author>Geffen, David B.</author><author>Steiner, Mariana</author><author>Soussan-Gutman, Lior</author><author>Merling, Shahar</author><author>Svedman, Christer</author><author>Rizel, Shulamith</author><author>Lieberman, Nicky</author></authors></contributors><titles><title>The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients</title><secondary-title>Breast Cancer Research and Treatment</secondary-title></titles><periodical><full-title>Breast Cancer Research and Treatment</full-title></periodical><pages>83-92</pages><volume>140</volume><issue>1</issue><keywords><keyword>Adjuvant chemotherapy</keyword><keyword>Breast cancer</keyword><keyword>Decision-making</keyword><keyword>Node positive</keyword><keyword>Oncotype DX</keyword><keyword>Recurrence Score</keyword></keywords><dates><year>2013</year></dates><accession-num>23801158</accession-num><electronic-resource-num>10.1007/s10549-013-2603-1</electronic-resource-num><urls><pdf-urls><url>internal-pdf://10549_2013_Article_2603.pdf</url></pdf-urls></urls><label>Oncotype DX;rogerjob</label><abstract>Oncotype DX testing is reimbursed in Israel for node-negative and node-positive (N1+; up to 3 positive nodes including micrometastases), estrogen receptor positive (ER+), breast cancer patients. This retrospective study evaluated the impact of Oncotype DX testing on treatment decisions in N1+/ER+ breast cancer patients. To this end, we compared treatments for all N+ patients for whom testing had been ordered with treatments for patients with similar characteristics where the test had not been available. The retrospective analysis included 951 patients (282 Oncotype DX, 669 controls), all of whom received endocrine therapy with or without chemotherapy. In Oncotype DX patients, 7.1, 37.0, and 100 % of those with low, intermediate, and high Recurrence Score results (Oncotype DX summary score) received chemotherapy, respectively (P &lt; 0.0001, all comparisons). Chemotherapy use was lower in Oncotype DX patients versus controls (24.5 vs. 70.1 %). In a multivariate logistic regression analysis in which the probability of receiving chemotherapy was modeled as a function of Oncotype DX testing, age, tumor size, tumor grade, nodal status, and the interactions between Oncotype DX testing and the other covariates, Oncotype DX testing was associated with significantly lower odds of receiving chemotherapy (odds ratio 0.16; 95 % CI 0.11-0.24; P &lt; 0.0001). In summary, our findings suggest that Oncotype DX testing has a significant impact on reducing chemotherapy use in N1+/ER+ breast cancer patients in Israel.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Carlson, Josh J.</author><author>Roth, Joshua a.</author></authors></contributors><titles><title>The impact of the Oncotype Dx breast cancer assay in clinical practice: A systematic review and meta-analysis</title><secondary-title>Breast Cancer Research and Treatment</secondary-title></titles><periodical><full-title>Breast Cancer Research and Treatment</full-title></periodical><pages>13-22</pages><volume>141</volume><issue>1</issue><keywords><keyword>Adjuvant chemotherapy</keyword><keyword>Breast cancer</keyword><keyword>Gene expression</keyword><keyword>Meta-analysis</keyword></keywords><dates><year>2013</year></dates><isbn>1573-7217 (Electronic)\r0167-6806 (Linking)</isbn><accession-num>23974828</accession-num><electronic-resource-num>10.1007/s10549-013-2666-z</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Carlson, Roth - 2013 - The impact of the Oncotype Dx breast cancer assay in clinical practice A systematic review and meta-analysis(2).pdf</url></pdf-urls></urls><label>Oncotype DX;rogerjob</label><abstract>The impact of the Oncotype Dx (ODX) breast cancer assay on adjuvant chemotherapy (ACT) treatment decisions has been evaluated in many previous studies. However, it can be difficult to interpret the collective findings, which were conducted in diverse settings with limited sample sizes. We conducted a systematic review and meta-analysis to synthesize the results and provide insights about ODX utility. Studies, identified from PubMed, Embase, ASCO, and SABCS, were included if patients had ER+, node -, early-stage breast cancer, reported use of ODX to inform actual ACT decisions. Information was summarized and pooled according to: (1) distribution of ODX recurrence scores (RS), (2) impact of ODX on ACT recommendations, (3) impact of ODX on ACT use, and (4) proportion of patients following the treatment suggested by the ODX RS. A total of 23 studies met inclusion criteria. The distribution of RS categories was 48.8 % low, 39.0 % intermediate, and 12.2 % high (21 studies, 4,156 patients). ODX changed the clinical-pathological ACT recommendation in 33.4 % of patients (8 studies, 1,437 patients). In patients receiving ODX, receipt of ACT were: 28.2 % overall, 5.8 % low, 37.4 % intermediate, and 83.4 % high. High RS patients were significantly more likely to follow the treatment suggested by ODX versus low RS patients RR: 1.07 (1.01-1.14). The pooled results are consistent with most individual studies to date. The increased proportion of intermediate scores relative to original estimates may have implications for the clinical utility and cost impacts of testing. In addition, low versus high RS patients were significantly more likely to follow the ODX results, suggesting a tendency toward less aggressive treatment, despite a high ODX RS. Finally, there was a lack of studies on the impact of ODX on ACT use versus standard approaches, suggesting that additional studies are warranted.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Ransohoff, David F</author></authors></contributors><titles><title>The process to discover and develop biomarkers for cancer: a work in progress.</title><secondary-title>Journal of the National Cancer Institute</secondary-title></titles><periodical><full-title>Journal of the National Cancer Institute</full-title></periodical><pages>1419-20</pages><volume>100</volume><issue>20</issue><keywords><keyword>Biological</keyword><keyword>Biological: analysis</keyword><keyword>Humans</keyword><keyword>Neoplasms</keyword><keyword>Neoplasms: diagnosis</keyword><keyword>Tumor Markers</keyword></keywords><dates><year>2008</year></dates><accession-num>18840815</accession-num><electronic-resource-num>10.1093/jnci/djn339</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Ransohoff - 2008 - The process to discover and develop biomarkers for cancer a work in progress(3).pdf</url><url>internal-pdf://Ransohoff - 2008 - The process to discover and develop biomarkers for cancer a work in progress.pdf</url><url>internal-pdf://Ransohoff - 2008 - The process to discover and develop biomarkers for cancer a work in progress(2).pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/18840815</url></web-urls></urls><label>NNT paper;OncoType DX;Oncotype DX;rogerjob</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Ethier, Josee-Lyne</author><author>Amir, Eitan</author></authors></contributors><titles><title>The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment</title><secondary-title>Molecular Diagnosis &amp; Therapy</secondary-title></titles><periodical><full-title>Molecular Diagnosis &amp; Therapy</full-title></periodical><pages>307-313</pages><volume>20</volume><issue>4</issue><keywords/><dates><year>2016</year></dates><publisher>Springer International Publishing</publisher><electronic-resource-num>10.1007/s40291-016-0209-0</electronic-resource-num><urls><pdf-urls><url>internal-pdf://art%3A10.1007%2Fs40291-016-0209-0.pdf</url></pdf-urls><web-urls><url>http://link.springer.com/10.1007/s40291-016-0209-0</url></web-urls></urls><label>Oncotype DX;rogerjob</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Laronga, Christine</author><author>Harness, Jay K</author><author>Dixon, Matthew</author><author>Borgen, Patrick I</author></authors></contributors><titles><title>The role of the breast cancer surgeon in personalized cancer care: clinical utility of the 21-gene assay.</title><secondary-title>American journal of surgery</secondary-title></titles><periodical><full-title>American journal of surgery</full-title></periodical><pages>751-8</pages><volume>203</volume><issue>6</issue><keywords><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Breast Neoplasms: surgery</keyword><keyword>Combined Modality Therapy</keyword><keyword>Decision Support Techniques</keyword><keyword>Female</keyword><keyword>Genetic Markers</keyword><keyword>Genetic Testing</keyword><keyword>Genetic Testing: methods</keyword><keyword>Humans</keyword><keyword>Individualized Medicine</keyword><keyword>Medical Oncology</keyword><keyword>Physician's Role</keyword><keyword>Prognosis</keyword><keyword>Specialties, Surgical</keyword><keyword>Tumor Markers, Biological</keyword></keywords><dates><year>2012</year></dates><publisher>Elsevier Inc.</publisher><accession-num>22516676</accession-num><electronic-resource-num>10.1016/j.amjsurg.2011.07.024</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Laronga et al. - 2012 - The role of the breast cancer surgeon in personalized cancer care clinical utility of the 21-gene assay.pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/22516676</url></web-urls></urls><label>Oncotype DX;rogerjob</label><abstract>Breast cancer surgeons represent the first line of defense for many patients battling this disease. They often have the first contact to discuss treatment options with the patient after diagnosis. However, the potential impact of this consultation has evolved with the arrival of commercialized multigene prognostic and predictive tests that continue to reshape the landscape of breast cancer management, including modern surgical practice.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Clark-Langone, Kim M</author><author>Sangli, Chithra</author><author>Krishnakumar, Jayadevi</author><author>Watson, Drew</author></authors></contributors><titles><title>Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay.</title><secondary-title>BMC cancer</secondary-title></titles><periodical><full-title>BMC cancer</full-title></periodical><pages>691</pages><volume>10</volume><issue>1</issue><keywords/><dates><year>2010</year></dates><publisher>BioMed Central Ltd</publisher><isbn>1471-2407 (Linking)</isbn><accession-num>21176237</accession-num><electronic-resource-num>10.1186/1471-2407-10-691</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Clark-Langone et al. - 2010 - Translating tumor biology into personalized treatment planning analytical performance characteristics o(2).pdf</url></pdf-urls><web-urls><url>http://www.biomedcentral.com/1471-2407/10/691</url></web-urls></urls><label>Oncotype DX;rogerjob</label><abstract>The Oncotype DX Colon Cancer Assay is a new diagnostic test for determining the likelihood of recurrence in stage II colon cancer patients after surgical resection using fixed paraffin embedded (FPE) primary colon tumor tissue. Like the Oncotype DX Breast Cancer Assay, this is a high complexity, multi-analyte, reverse transcription (RT) polymerase chain reaction (PCR) assay that measures the expression levels of specific cancer-related genes. By capturing the biology underlying each patient's tumor, the Oncotype DX Colon Cancer Assay provides a Recurrence Score (RS) that reflects an individualized risk of disease recurrence. Here we describe its analytical performance using pre-determined performance criteria, which is a critical component of molecular diagnostic test validation.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Zujewski, Jo Anne</author><author>Kamin, Leah</author></authors></contributors><titles><title>Trial Assessing Individualized Options for Treatment for breast cancer: the TAILORx trial</title><secondary-title>Future Oncology</secondary-title></titles><periodical><full-title>Future Oncology</full-title></periodical><pages>603-610</pages><volume>4</volume><issue>5</issue><keywords/><dates><year>2008</year></dates><publisher>Future Medicine London, UK</publisher><language>EN</language><urls><pdf-urls><url>internal-pdf://Zujewski, Kamin - 2008 - Trial Assessing Individualized Options for Treatment for breast cancer the TAILORx trial(3).pdf</url><url>internal-pdf://Zujewski, Kamin - 2008 - Trial Assessing Individualized Options for Treatment for breast cancer the TAILORx trial(2).pdf</url><url>internal-pdf://14796694%2E4%2E5%2E603.pdf</url></pdf-urls><web-urls><url>http://www.futuremedicine.com/doi/abs/10.2217/14796694.4.5.603?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed&amp;</url></web-urls></urls><label>Oncotype DX;rogerjob</label><abstract>Novel genetic profiling tests of breast cancer tissue have been shown to be prognostic for overall survival and predictive of local and distant rates of recurrence in breast cancer patients. One of these tests, Oncotype DX™, is a diagnostic test comprised of a 21-gene assay applied to paraffin-embedded breast cancer tissue, which allows physicians to predict subgroups of hormone-receptor-positive, node-negative patients who may benefit from hormonal therapy alone or require adjuvant chemotherapy to attain the best survival outcome. The results of the assay are converted to a recurrence score (0–100) that has been found to be predictive of 10- and 15-year local and distant recurrence in node-negative, estrogen-receptor-positive breast cancer patients. Previous studies have shown that patients with high recurrence scores benefit from adjuvant chemotherapy, whereas patients with low recurrence scores do not. To evaluate the ability to guide treatment decisions in the group with a mid-range recurrence score, ...</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Tine, Brian A Van</author><author>Ellis, Matthew J</author></authors></contributors><titles><title>Understanding the Estrogen Receptor – Positive Breast Cancer Genome : Not Even the End of the Beginning</title><secondary-title>Journal of the National Cancer Institute</secondary-title></titles><periodical><full-title>Journal of the National Cancer Institute</full-title></periodical><pages>526-7</pages><volume>103</volume><issue>7</issue><keywords/><dates><year>2011</year></dates><electronic-resource-num>10.1093/jnci/djr072</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Tine, Ellis - 2011 - Understanding the Estrogen Receptor – Positive Breast Cancer Genome Not Even the End of the Beginning(3).pdf</url><url>internal-pdf://Tine, Ellis - 2011 - Understanding the Estrogen Receptor – Positive Breast Cancer Genome Not Even the End of the Beginning.pdf</url><url>internal-pdf://Tine, Ellis - 2011 - Understanding the Estrogen Receptor – Positive Breast Cancer Genome Not Even the End of the Beginning(2).pdf</url></pdf-urls></urls><label>NNT paper;OncoType DX;Oncotype DX;rogerjob</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Goncalves, Rodrigo</author><author>Bose, Ron</author></authors></contributors><titles><title>Using multigene tests to select treatment for early-stage breast cancer</title><secondary-title>JNCCN Journal of the National Comprehensive Cancer Network</secondary-title></titles><periodical><full-title>JNCCN Journal of the National Comprehensive Cancer Network</full-title></periodical><pages>174-182</pages><volume>11</volume><issue>2</issue><keywords/><dates><year>2013</year></dates><isbn>1540-1413; 1540-1405</isbn><accession-num>23411384</accession-num><electronic-resource-num>11/2/174 [pii]</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Goncalves, Bose - 2013 - Using multigene tests to select treatment for early-stage breast cancer(3).pdf</url><url>internal-pdf://Goncalves, Bose - 2013 - Using multigene tests to select treatment for early-stage breast cancer(2).pdf</url><url>internal-pdf://J Natl Compr Canc Netw-2013-Goncalves-174-82.pdf</url></pdf-urls></urls><label>Oncotype DX;TAILORx;mammaprint;rogerjob</label><abstract>Oncotype DX, PAM50, and MammaPrint are multigene tests that are being used clinically for early-stage breast cancer to predict recurrence risk and guide adjuvant chemotherapy decisions. These tests have been validated in multiple retrospective studies, and prospective clinical trials are in progress. The TAILORx trial uses the Oncotype DX recurrence score to assign estrogen receptor-positive (ER+), node-negative patients to chemotherapy plus hormonal therapy versus hormonal therapy alone. The RxPONDER (SWOG S1007) trial uses Oncotype DX in a similar approach but on node-positive patients, and it includes the PAM50 test as a secondary analysis. The MINDACT trial uses Mamma-Print and Adjuvant! Online for treatment arm assignments. MINDACT has very broad eligibility criteria and 2 secondary randomizations for selecting chemotherapy and hormonal therapy regimens. This article discusses how the latest results on cancer genome sequencing apply to early-stage breast cancer. Several hundred breast cancers have already undergone genome sequencing, and the somatic DNA changes found in the tumor, compared with the patient's normal DNA, have been identified. Higher rates of point mutations and chromosomal translocations are found in aromatase inhibitor-resistant ER+ cancers and in the basal-like and HER2-enriched breast cancer subtypes. Correlations of somatic mutations with neoadjuvant aromatase inhibitor response are discussed. Genome sequencing can potentially identify the molecular abnormalities that underlie the poor risk identified by multigene tests and provide potential new targets for therapy, but more clinical trials correlating clinical outcome and somatic DNA changes are needed.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Blohmer, J U</author><author>Rezai, M</author><author>Kümmel, S</author><author>Kühn, T</author><author>Warm, M</author><author>Friedrichs, K</author><author>Benkow, A</author><author>Valentine, W J</author><author>Eiermann, W</author></authors></contributors><titles><title>Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.</title><secondary-title>Journal of medical economics</secondary-title></titles><periodical><full-title>Journal of medical economics</full-title></periodical><pages>30-40</pages><volume>16</volume><issue>1</issue><keywords><keyword>21-gene assay</keyword><keyword>Breast cancer</keyword><keyword>Cost</keyword><keyword>Cost-effectiveness</keyword><keyword>Germany</keyword></keywords><dates><year>2013</year></dates><publisher>Informa UK Ltd London</publisher><accession-num>22966753</accession-num><electronic-resource-num>10.3111/13696998.2012.722572</electronic-resource-num><language>en</language><urls><web-urls><url>http://informahealthcare.com.pitt.idm.oclc.org/doi/abs/10.3111/13696998.2012.722572</url></web-urls></urls><label>Oncotype DX;rogerjob</label><abstract>The 21-gene assay (Oncotype DX Breast Cancer Test (Genomic Health Inc., Redwood City, CA)) is a well validated test that predicts the likelihood of adjuvant chemotherapy benefit and the 10-year risk of distant recurrence in patients with ER+, HER2- early-stage breast cancer. The aim of this analysis was to evaluate the cost-effectiveness of using the assay to inform adjuvant chemotherapy decisions in Germany.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Azim, H</author><author>Michiels, S</author><author>Zagouri, F</author><author>Delaloge, S</author><author>Filipits, M</author><author>Namer, M</author><author>Neven, P</author><author>Symmans, W F</author><author>Thompson, A</author><author>André, F</author><author>Loi, S</author><author>Swanton, C</author></authors></contributors><titles><title>Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.</title><secondary-title>Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</secondary-title></titles><periodical><full-title>Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</full-title></periodical><pages>647-54</pages><volume>24</volume><issue>3</issue><keywords><keyword>Breast Neoplasms</keyword><keyword>Breast Neoplasms: diagnosis</keyword><keyword>Breast Neoplasms: genetics</keyword><keyword>Evaluation Studies as Topic</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Molecular Diagnostic Techniques</keyword><keyword>Molecular Diagnostic Techniques: standards</keyword><keyword>Multivariate Analysis</keyword><keyword>Oligonucleotide Array Sequence Analysis</keyword><keyword>Practice Guidelines as Topic</keyword><keyword>Real-Time Polymerase Chain Reaction</keyword><keyword>Reproducibility of Results</keyword><keyword>Reverse Transcriptase Polymerase Chain Reaction</keyword><keyword>breast cancer</keyword><keyword>genomic signatures</keyword><keyword>prediction</keyword><keyword>prognosis</keyword></keywords><dates><year>2013</year></dates><accession-num>23337633</accession-num><electronic-resource-num>10.1093/annonc/mds645</electronic-resource-num><urls><pdf-urls><url>internal-pdf://Azim et al. - 2013 - Utility of prognostic genomic tests in breast cancer practice The IMPAKT 2012 Working Group Consensus Statement(2)-annotated.pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/23337633</url></web-urls></urls><label>NNT paper;Oncotype DX;rogerjob</label><abstract>BACKGROUND: We critically evaluated the available evidence on genomic tests in breast cancer to define their prognostic ability and likelihood to determine treatment benefit. DESIGN: Independent evaluation of six genomic tests [Oncotype Dx™, MammaPrint(®), Genomic Grade Index, PAM50 (ROR-S), Breast Cancer Index, and EndoPredict] was carried out by a panel of experts in three parameters: analytical validity, clinical validity, and clinical utility based on the principles of the EGAPP criteria. PANEL STATEMENTS: The majority of the working group members found the available evidence on the analytical and clinical validity of Oncotype Dx™ and MammaPrint(®) to be convincing. None of the genomic tests demonstrated robust evidence of clinical utility: it was not clear from the current evidence that modifying treatment decisions based on the results of a given genomic test could result in improving clinical outcome. CONCLUSIONS: The IMPAKT 2012 Working Group proposed the following recommendations: (i) a need to develop models that integrate clinicopathologic factors along with genomic tests; (ii) demonstration of clinical utility should be made in the context of a prospective randomized trial; and (iii) the creation of registries for patients who are subjected to genomic testing in the daily practice.</abstract></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Guth, Amber A</author><author>Fineberg, Susan</author><author>Fei, Kezhen</author><author>Franco, Rebeca</author><author>Bickell, Nina A</author></authors></contributors><titles><title>Utilization of Oncotype DX in an Inner City Population : Race or Place ?</title></titles><periodical/><volume>2013</volume><keywords/><dates><year>2013</year></dates><urls><pdf-urls><url>internal-pdf://IJBC2013-653805.pdf</url><url>internal-pdf://Guth et al. - 2013 - Utilization of Oncotype DX in an Inner City Population Race or Place.pdf</url></pdf-urls></urls><label>Oncotype DX;economic focus;rogerjob</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Schneider, Jeffrey G.</author><author>Khalil, Danny N</author></authors></contributors><titles><title>Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use?</title><secondary-title>Breast Cancer Res Treat</secondary-title></titles><periodical><full-title>Breast Cancer Res Treat</full-title></periodical><pages>1125-1132</pages><volume>134</volume><issue>3</issue><keywords><keyword>adjuvant therapy</keyword><keyword>breast cancer</keyword><keyword>breast cancer genetic signature</keyword><keyword>oncotype dx recurrence score</keyword><keyword>treatment decision making</keyword></keywords><dates><year>2012</year></dates><electronic-resource-num>10.1007/s10549-012-2134-1.Why</electronic-resource-num><urls><pdf-urls><url>internal-pdf://nihms666638.pdf</url></pdf-urls></urls><label>Oncotype DX;doctor focus;rogerjob</label></record><record><database name="julia-et-al-oncotype.enl" path="julia-et-al-oncotype.enl">julia-et-al-oncotype.enl</database><ref-type name="Journal Article">0</ref-type><contributors><authors><author>Hayes, Daniel F</author><author>Khoury, Muin J</author><author>Ransohoff, David</author><author>Hayes, Daniel F</author><author>Khoury, Muin J</author><author>Ransohoff, David</author></authors></contributors><titles><title>Why Hasn’t Genomic Testing Changed the Landscape in Clinical Oncology?</title><secondary-title>American Society of Clinical Oncology educational book</secondary-title></titles><periodical><full-title>American Society of Clinical Oncology educational book</full-title></periodical><pages>52-55</pages><keywords/><dates><year>2012</year></dates><accession-num>24451831</accession-num><electronic-resource-num>10.14694/EdBook_AM.2012.32.e52</electronic-resource-num><notes>Summary of differnet kinds of 'validation'.
No endpoints or overview.
Do not review.</notes><research-notes>Summary of differnet kinds of 'validation'.
No endpoints or overview.
Do not review.</research-notes><urls><pdf-urls><url>internal-pdf://zds00112000e52.pdf</url></pdf-urls><web-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/24451831</url></web-urls></urls><label>Oncotype DX;rogerjob</label><abstract>The &quot;omics&quot; revolution produced great optimism that tumor biomarker tests based on high-order analysis of multiple (sometimes thousands) of factors would result in truly personalized oncologic care. Unfortunately, 10 years into the revolution, the promise of omics-based research has not yet been realized. The factors behind the slow progress in omics-based clinical care are many. First, over the last 15 years, there has been a gradual recognition of the importance of conducting tumor biomarker science with the kind of rigor that has traditionally been used for therapeutic research. However, this recognition has only recently been applied widely, and therefore most tumor biomarkers have insufficiently high levels of evidence to determine clinical utility. Second, omics-based research offers its own particular set of concerns, especially in regard to overfitting computational models and false discovery rates. Researchers and clinicians need to understand the importance of analytic validity, and the difference between clinical/biologic validity and clinical utility. The latter is required to introduce a tumor biomarker test of any kind (single analyte or omics-based), and are ideally generated by carefully planned and properly conducted &quot;prospective retrospective&quot; or truly prospective clinical trials. Only carefully planned studies, which take all three of these into account and in which the investigators are aware and recognize the enormous risk of unintended bias and overfitting inherent in omics-based test development, will ultimately result in translation of the exciting new technologies into better care for patients with cancer.</abstract></record></records></xml>
